Contents

Review

Remote Testing Apps for Multiple Sclerosis Patients: Scoping Review of Published Articles and Systematic Search and Review of Public Smartphone Apps (e37944)
Jacob Michaud, Cameron Penny, Olivia Cull, Eric Hervet, Ludivine Chamard-Witkowski. ................................................................. 2

Original Papers

A Novel System to Monitor Tic Attacks for Tourette Syndrome Using Machine Learning and Wearable Technology: Preliminary Survey Study and Proposal for a New Sensing Device (e43351)
Agni Rajinikanth, Davis Clark, Marianna Kapsetaki. ................................................................. 16

A Digital Telehealth System to Compute Myasthenia Gravis Core Examination Metrics: Exploratory Cohort Study (e43387)
Marc Garbey, Guillaume Joerger, Quentin Lesport, Helen Girma, Sienna McNett, Mohammad Abu-Rub, Henry Kaminski. ......................... 28

Clinical Perspectives on Using Remote Measurement Technology in Assessing Epilepsy, Multiple Sclerosis, and Depression: Delphi Study (e41439)

A Semantic Relatedness Model for the Automatic Cluster Analysis of Phonematic and Semantic Verbal Fluency Tasks Performed by People With Parkinson Disease: Prospective Multicenter Study (e46021)
Tom Hähnel, Tim Feige, Julia Kunze, Andrea Epler, Anika Frank, Jonas Bendig, Nils Schnalke, Martin Wolz, Peter Themann, Björn Falkenburger. ........................................................................................................ 66
Remote Testing Apps for Multiple Sclerosis Patients: Scoping Review of Published Articles and Systematic Search and Review of Public Smartphone Apps

Jacob B Michaud¹,², MD; Cameron Penny³, BSc; Olivia Cull², BSc; Eric Hervet⁴, PhD; Ludivine Chamard-Witkowski²,⁵, MD

¹Department of Internal Medicine, Dalhousie University, Halifax, NS, Canada
²Centre de Formation Médicale du Nouveau-Brunswick, Moncton, NB, Canada
³Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
⁴Department of Computer Science, Université de Moncton, Moncton, NB, Canada
⁵Department of Neurology, Dr.-Georges-L.-Dumont University Hospital Center, Moncton, NB, Canada

Corresponding Author:
Ludivine Chamard-Witkowski, MD
Department of Neurology
Dr.-Georges-L.-Dumont University Hospital Center
330 Université Ave
Moncton, NB, E1C 2Z3
Canada
Phone: 1 506 869 721
Email: Ludivine.Witkowski@vitalitenb.ca

Abstract

Background: Many apps have been designed to remotely assess clinical status and monitor symptom evolution in persons with multiple sclerosis (MS). These may one day serve as an adjunct for in-person assessment of persons with MS, providing valuable insight into the disease course that is not well captured by cross-sectional snapshots obtained from clinic visits.

Objective: This study sought to review the current literature surrounding apps used for remote monitoring of persons with MS.

Methods: A scoping review of published articles was conducted to identify and evaluate the literature published regarding the use of apps for monitoring of persons with MS. PubMed/Medline, EMBASE, CINAHL, and Cochrane databases were searched from inception to January 2022. Cohort studies, feasibility studies, and randomized controlled trials were included in this review. All pediatric studies, single case studies, poster presentations, opinion pieces, and commentaries were excluded. Studies were assessed for risk of bias using the Scottish Intercollegiate Guidelines Network, when applicable. Key findings were grouped in categories (convergence to neurological exam, feasibility of implementation, impact of weather, and practice effect), and trends are presented. In a parallel systematic search, the Canadian Apple App Store and Google Play Store were searched to identify relevant apps that are available but have yet to be formally studied and published in peer-reviewed publications.

Results: We included 18 articles and 18 apps. Although many MS-related apps exist, only 10 apps had published literature supporting their use. Convergence between app-based testing and the neurological exam was examined in 12 articles. Most app-based tests focused on physical disability and cognition, although other domains such as ambulation, balance, visual acuity, and fatigue were also evaluated. Overall, correlations between the app versions of standardized tests and their traditional counterparts were moderate to strong. Some novel app-based tests had a stronger correlation with clinician-derived outcomes than traditional testing. App-based testing correlated well with the Multiple Sclerosis Functional Composite but less so with the Expanded Disability Status Scale; the latter correlated to a greater extent with patient quality of life questionnaire scores.

Conclusions: Although limited by a small number of included studies and study heterogeneity, the findings of this study suggest that app-based testing demonstrates adequate convergence to traditional in-person assessment and may be used as an adjunct to and perhaps in lieu of specific neurological exam metrics documented at clinic visits, particularly if the latter is not readily accessible for persons with MS.

(JMIR Neurotech 2023;2:e37944) doi:10.2196/37944

https://neuro.jmir.org/2023/1/e37944
KEYWORDS
multiple sclerosis; mobile application; mobile phone; app; mHealth; eHealth; digital health; telehealth

Introduction
Multiple sclerosis (MS) has a fluctuating clinical course punctuated by relapses, remissions, and progressive deterioration for many affected patients. As such, the neurologist requires an accurate representation of the symptomatology of the patient with MS in order to evaluate the efficacy of treatment [1].

Infrequent and intermittent monitoring as provided at office visits may not truly reflect the day-to-day functioning and quality of life of patients living with MS [2]. Persons with MS may also have recall bias when reporting symptoms to their neurologist [2]. Additionally, symptoms in MS can fluctuate depending on fatigue, mood, and weather; thus, the cross-sectional nature of the information obtained from an individual clinic visit may be of limited accuracy compared with trends in symptoms over time [3,4]. The need for at-home MS follow-up has been further emphasized by the current COVID-19 pandemic, in which many medical centers have implemented in-person patient visit limits to reduce the spread of the virus [5].

Remote evaluation of clinical status and symptoms in persons with MS could serve as a means of obtaining additional information that is not provided by the traditional office visit. Many apps for remote assessment of persons with MS exist, ranging from symptom logs, patient-reported outcome trackers, assessments of cognitive function and fine motor skills, as well as drug adherence and adverse drug event trackers [6-8]. The objective of this review was to identify and evaluate apps designed to enable remote assessment of persons with MS and whether the means of assessment utilized in these various apps are supported by scientific evidence.

Methods
Review Sources
A scoping review was performed to identify articles evaluating apps dedicated to the remote testing and follow-up of persons with MS. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed for this portion of the review [9]. No protocol for this review was previously published.

A separate review of the Canadian Apple App Store and Google Play Store was conducted in parallel. This was done in order to identify apps available for public use, including some identified in the literature search as well as those that had not been formally studied prior to dissemination.

Eligibility Criteria
Scientific papers were included if they met the following criteria:

- The study evaluated the use of remote monitoring of persons with MS via smartphone or tablet app and was published in English, French, or Spanish prior to January 17, 2022. Cohort studies, feasibility studies, and randomized controlled trials were included in this review. Studies were included if the application was used to measure one or more of the following functional domains: physical disability, fatigue, visual symptoms, urinary symptoms, balance, mood symptoms, pain, cognition, or ambulation. Exclusion criteria included pediatric studies, single case studies, poster presentations, opinion pieces, and commentaries.

- Publicly available apps that were intended for symptom tracking or app-based testing of persons with MS were included in the app review portion of this paper if they were able to measure one or more of the aforementioned metrics.

Search Strategy
PubMed/Medline, EMBASE, CINAHL, and Cochrane databases were searched from inception to January 17, 2022, to identify studies suitable for inclusion. The search strategy is detailed in Figure 1, and the detailed search strategy is presented in Multimedia Appendix 1.

As for the apps, the Canadian iOS Apple App Store and Android Google Play Store were searched using the term “Multiple Sclerosis” for publicly available apps.
grouped in primary outcome categories, and data were presented qualitatively.

Authors JBM and CP independently screened the title and description of the apps, and inclusion was determined by consensus. The included apps were then reviewed, and the functional domains evaluated were documented.

**Presentation**

For the purpose of readability, this article considered correlation coefficients $|r| \geq 0.75$ to be strong, $0.75 > |r| \geq 0.5$ to be moderate, $0.5 > |r| \geq 0.25$ to be weak, and $|r| < 0.25$ to not be correlated.

**Results**

**Study and App Identification**

A total of 2433 studies were identified using the search strategy defined in the Methods section. Following duplicate removal and title and abstract screening, 77 studies were selected for full-text review. Of these studies, 18 were in keeping with the predefined inclusion criteria (Figure 2). All 18 studies were found to be of acceptable or high quality using the SIGN checklist [10].

As for the app store review, the search yielded 79 apps in the Apple App Store and 339 apps in the Google Play Store. After removal of duplicates and title and description screening, 25 apps were selected for full app review. Of these apps, only 18 were deemed to fit the inclusion criteria (Figure 3). Of the 18 apps included, 2 had supporting literature that was identified in the scoping review portion of this paper [11-14].

![Flowchart](image-url)
Characteristics of Included Studies

Of the 18 articles included, 12 sought to compare apps with a neurologist exam, disability scale, or recognized standardized tests [11-13,15-23]. The feasibility of implementing an app designed for remote monitoring of persons with MS was evaluated in 3 studies [24-26], 2 articles compared quality of life questionnaires with app-based functional tests and clinician-reported outcomes [25,27], and 2 apps assessed the local weather’s impact on persons with MS-reported fatigue and app functional test results [25,28]. Finally, 1 article evaluated the practice effect of repeated at-home MS testing [14] (Table 1).
Table 1. Characteristics of included studies.

<table>
<thead>
<tr>
<th>Author(s), year</th>
<th>Countries</th>
<th>Study design</th>
<th>Type of multiple sclerosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hsu et al, 2021 [22]</td>
<td>United States</td>
<td>Prospective cohort</td>
<td>RR, PP, SP, CISd, unknown</td>
</tr>
<tr>
<td>Golan et al, 2021 [27]</td>
<td>Israel</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
<tr>
<td>Pratap et al, 2020 [28]</td>
<td>United States</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
<tr>
<td>Newland et al, 2019 [26]</td>
<td>United States</td>
<td>Descriptive study</td>
<td>RR</td>
</tr>
<tr>
<td>Midaglia et al, 2019 [24]</td>
<td>Spain, United States</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
<tr>
<td>Montalban et al, 2021 [12]</td>
<td>Spain, United States</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
<tr>
<td>Woelfle et al, 2021 [14]</td>
<td>Switzerland</td>
<td>Prospective cohort</td>
<td>N/Ae</td>
</tr>
<tr>
<td>Lam et al, 2021 [18]</td>
<td>Netherlands</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
<tr>
<td>van Oirschot et al, 2020 [19]</td>
<td>Netherlands</td>
<td>Prospective cohort</td>
<td>RR</td>
</tr>
<tr>
<td>van Oirschot et al, 2021 [23]</td>
<td>Netherlands</td>
<td>Prospective cohort</td>
<td>RR</td>
</tr>
<tr>
<td>Lam et al, 2021 [20]</td>
<td>Netherlands</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
<tr>
<td>Lam et al, 2022 [21]</td>
<td>Netherlands</td>
<td>Prospective cohort</td>
<td>RR, PP, SP</td>
</tr>
</tbody>
</table>

aRR: relapsing remitting multiple sclerosis.
bPP: primary progressive multiple sclerosis.
cSP: secondary progressive multiple sclerosis.
dCIS: clinically isolated syndrome.
eN/A: not available.

Characteristics of Included Apps

Of the 18 apps included, 5 had objective symptom testing through mobile phone sensors. The other 13 did not have active tests but did allow for symptom logging. Of the apps included in this study, 2 had complimentary data that were identified during the scoping review portion of the current study.

Four apps were exclusively found on the Apple App Store, 8 apps were exclusively found in the Google Play Store, and 6 apps were found in both stores. All but 2 of the apps included were free of charge.

Scoping Review Outcomes

As aforementioned, the reviewed articles were categorized according to 4 main objectives: evaluating convergence with neurological exam, feasibility of implementation of an app for persons with MS, evaluating the practice effect of repeated at-home testing, and comparing app-based tests with quality of life questionnaires and local weather.

Convergence With the Neurological Exam

Of the 18 articles, 14 articles described 12 apps that measured physical disability and correlated these with findings on clinical exam. These measures of physical disability were done by tap tests [16], shape drawing tests [11,13], pinching tests [12], assessment of passively acquired keyboard metrics [18,20], or using a level test wherein one must balance their phone in order to keep a ball in a designated screen area [17]. Visual symptoms were measured in 2 apps using tests of steering around obstacles [15] or a mobile vision test [11]. Cognitive function was measured in 6 apps: 3 apps used an electronic version of the Symbol Digit Modalities Test (SDMT) [11-13,18,19]; 1 used a go-no go test coupled with multitasking and visuomotor steering [15]; 1 used a battery of attention, working memory, and goal management evaluations [22]; and 1 measured keystroke dynamics including keystroke latency, emoji use, and word length [20,21]. Ambulation was measured in 3 apps using an app-based timed 25-foot walk test (T25FW) [11,13], 2-minute walk test (2MWT) [23], U-turn test [12], or maximum distance walked test [11,13]. The main tests and functional domains can be found in Table 2.

One study compared the MS Suite app balloon popping test to the 9-Hole Peg Test (9HPT) and found that the app slightly outperformed the 9HPT in its ability to correlate with clinician-derived outcomes [16]. The number of balloons popped correlated strongly with cerebellar function and moderately with upper extremity strength and motor exam. The study also included 4 patients who could no longer perform the 9HPT due to severe disease but were able to perform the balloon popping test.
<table>
<thead>
<tr>
<th>App and functional domains</th>
<th>App test</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adaptive Cognitive Evaluation</strong> [22]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognition</td>
<td>Boxed task, sustained attention task, spatial span</td>
<td>SDMT&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>ElevateMS</strong> [28]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Finger tapping, finger to nose</td>
<td>PDDS&lt;sup&gt;c&lt;/sup&gt;, Neuro-QoL&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ambulation, balance</td>
<td>Walk and balance test</td>
<td>PDDS, Neuro-QoL</td>
</tr>
<tr>
<td>Cognition</td>
<td>Voice-controlled DSST&lt;sup&gt;e&lt;/sup&gt;</td>
<td>PDDS, Neuro-QoL</td>
</tr>
<tr>
<td><strong>Evo Monitor</strong> [15]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>Go/no go, tilt to steer, and combination of both tasks</td>
<td>MSFC-4&lt;sup&gt;f&lt;/sup&gt;, EDSS&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cognition</td>
<td>Go/no go, tilt to steer, and combination of both tasks</td>
<td>BICAMS&lt;sup&gt;h&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Floodlight</strong> [12,14]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>Draw a shape, pinching test</td>
<td>9HPT&lt;sup&gt;i&lt;/sup&gt;, EDSS</td>
</tr>
<tr>
<td>Balance</td>
<td>Static balance test</td>
<td>BBS&lt;sup&gt;j&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cognition</td>
<td>sSDMT&lt;sup&gt;k&lt;/sup&gt;</td>
<td>SDMT</td>
</tr>
<tr>
<td>Ambulation</td>
<td>2MWT&lt;sup&gt;l&lt;/sup&gt;, U-turn test</td>
<td>T25FW&lt;sup&gt;m&lt;/sup&gt;, EDSS</td>
</tr>
<tr>
<td><strong>MSCopilot</strong> [11,13]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>Spiral test</td>
<td>9HPT</td>
</tr>
<tr>
<td>Visual</td>
<td>Vision test</td>
<td>SLCLAT&lt;sup&gt;n&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cognition</td>
<td>Cognition test (sSDMT)</td>
<td>SDMT, PASAT&lt;sup,o&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ambulation</td>
<td>Walking test</td>
<td>T25FW, EDSS</td>
</tr>
<tr>
<td><strong>MS Sherpa</strong> [18,19,23]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognition</td>
<td>sSDMT</td>
<td>SDMT</td>
</tr>
<tr>
<td>Ambulation</td>
<td>e-2MWT&lt;sup&gt;p&lt;/sup&gt;</td>
<td>2MWT</td>
</tr>
<tr>
<td><strong>MS Suite</strong> [16,17]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>Balloon popping, tap test, tilt test</td>
<td>NeurEx&lt;sup&gt;q&lt;/sup&gt;, EDSS</td>
</tr>
<tr>
<td>Cognition</td>
<td>Tilt test</td>
<td>SDMT</td>
</tr>
<tr>
<td><strong>NeuroKeys</strong> [20,21]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>Press-press latency, release-release latency, hold time, flight time, pre correction slowing, correction duration, post correction slowing, after punctuation pause, emoji sentiment score [11]</td>
<td>CIS-F&lt;sup&gt;r&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>SDMT: Symbol Digit Modalities Test.
<sup>b</sup>PD: physical disability.
<sup>c</sup>PDSS: Patient-Determined Disease Steps.
<sup>d</sup>Neuro-QoL: Quality of Life in Neurological Disorders.
<sup>e</sup>DSST: Digit Symbol Substitution Test.
<sup>f</sup>MSFC-4: Multiple Sclerosis Functional Composite 4.
<sup>g</sup>EDSS: Expanded Disability Status Scale.
Adherence rates for app-based 2MWT and EDSS were assessed in 3 studies. In one study, the feasibility of implementing an app to monitor symptoms was evaluated in 2MWT, 9-HPT, and EDSS [23]. A statistically significant correlation was identified between the Floodlight tests, the U-turn test had the strongest correlation with the 9-HPT. It also found that Floodlight's sSDMT correlated moderately with the SDMT [17]. These same 2 studies compared the multitasking test and level test with the EDSS. Both correlated weakly with the EDSS [15,17].

The MS Copilot app included several tests: spiral drawing test, maximum distance walked, verbal SDMT, and low contrast vision test. The z score of participants' test batteries correlated strongly with the Multiple Sclerosis Functional Composite (MSFC) z score [11]. Another MS Copilot battery comprising of maximum walking distance, shape drawing, and SDMT correlated moderately with the EDSS [13].

In 1 study, the Floodlight app's pinching test correlated moderately with the 9-HPT. It also found that Floodlight's U-turn test correlated moderately with the T25FW. Of the Floodlight tests, the U-turn test had the strongest correlation with the EDSS despite the weak correlation ($r=-0.45; P<0.001$) [12]. Individual test scores were not compounded in this study as they were in the MS Copilot study [13].

Finally, MS Sherpa’s smartphone 2MWT measurements were found to be approximately 8.43 meters greater than those measured traditionally. In this same study, there was no statistically significant correlation identified between the app-based 2MWT and EDSS [23].

### Feasibility of Implementation

The feasibility of implementing an app to monitor symptoms in persons with MS was assessed in 3 studies. Adherence rates were 51% for an app requiring 12 months of daily data collection (n=38) [25]; 70% for an app requiring daily, weekly, fortnightly, or on-demand activities (n=76) [24]; and 87% for an app requiring 7 consecutive days of testing and a repeat test 4 weeks later (n=32) [26].

### Quality of Life Questionnaires

App-based quality of life questionnaires were evaluated in 2 studies: 1 compared app-derived neurological quality of life (Neuro-QoL) questionnaires to in-app functional tests. Using a linear mixed effects model, the study found that the following Neuro-QoL domains correlated significantly with app tests: Upper extremity function was correlated with finger tapping test, lower extremity function was correlated with walk and balance tests, and cognitive function was correlated with the voice-based Digit Symbol Substitution Test (DSST) [28].

Another study assessed the e-Diary app, in which an app-based questionnaire was used to derive a Bodily Function Summary Score that was then compared to clinician-reported outcomes. This study found a strong correlation between the Bodily Function Summary Score and EDSS scores [27].

### Weather

Whether increasing local temperature had a negative impact on in-app tests was evaluated in 2 studies [25,28]. The first included 495 persons with MS and found that increasing temperature had a significant negative impact on finger tapping, DSST, and finger to nose [28]. However, the second study, following 22 persons with MS, found no statistically significant association between the Modified Fatigue Inventory Scale and temperature or daylight hours [25].

### Practice Effect

The development of a practice effect with repeated at-home app-based MS testing was assessed in 1 study. Data included in this study were derived from the Floodlight app. Domains assessed included daily repetition of finger pinching, shape drawing, 2MWT, U-turn test, static balance test, and weekly repetition of virtual SDMT. The study found improvement in test scores ranging from 11% to 54.2% on daily repetition of tests with the exception of the 2MWT. For the sSDMT, an average improvement of 40.8% was observed after 5 weeks of weekly testing [14].

The key findings of each included article are presented in Table 3.
### Table 3. Key findings of included studies.

<table>
<thead>
<tr>
<th>App and author, year</th>
<th>All assessed functional domains</th>
<th>Number of people with MS</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adaptive Cognitive Evaluation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hsu et al, 2021 [22]</td>
<td>Cognition</td>
<td>53</td>
<td>Boxed reaction time of persons with MS correlated most strongly with SDMT(^b) ((r=–0.50; P&lt;.001)), including when covariates were accounted for ((r=–0.43; P=0.002)). Sustained attention span and spatial span were not significantly correlated with SDMT.</td>
</tr>
<tr>
<td>Golan et al, 2021 [27]</td>
<td>PD(^c), visual, urinary, mood, pain, cognition</td>
<td>97</td>
<td>e-diary–derived PROs(^d) were significantly correlated with corresponding functional system scores (0.38&lt;(r&lt;0.8; P&lt;.001)). The sum of bodily functions showed a correlation coefficient of (r=0.77 (P&lt;.001)) with clinician EDSS(^e).</td>
</tr>
<tr>
<td><strong>ElevateMS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pratap et al, 2020 [28]</td>
<td>PD, balance, cognition, weather</td>
<td>495</td>
<td>Neuro-QoL(^f) categories correlated significantly with finger tapping ((\beta=0.4; P&lt;.001)), walk and balance ((\beta=–99.18; P=0.02)), and DSST(^h) ((\beta=1.60; P=0.03)). Baseline PDDS was associated with finger to nose ((\beta=0.01; P=0.01)). Increasing temperature had a significant impact on finger tapping, DSST ((\beta=–0.06; P=0.009)), and finger to nose.</td>
</tr>
<tr>
<td><strong>Fatigue</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newland et al, 2019 [26]</td>
<td>PD, pain, cognition</td>
<td>32</td>
<td>Most participants (87%) completed all of the surveys required (7 consecutive days and repeat 4 weeks later).</td>
</tr>
<tr>
<td><strong>Floodlight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midaglia et al, 2019 [24]</td>
<td>PD, fatigue, balance, mood, pain, cognition, ambulation</td>
<td>76</td>
<td>70% of participants were adherent to all active tests. 75% of participants were adherent to all tests except 2MWT(^i). Mean satisfaction with the app at week 12 was 74.1% and at week 24 was 73.7%.</td>
</tr>
<tr>
<td>Montalban et al, 2021 [12]</td>
<td>PD, balance, cognition</td>
<td>76</td>
<td>Strongest correlation was found between sSDMT(^k) and SDMT ((r=0.82; P&lt;.001)). Pinching test correlated with 9HPT(^l) ((r=0.64, P&lt;.001)). U-turn test correlated with T25FW ((r=–0.41; P&lt;.001)). Go/no go and tilt to steer tests were associated with SDMT ((r=–0.31; P=0.01) and (r=0.40; P&lt;.001), respectively).</td>
</tr>
<tr>
<td>Woelfle et al, 2021 [14]</td>
<td>PD, balance, cognition, ambulation</td>
<td>171-262</td>
<td>sSDMT, when repeated at 7-day intervals, had an average improvement of 40.8%. The practice effect was reached after 11 repetitions for one-half and after 35 repetitions for 90%. Finger pinching, draw a shape, U-turn, and static balance had average improvements of 54.2%, 23.9%, 11.0%, and 28.6%, respectively. 2MWT was not significantly associated with improvement.</td>
</tr>
<tr>
<td><strong>MS Copilot</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maillart et al, 2019 [11]</td>
<td>PD, visual, cognition, ambulation</td>
<td>141</td>
<td>App combined task (z) score correlated with the MSFC(^m)(^z) score ((r=0.81; P&lt;.001)).</td>
</tr>
<tr>
<td>Tanoh et al, 2021 [13]</td>
<td>PD, visual, cognition, ambulation</td>
<td>116</td>
<td>Summed scores of maximum walking distance, draw a shape, and mobile SDMT correlated with EDSS ((r=–0.65; P&lt;.001)).</td>
</tr>
<tr>
<td><strong>MS Sherpa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lam et al, 2021 [18]</td>
<td>Cognition</td>
<td>102</td>
<td>sSDMT and SDMT correlation coefficients were (r=0.687 (P&lt;.001)) in the morning and (r=0.622 (P&lt;.001)) in the evening, with a regression coefficient of 0.87. The interclass correlation coefficient between SDMT and sSDMT results was 0.784, and the Pearson correlation coefficient was (r=0.85 (P&lt;.001)).</td>
</tr>
<tr>
<td>van Oirschot et al, 2020 [19]</td>
<td>Cognition</td>
<td>25</td>
<td>Distance walked on e-2MWT was, on average, 8.43 meters greater than that with traditional 2MWT. There was no significant correlation between EDSS and e-2MWT.</td>
</tr>
</tbody>
</table>

---

\(^a\) Number of people with MS.
\(^b\) SDMT = Symbol Digit Modalities Test.
\(^c\) PD = Postural drift.
\(^d\) PROs = Patient-Reported Outcomes.
\(^e\) EDSS = Expanded Disability Status Scale.
\(^f\) Neuro-QoL = Neuro-Quality of Life Study.
\(^g\) Neuro-QoL \(\beta\) = Beta coefficient.
\(^h\) DSST = Digit Symbol Substitution Test.
\(^i\) T25FW = Timed 25-Foot Walk.
\(^j\) 2MWT = Timed 2-Minute Walk Test.
\(^k\) sSDMT = Scaled Symbol Digit Modalities Test.
\(^l\) 9HPT = Nine-Hole Peg Test.
\(^m\) MSFC = Multiple Sclerosis Functional Composite.
\(^n\) MSFC \(z\) score = MSFC score adjusted for age, sex, and education.

---

Hsu et al, 2021 [22]  
Golan et al, 2021 [27]  
Pratap et al, 2020 [28]  
Newland et al, 2019 [26]  
Midaglia et al, 2019 [24]  
Montalban et al, 2021 [12]  
Woelfle et al, 2021 [14]  
Tanoh et al, 2021 [13]  
Lam et al, 2021 [18]  
van Oirschot et al, 2020 [19]  
van Oirschot et al, 2021 [23]
### Key findings

<table>
<thead>
<tr>
<th>App and author, year</th>
<th>All assessed functional domains</th>
<th>Number of people with MS</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MS Suite</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boukhvalova et al, 2018 [16]</td>
<td>PD, cognition</td>
<td>76</td>
<td>Balloon popping had correlation coefficients of $r=0.62$, $r=0.75$, and $r=0.62$ ($P&lt;.0001$) with upper extremity strength, cerebellar function, and upper extremity motor exam, respectively. These values were $r=0.59$, $r=0.57$, and $r=0.61$ for the traditional 9HPT. Tap test was associated with 9HPT ($r=0.66$; $P&lt;.0001$)</td>
</tr>
<tr>
<td>Boukhvalova et al, 2019 [17]</td>
<td>PD, cognition</td>
<td>112</td>
<td>Level test time spent in center of the level test correlated with SDMT ($r=0.57$; $P&lt;.0001$) and, to a lesser degree, with EDSS ($r=-0.35$; $P&lt;.01$).</td>
</tr>
<tr>
<td><strong>N/A</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bove et al, 2015 [25]</td>
<td>PD, balance, cognition, weather</td>
<td>38</td>
<td>Adherence rate for the app was 51% at 12 months. Of those who completed the 1-year study ($n=22$), no significant association between MFIS&lt;sup&gt;o&lt;/sup&gt; and temperature ($P=0.18$) nor daylight hours ($P=0.091$) was noted.</td>
</tr>
<tr>
<td><strong>Neuro keys</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lam et al, 2021 [20]</td>
<td>PD, cognition, fatigue</td>
<td>85</td>
<td>EDSS was most correlated with latency between key release ($r=0.407$, $P&lt;.001$). Overall, the release-release latency keystroke metric correlated the most with SDMT ($r=-0.553$ $P&lt;.01$).</td>
</tr>
<tr>
<td>Lam et al, 2022 [21]</td>
<td>PD, cognition</td>
<td>94</td>
<td>The keystroke features most responsive to changes in EDSS were emoji sentiment neutrality and word length, with AUCs&lt;sup&gt;p&lt;/sup&gt; of 0.79 and 0.72, respectively.</td>
</tr>
</tbody>
</table>

<sup>a</sup>MS: multiple sclerosis.  
<sup>b</sup>SDMT: Symbol Digit Modalities Test.  
<sup>c</sup>PD: physical disability.  
<sup>d</sup>PROs: patient-reported outcomes.  
<sup>e</sup>EDSS: Expanded Disability Status Scale.  
<sup>f</sup>Neuro-QoL: quality of life in neurological disorders.  
<sup>g</sup>Linear mixed effects estimate.  
<sup>h</sup>DSST: Digit Symbol Substitution Test.  
<sup>i</sup>T25FW: timed 25-foot walk.  
<sup>j</sup>2MWT: 2-minute walk test.  
<sup>k</sup>SDMT: smartphone SDMT.  
<sup>l</sup>9HPT: 9-Hole Peg Test.  
<sup>m</sup>MSFC: Multiple Sclerosis Functional Composite.  
<sup>n</sup>N/A: not available.  
<sup>o</sup>MFIS: Modified Fatigue Impact Scale.  
<sup>p</sup>AUCs: areas under the curves.

### App Review

Of the 18 identified apps, 5 had a remote testing function. Of the 5 apps with remote testing abilities, all tested for physical disability and fine motor skills. Assessment of motor skills was done through tapping tests as in BeCare and MS Care Connect; drawing a shape or following a path as in Floodlight, MS Care, and MS Copilot; or a 9HPT equivalent as in Neurons. With regard to disability, 1 app, BeCare, measured arm raises, while Floodlight measured pinch and thumb strength.

Visual symptoms were evaluated by 3 of the apps. This was done by contrast sensitivity tests and measured optokinetic nystagmus as in BeCare, color vision tests as in MS Care Connect, or low-contrast vision tests as in MS Copilot.

Cognitive testing was performed in all 5 apps: 4 apps (BeCare, Floodlight, MS Care Connect, and MS Copilot) used the SDMT; 2 apps used modified versions of recognized MS tests like the Paced Auditory and Visual Serial Addition Test as in Neurons and the Stroop test as in BeCare; and some apps used other tests like stacking donuts in ascending size on pegs, memorizing words and matching them to categories, and tapping blocks in a memorized sequence as in MS Care Connect or memorizing animals as in BeCare.

All 5 apps had measures of ambulation: 3 apps (BeCare, Neurons, and MS Care Connect) had the T25FW, and 2 apps had time-limited walk tests such as BeCare’s 6-minute walk test or Floodlight’s 2MWT. BeCare also measured the Timed Up and Go test. Floodlight implemented passive monitoring of daily ambulation, while MS Copilot measured maximum distance walked.

Only 1 app, Floodlight, had a dedicated static balance test. Another app, MS Care Connect, measured reaction time. The BeCare app measured the ability to discriminate between mobile
device vibration frequency. That same app also had an audio transcription test.

Symptom logging functions were found in 13 other apps, either through free-text entry or selecting within a list of suggested neurological symptoms. These are included in Table 4.

Table 4. Characteristics of included apps.

<table>
<thead>
<tr>
<th>App name</th>
<th>Platform</th>
<th>Developer</th>
<th>Brief description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aby</td>
<td>Both</td>
<td>Biogen Inc</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>Bearable - Symptom and Mood Tracker</td>
<td>GPS&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Bearable</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>BeCare MS Link</td>
<td>Both</td>
<td>BeCare Link LLC</td>
<td>Testing for PD&lt;sup&gt;c&lt;/sup&gt;, visual, cognitive, ambulation, mood</td>
</tr>
<tr>
<td>Emelyn: My MS Companion</td>
<td>Both</td>
<td>BreakthroughX Health GmbH</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>Floodlight&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Both</td>
<td>Roche SAS</td>
<td>Log MS symptoms; testing for PD, cognitive, balance, ambulation</td>
</tr>
<tr>
<td>Healthstories MS</td>
<td>AAS&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Jacob Wachsman</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>icompanion</td>
<td>Both</td>
<td>Icometrix Inc</td>
<td>Log MS symptoms, may perform prEDSS&lt;sup&gt;f&lt;/sup&gt; or Neuro-QoL&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Innov SEP</td>
<td>GPS</td>
<td>Mallouki Adil</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>MSAA-My MS Manager</td>
<td>AAS</td>
<td>At Point of Care, LLC</td>
<td>Log MS symptoms, generate MFIS&lt;sup&gt;h&lt;/sup&gt; score</td>
</tr>
<tr>
<td>MS Care Connect</td>
<td>GPS</td>
<td>InterPro Bioscience Inc</td>
<td>Log MS symptoms; testing for PD, cognitive, ambulation</td>
</tr>
<tr>
<td>MS Copilot&lt;sup&gt;d&lt;/sup&gt;</td>
<td>GPS</td>
<td>Ad Scientiam</td>
<td>Testing for PD, visual, cognitive, ambulation</td>
</tr>
<tr>
<td>MS Corner</td>
<td>GPS</td>
<td>Progentec Diagnostics</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>MS Notes Journal</td>
<td>GPS</td>
<td>Roger Hartley</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>MS Relapse Tool</td>
<td>Both</td>
<td>Darin Okuda</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>MS Relapse Tracker/MS Attack</td>
<td>AAS</td>
<td>Flavia Chapa</td>
<td>Log MS symptoms, relapse probability assessment</td>
</tr>
<tr>
<td>Multiple Sclerosis Manager</td>
<td>GPS&lt;sup&gt;f&lt;/sup&gt;</td>
<td>KingFishApps</td>
<td>Log MS symptoms</td>
</tr>
<tr>
<td>Multiple Sclerosis Messenger</td>
<td>GPS</td>
<td>KingFishApps</td>
<td>Log MS symptoms and may send to MS nurse</td>
</tr>
<tr>
<td>Neurons</td>
<td>AAS</td>
<td>shazino</td>
<td>Testing for PD, cognitive, ambulation</td>
</tr>
</tbody>
</table>

<sup>a</sup>MS: multiple sclerosis.
<sup>b</sup>GPS: Google Play Store.
<sup>c</sup>PD: physical disability.
<sup>d</sup>App found to have supporting literature in the scoping review of scientific evidence.
<sup>e</sup>AAS: Apple App Store.
<sup>f</sup>prEDSS: patient-reported Expanded Disability Status Scale.
<sup>g</sup>Neuro-QoL: quality of life in neurological disorders.
<sup>h</sup>MFIS: Modified Fatigue Impact Score.

**Discussion**

This review sought to evaluate and summarize available literature and apps assessing remote testing for persons with MS. Though well-designed studies evaluating concordance between app testing and the neurological exams do exist, many apps operate outside the realm of currently available scientific evidence.

**Comparison With Prior Work**

To the authors’ knowledge, this is the first scoping review with a specific focus on the use of apps for symptom monitoring and tracking clinical course in persons with MS. Previous reviews on this topic have employed a wider scope, examining all clinical trials with data pertaining to apps used in MS [6,7], while others narrowed the scope to apps used for self-assessment and rehabilitation [29] or to gait and postural control [30]. Of the 2 reviews with wider scopes, one was published in 2018 and predates all but one of the included articles [6], and the other included only 3 studies that focused on apps employing dexterity tests, accelerometers, or other sensing technologies [7].

**Principal Findings**

Many of the included studies demonstrated concordance between mobile testing for MS and various aspects of the neurological exam [11-13,15-23]. For example, the Adaptive Cognitive Evaluation, Elevate MS, EVO monitoring, Floodlight, MS Copilot, MS Suite, and NeuroKeys have all shown statistically significant correlations between the app and the physician’s
exam. The strongest correlation coefficients with standardized scales were seen with MS Copilot, when test results were pooled and compared with the MSFC [11]. However, pooled results did not have the same correlation strength with the EDSS. This may reflect the stronger similarities in the MS Copilot battery and the tests administered during the MSFC.

Although the EDSS remains an important aspect of the evaluation of persons with MS both in clinic and in the context of clinical trials, most apps seeking to correlate in-app testing with EDSS have obtained weak to moderate, albeit statistically significant, correlation coefficients [12,13,15,18,20]. The correlation coefficients were much greater with app-based e-diary scores [27]. This is notable, as the EDSS has previously been criticized for its poor assessments of upper limb and cognitive functions, which are 2 domains that are evaluated in most apps for which published data exists [31]. Additionally, the EDSS’s nonlinearity may make it more difficult for testing-based apps to correctly obtain the EDSS score based on quantitative data derived from app-based testing [32].

One advantage to app-based evaluation of persons with MS is that virtual tests can be performed by persons with MS with more significant disability. One study found that some persons with MS were unable to perform the 9HPT yet were able to participate in app-based testing [16]. That said, app-based testing may be an obstacle to those with MS-related visual impairment who rely on tactile sensations to complete the required testing.

In terms of feasibility, adherence rates to the apps were lower for apps requiring daily participation for extended periods and higher for apps with less frequent testing [24-26]. This would suggest that adherence would be higher for apps that require less frequent active participation from persons with MS. Thus, striking the optimal balance between participant engagement and the adequacy of remote monitoring becomes important.

The increased frequency of app-based testing, when compared with infrequent office testing, may improve certain test results due to repeated practice. Woelfle et al [14] demonstrated improvement related to practice effect in most of the tests that comprise the Floodlight testing battery, an app that allows users to perform tests daily or weekly; however, this practice effect was not observed with the 2MWT, which evaluates walking, an activity generally performed daily by those who remain ambulatory. Similar practice effects have been described for the MSFC [33]. Clinicians who plan to use app-based testing as part of their evaluation of persons with MS should be wary of these effects when interpreting results, as they may mask deterioration or feign clinical improvement. Where applicable, a possible mitigation strategy would be to use alternating versions of tests. No studies have yet determined the optimal testing interval to avoid practice effect–related improvement.

Data on local temperature and its impact on app-based test performance have shown that increasing temperatures correlate negatively with test scores [28]. As such, apps that monitor local temperature may offer additional insight to the MS specialist who may not consider this factor when evaluating persons with MS.

Although many apps designed to track symptoms in persons with MS are publicly available on app stores, only 10 apps were identified in our scoping review as having published evidence supporting their use.

**Limitations**

This scoping review is limited first by the relatively small number of included articles as well as the heterogeneity of included articles. This renders drawing generalized conclusions difficult given the limited number of studies and the different comparators. As more data become available with the growth of mobile health (mHealth), future reviews may be able to compare different testing metrics with more certainty. The second limitation relates to the rapid evolution of mHealth publications and app development. This is supported by the fact that two-thirds of the included articles were published within the last 2 years. At the time of its publication, this review may not reflect the most recent data available.

**Future Directions**

Future app developers may wish to include both objective measures of clinical status as well as patient-reported outcomes in order to aid the neurologist in evaluating persons with MS, especially if the app is to assess the EDSS. The mobile version of the SDMT correlated well with the traditional SDMT and could be included as a measure of cognitive decline. Although current research does not describe the optimal testing interval, app testing should be used sparingly to encourage participation and reduce the practice effect. Developers may also wish to include local weather data at time of testing to allow for contextualization of at-home results.

**Conclusion**

The current review serves as a summary of the existing apps designed for monitoring of persons with MS and their supporting literature. Current evidence demonstrates adequate convergence of app-based testing to traditional in-person assessment. Although persons with MS will likely always require the human interaction of in-person follow-up, apps may be used as an adjunct to these visits for patients who are unable to see their neurologist on a regular basis. Although many apps with remote testing abilities are available to the public, a minority have published evidence supporting their use. Several apps had unique beneficial features; however, there was a significant amount of redundancy. Most app-based tests had a focus on physical disability and cognition. There remains a need for a comprehensive validated app that combines both patient-reported outcomes and multiple types of remote testing to better understand and care for persons with MS.

**Acknowledgments**

This study was supported by the Centre de formation médicale du Nouveau-Brunswick, Moncton, New Brunswick, Canada.
Data Availability
The data sets generated during or analyzed during the current study are available in Multimedia Appendix 2.

Authors' Contributions
JBM authored the original draft of this scoping review. JBM and CP independently screened studies for inclusion criteria. EH, OC, and LCW provided critical feedback and helped shape the final version of the manuscript.

Conflicts of Interest
None declared.

Multimedia Appendix 1
Detailed search strategy.
[DOCX File, 15 KB - neuro_v2i1e37944_app1.docx ]

Multimedia Appendix 2
Data sets.
[XLSX File (Microsoft Excel File), 23 KB - neuro_v2i1e37944_app2.xlsx ]

References


Abbreviations

2MWT: 2-minute walk test
9HPT: 9-Hole Peg Test
DSST: Digit Symbol Substitution Test
EDSS: Expanded Disability Status Scale
mHealth: mobile health
MS: multiple sclerosis
MSFC: Multiple Sclerosis Functional Composite
Neuro-QoL: neurology quality of life
SDMT: Symbol Digit Modalities Test
SIGN: Scottish Intercollegiate Guidelines Network
sSDMT: smartphone SDMT
T25FW: timed 25-foot walk test

Edited by P Kubben; submitted 12.03.22; peer-reviewed by S El kefi, H Gandhi, H Mehdizadeh, M Tummalacherla, S Holm; comments to author 13.07.22; revised version received 06.09.22; accepted 30.12.22; published 06.02.23.

Please cite as:
Michaud JB, Penny C, Cull O, Hervet E, Chamard-Witkowski L
Remote Testing Apps for Multiple Sclerosis Patients: Scoping Review of Published Articles and Systematic Search and Review of Public Smartphone Apps
JMIR Neurotech 2023;2:e37944
URL: https://neuro.jmir.org/2023/1/e37944
doi: 10.2196/37944
PMID:

Agni Rajinikanth1*; Davis Kevin Clark2*; Marianna Evangelia Kapsetaki3, MD, MSc, PhD

1Rutgers Preparatory School, Somerset, NJ, United States
2St George's School, Vancouver, BC, Canada
3Faculty of Life Sciences, Division of Biosciences, University College London, London, United Kingdom

*these authors contributed equally

Corresponding Author:
Marianna Evangelia Kapsetaki, MD, MSc, PhD
Faculty of Life Sciences
Division of Biosciences
University College London
Gower Street
London, WC1E 6BT
United Kingdom
Phone: 44 07392970494
Email: marianna.kapsetaki.15@ucl.ac.uk

Abstract

Background: Tourette syndrome is a neurological disorder that is characterized by repeated unintentional physical movement and vocal sounds, better known as tics. Cases of mild Tourette can have tics numerous times throughout the day, while severe cases may have tics every 5 to 10 seconds. At certain times, typically during high levels of stress, tics become chained in an incessant, continuous fashion—this is known as a tic attack. Tic attacks incapacitate the patient, rendering it difficult for them to move, perform daily actions, and even communicate with others. Caretakers—usually guardians, family members, or nurses—can help reduce the time tic attacks last with their presence and by providing emotional support to the patient.

Objective: We describe TSBand, a wearable wristband that uses machine learning algorithms and a variety of sensors to monitor for tic attacks and notify caretakers when an attack occurs.

Methods: We conducted a research survey with 70 Tourette patients to determine the usability and functionality of TSBand; internal review board approval was not required.

Results: This study has resulted in a smart wristband prototype that costs US $62.74; it uses movement, heart rate, sweat, and body temperature to detect tic attacks using a hybrid local outlier factoring and regression algorithm. An audio tic attack detection mechanism is also included, using recurrent neural networks, and a manually activated backup button and backup audio mechanism are fitted to alert caretakers on the personalized companion app.

Conclusions: TSBand enables the caretaker to provide support faster and prevent excessive self-harm or injury during the attack. It is an affordable and effective solution, solving a problem that many Tourette patients, often children, face. This study has not had the opportunity to test TSBand with any Tourette patients, and we aim to perform rigorous testing and analysis after grant funding is secured.

(JMIR Neurotech 2023;2:e43351) doi:10.2196/43351

KEYWORDS
Tourette syndrome; neurological diseases; tic attacks; wearable technology; movement disorders; tremor monitoring; biosensing technology; automatic tic detection

https://neuro.jmir.org/2023/1/e43351
**Introduction**

**Background**

An estimated 350,000 to 450,000 children and adults in the United States alone have Tourette syndrome (TS), a neurological disorder that causes involuntary movements or vocal sounds known as tics, and about 1 million children and adults in the United States have other persistent tic disorders [1]. Tics are usually most prevalent in adolescents, and the severity of the disorder tends to decrease with age, making children with TS a community that needs medical and technological innovation. Research has shown that around 1% to 3% of children in mainstream schools are affected by TS [2]. Specific tics and their severity vary from person to person (eg, hand gestures vs whole-arm movements), but nearly all tics can be categorized as uncontrollable movements or audible noises. Specific tics can both develop and disappear at random. People who have TS often also experience symptoms of obsessive-compulsive disorder and attention deficit hyperactivity disorder in addition to tics [3].

Under certain situations of high stress or anxiety, a tic attack may occur, an event characterized by nonstop tics of higher severity that often incapacitate the physical motion and verbal communication of the patient. The frequency of tic attacks can range from occasional (less than once a month) to daily; attacks can vary dramatically from person to person, and they can last from a few minutes to several hours [4]. There is no cure for tics or tic attacks, but the severity of tic attacks can potentially be reduced by medications such as neuroleptics or fluphenazine [5]. Providing medicine and emotional support is typically the job of caretakers, such as parents, guardians, and nurses, but constant surveillance is not always possible.

**Product/Need**

Few products currently exist for patients with TS. There are some products designed to mitigate tics through slight electrical pulses, but these do not help solve the problem of detection and alerting someone for help. TS Band is a wearable wrist device that aims to automatically detect when a tic attack is occurring and then alert a nearby caretaker with a mobile notification. The device serves as a bridge between caretakers and patients, allowing those in need to receive help without physically needing to call for it. This can potentially decrease the span of a tic attack from hours to just a few minutes with help from the caretaker, limiting the time of struggle and the possibility of self-harm. This is helpful for adults but is especially helpful for children, who are more unexperienced with handling attacks, as caretakers can be notified instantly via TS Band and help the child by quickly practicing behavioral techniques to calm the child down, reducing the time of the attack. Additionally, studies have shown that medical technologies integrating mobile phones and wearable sensors need improvement and further scrutiny [6]. This paper proposes the development of TS Band to detect tic attacks and notify caretakers.

https://neuro.jmir.org/2023/1/e43351

Rajinikanth et al

**Methods**

**Sensors Used for Detection**

To facilitate the detection mechanism of the device, common patterns that people with TS usually exhibit must be analyzed. TS Band is equipped with a triaxial gyroscope and accelerometer, a pulse sensor, and a body temperature and humidity sensor. When tic attacks occur, patients usually exhibit uncontrollable and repetitive upper limb movement. The gyroscope and accelerometer help in providing data to perform the necessary computations to determine tic attacks from arm movement. The accelerometer is used to gather data on the speed and acceleration of the arm during tic attacks, while the gyroscope is used to provide information on roll, pitch, and yaw to account for the variation in angle and thus calculate the angular speed and acceleration. Furthermore, a microphone is used to assist with the detection and account for vocal tics as well (described in the Audio Analysis section).

In one previously published paper, researchers described a detailed clinical study showing that high blood pressure, stress, and an increased heart rate during tic attacks are all signs and symptoms commonly reported by patients with TS [7]. By using these vital signs in combination with movement, the tic detection algorithm can be enhanced for a higher degree of accuracy. To measure these factors and symptoms, TS Band includes a pulse sensor that actively measures the heart rate of the user. As temperature and sweat can increase because of both movement and stress, the body temperature and humidity sensor monitors for increasing fluctuations in these 2 vital signs. Combined, these sensors are used to detect changes in the vital signs of patients with TS and serve as another method to monitor for tic attacks.

**Machine Learning**

Because tics and tic attacks vary from person to person, the detection model cannot be generalized, rather, it needs to be custom-tailored to each individual. To monitor for and detect tic attacks, TS Band requires a 2-day calibration period in which the user’s movement patterns are stored to determine the tic patterns of the individual patient. The wristband will need to be worn both during the day and at night for calibration, as severe tics persist throughout the night and during sleep in some people. The device calibration is used primarily to detect the regular movement patterns of the user to determine a common baseline and allow the wristband to adapt to the unique baseline of the patient. There does not need to be any tic attack during the calibration period for the algorithm to work as intended; if there are any tic attacks, the algorithm will likely classify them as outliers based on the other data collected during this period. Using the local outlier factor (LOF) algorithm, TS Band separates tic attacks from normal, everyday movements. The variables that the LOF model analyzes are speed and acceleration; these were chosen because traditional models such as random forest and regression are less accurate at detecting tic attacks with these parameters. LOF models use a vast amount of data to form clusters and, when optimized, can be used to find outliers in the data set.
LOF uses unsupervised machine learning techniques that use the density distribution and standard deviation of data points to detect outliers in the data. Considering reachability distance and the density of the data values, TSBand uses a fine-tuned algorithm to limit the nearest neighbor’s parameter to ensure that clusters will not be formed near a tic attack, helping reduce the number of false positives:

\[ y = b_0 + b_1x_1 \]

Threshold Range: \(-43 \leq y' \leq 43\)

The algorithm uses this principle to determine whether vital signs such as stress, sweat, body temperature, and heart rate are increasing or are predicted to increase for the wristband bearer. This mechanism can be used to find general trends in vital signs that are clear indicators of tic attacks. The combined algorithms output a percentage that conveys the likeliness of a tic attack occurring. Although variations in heart rate, temperature, and humidity might signify an attack, these parameters are not always correlated with a tic attack, while movements are. To place greater emphasis on movement, 70% of the final prediction relies on this parameter, while the other values equally share the remaining 30%. These ratios are subject to change after refinement of the algorithms with patient testing:

\[ P_{Total} = 0.7P_{Movement} + 0.1P_{HeartRate} + 0.1P_{Temperature} + 0.1P_{Sweat/Humidity} \]

Once the probability of the total attack (\(P_{Total}\)) is calculated, any result over 80% will register an alert and notify the caretaker. When the threshold is passed for the linear regression models, the attack is considered “true” (ie, \(P_{Vital}=1\)), and the model will stop analyzing new data until the patient can confirm the attack is over on the mobile app or there has not been a tic attack registered (ie, \(P_{Total}>80\%\)) for an hour. When either of these conditions is met, the model will then assess the data from the last hour and continue monitoring new vital sign data from then on. The value of 80% for \(P_{Total}\) is a default value and can be changed manually by the caretaker and the patient to suit their specific needs through our companion mobile app. This feature was added in consideration of people who may not experience large fluctuations in health vital signs during tic attacks; however, the value should remain above 70% so as to not rely only on movement.

### Band Design and Schematics

The wristband has a sleek design to enhance the experience of the user. The band is powered using an ESP32 Wi-Fi chip (Espressif Systems), which is used to send data to a live-updated database hosted on Firebase (Google Inc). To program the ESP32, the Arduino C++ language was used. All the sensor data collected from the user are securely stored in Google’s real-time Firebase server, where the algorithms, hosted on Google Cloud, execute decisions and determine whether a tic attack is occurring. The wristband may also potentially be able to predict tic attacks before they occur. Although movement cannot be used as the sole factor for prediction because stress is often a precursor to tic attacks, increased heart rate and body temperature can potentially be used as a predictive mechanism. When a tic attack is detected, an alert is immediately sent to the caretaker’s phone through the companion mobile app. A buzzer is built into the band that sounds to act as an audio cue to notify the user that an alert has been sent.

A backup method exists in case a tic attack occurs but the algorithm does not detect the attack; this allows the user to manually send an alert to the caretaker. A button on the device can be pressed and held for 5 seconds to send a request to the caretaker for help. A potential issue with the button is that a user could develop a motor tic and press the button without the intention to call a caretaker for help. Therefore, the button must be held for 5 seconds to give the user time to reconsider the action and let go of the button if necessary. Additionally, a cancellation feature was implemented in case a faulty alert was sent for any reason. If the user notices the buzzer going off, they can press the button 3 times (or more) in the span of 1 second to cancel the request to the caretaker.

### Figures 1 and 2

Figures 1 and 2 show a computer-aided design model of the prototype, and Figure 3 displays the prototype being worn. Because of budget constraints, we were not able to scale down the size of our central processing unit, which is why wires can be seen coming out of the device in Figure 3.
Audio Analysis

Tics do not only occur in the form of motor movements—they can also appear as verbal noises. Vocal tics are common and words or specific phrases are typically blurted out at random moments. During tic attacks, patients with TS usually repeat those specific phrases or other sounds over a very short period. On the device, audio files obtained through a microphone are passed through a high-pass filter to limit background noise. By converting speech to text and analyzing patterns in speech over a certain time interval, the wristband is able to detect and process vocal tics. The model used to train the speech recognition software is a recurrent neural network model that uses a long short-term memory algorithm. The data were compared with the Google Speech data set and had an accuracy rate of 92%. To limit the amount of error in this trial, the algorithm was designed to listen for and catch the frequency of a specific word repeated over a period of 10 seconds. If the repetition occurs for a duration that is longer than average for the user, a notification is sent to the caretaker. This audio detection mechanism is independent of the physical detection mechanism; if one detects an attack while the other does not, an alert will still be sent.

Furthermore, a backup vocal alert system is also included in the band as a supplement to the audio analysis. Much like smart home devices such as Amazon Alexa or Google Home Mini, a prerecorded audio cue phrase can be set to instantly send an alert notification to the caretaker. For example, if the cue phrase is “notify TSBand,” a notification is sent to the caretaker alerting them of an ongoing attack any time the wristband detects this specific phrase. The phrase only needs to be said once, which is why it is important to pick a specific, uncommon phrase. This is intended for an absolute emergency backup case, such as when the automatic detection and repeated phrase detection fail and the backup button is not pressable due to an excessive number of tics that limit movement. There is potential that the...
user develops a regular verbal tic for this exact phrase, causing the alert to be triggered when there is no tic attack. Thus, the audio phrase that triggers the alert can be changed and prerecorded again through the mobile app to preserve the use of this feature. Again, the buzzer will sound to notify the user that an alert has been sent, and the cancellation feature is still valid in this scenario if it is necessary to cancel the request. The flowchart in Figure 4 summarizes the process. Figure 5 shows the vocalization diagram of the phrase “notify TSBand” in a signal diagram. Figure 6 shows the vocalization in a spectrum diagram. Figures 7 and 8 show the audio vocalization under a spectrogram and a mel spectrogram, respectively.

Figure 4. Flowchart diagram and schematics of the TSBand in operation. LOF: local outlier factor.
Figure 5. "Notify TSBand" vocalization signal diagram.

Figure 6. TSBand spectrum diagram.

Figure 7. TSBand spectrogram diagram.
Mobile App

TSBand has a companion mobile app to send notifications to caretakers. After downloading the app, a caretaker or a group of caretakers can pair with the wristband—this can be done as each band has a unique hash code associated with it that can be used to accurately pair up with the app. The app displays certain health vitals, namely heart rate and body temperature, and an audio monitor that shows the frequency of words and reports if there is anything abnormal. The value is shown as either “stable” or “unstable” depending on the count of the repetition of words (it is determined the same way as described in the Audio Analysis section). Heart rate and body temperature are read directly from Firebase and are displayed live on the app.

As shown in Figure 9, typical activity will result in the bar at the top showing the status “no issues.” If a tic attack is detected by the algorithm, a push notification (pop-up notification) will appear on the phone to alert the caretaker. Upon opening the app, as shown in Figure 10, the “no issues” bar at the bottom will have changed to the “possible attack” status. The app will not send any new push notifications on the phone while the status is “possible attack.” If the situation has been handled, the “possible attack” button can be pressed on the app to revert the status back to the normal “no issues” value, and at that point, the app will once again send push notifications in case another tic attack happens. Pressing this button will lead to the restart of the regression models.
Figure 9. Mobile app when tic attack is not occurring.

Figure 10. Mobile app when tic attack is occurring.
Additional Procedure
We have not yet had the opportunity to evaluate or test our device with physical participants or patients due to funding and time constraints. This paper focuses on introducing the technology behind the device and analyzes its potential introduction into the market. We have performed said analysis through a preliminary research survey to obtain perspective on the potential of the device. This survey—mainly consisting of questions inquiring about the personal experiences of tic attacks among patients with TS and asking for feedback and new features for the wristband—was filled out by 70 people with TS and is detailed in the sections below.

Ethical Considerations
The survey did not contain any questions that would induce physiological stress or anxiety and collected only nonsensitive data; thus, we did not need ethics approval. A link to the quantitative questions and results is available in the Data Availability section.

Table 1. Prototype cost structure.

<table>
<thead>
<tr>
<th>Components</th>
<th>Cost (US $)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESP32 feather</td>
<td>9.95</td>
</tr>
<tr>
<td>Pulse sensor</td>
<td>10.99</td>
</tr>
<tr>
<td>Humidity and temperature sensor (DHT11)</td>
<td>5.00</td>
</tr>
<tr>
<td>Gyroscope and accelerometer sensor (GY-521)</td>
<td>6.00</td>
</tr>
<tr>
<td>Audio microphone (AOM-5035L-HD3-R; PUI Audio)</td>
<td>4.45</td>
</tr>
<tr>
<td>Buzzer (WT-1614T; Soberton Inc)</td>
<td>1.25</td>
</tr>
<tr>
<td>Battery source (130 maH)</td>
<td>19.99</td>
</tr>
<tr>
<td>Velcro</td>
<td>0.11</td>
</tr>
<tr>
<td>3D printing</td>
<td>5.00</td>
</tr>
<tr>
<td>Total cost</td>
<td>62.74</td>
</tr>
</tbody>
</table>

Research Survey
The questionnaire was an online survey consisting of 11 questions, both qualitative and quantitative, directly addressing the TS community. The survey was a completely blinded review survey performed online on social media platforms that posed both quantitative and open-ended questions. To ensure anonymity and to abide by Health Insurance Portability and Accountability Act and the General Data Protection Regulation, data on the participants were not tracked so that responses would be more transparent. The collected data are held securely.

Survey Findings
Notably, 64 of 70 (91%) respondents said that they struggle to communicate with caretakers when having a tic attack, and 67 of 70 (96%) respondents believed that stress and anxiety are contributing causes of tic attacks. In qualitative responses, one common comment was that an alert could help bring forth a trusted caretaker who could help calm the patient down and ensure they do not cause self-harm. Some mentioned that the material of the wristband is also extremely important due to skin irritation that some face. In addition, the structural integrity of the band must be strong to ensure longevity and so the band does not break when exposed to movement during an attack. We found that 30 of 70 (43%) respondents believed that having a person near them would help them cope with the attack, while 13 of 70 (19%) respondents said it would only help if the figure was trusted. Overall, 53 of 70 (76%) respondents stated that such a device would be useful for them. Those who stated that the device would not be beneficial to them were adults who did not have caretakers or did not use medication, as their tic attacks were of shorter duration.

Discussion
Limitations
Certain limitations still exist with wristband detection. For example, it is difficult to differentiate exercise from a tic attack, as both include excessive movement of the body. If the machine-learning model is not trained with exercise data, it may consider simple tasks like running to be a tic attack, but if the model is trained with exercises like running, it may potentially consider a tic attack to be another aspect of a daily routine and...
not trigger an alert. A model trained without exercise would force the user to take off the wristband during physical activity and leave them vulnerable to a sudden tic attack with no automatic detection. Ideally, someone else would supervise them in this scenario, but adding measures such as the ability to turn off the automatic detection algorithm of the band while still keeping backup elements active would be optimal for users when exercising. Alternatively, if the model is trained with exercise, there is potential that with vast data on previous patterns of the patient and an exercise mode built into the wristband, the algorithm can stay powered on during activities like running and assess differences between tic attacks and exercise. Creating an exercise mode would need much experimentation and previous data on the user’s personal tic attacks to accurately differentiate between physical activity and tic attacks. We also recognize that the survey of 70 respondents does not represent the entire population of people with TS.

### Comparisons to Similar Wristbands

Similar studies have been conducted for tic movements and other tremors, such as those caused by Parkinson disease (Table 2).

#### Table 2. Comparison with similar wearable technologies.

<table>
<thead>
<tr>
<th>Paper</th>
<th>Project purpose</th>
<th>Measure of movement</th>
<th>Measure of vital signs</th>
<th>Recognition method</th>
<th>Audio analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>This paper</td>
<td>Monitor for and detect tic</td>
<td>Accelerometer, gyroscope</td>
<td>Heart rate, body temperature, sweat</td>
<td>Local outlier factor, regression,</td>
<td>Long short-term memory</td>
</tr>
<tr>
<td>Bernabei et al [8]</td>
<td>attacks</td>
<td></td>
<td></td>
<td>threshold</td>
<td></td>
</tr>
<tr>
<td>Fraiwan et al [9]</td>
<td>Detect tic movements</td>
<td>Accelerometer</td>
<td>None</td>
<td>Time variant threshold</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>tremors from regular</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>movement</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The most similar wristband to TSBand is the band developed by Bernabei et al [8], which uses a triaxial accelerometer to determine tic movements. It corroborates video analysis with the wristband data to detect tic activities, but it cannot detect tic attacks. Furthermore, it does not use any other factors, such as angular acceleration, vital signs fluctuations, or audio analysis to determine tic movements, and is not tailored to each individual that uses it. Kim et al [10] applied an inertial measurement unit on a worn device to differentiate typical daily movement from tremors in the upper limbs. Artificial tremors were generated, and the data were passed through statistical pattern recognition to determine if a reading was a tremor or standard activity. The studies conducted by Fraiwan et al [9] and Cole et al [11] both monitored for tremors in Parkinson patients, with the former using the accelerometer in a smartphone and the latter using a separate accelerometer sensor. Both used neural networks for the detection of tremors, but Cole et al also used surface electromyography for a higher rate of accuracy. The machine-learning techniques used in both studies were used only for tremor detection accuracy and did not incorporate customizability for individual patients, as all Parkinson tremors are quite similar. The machine learning models used in TSBand, however, are intended to adapt to each person’s unique tics and tic attacks for better detection purposes. This wristband serves as a complete solution that could immediately be used by those in need, with backup and emergency situations accounted for in its design. Because of the personalization TSBand provides, it could also potentially be used for similar conditions with similar symptoms, including myoclonus, tremors, chorea, athetosis, dystonia, akathisia movements, paroxysmal dyskinesias, and ballistic movements.

### Future Work

Initially, TSBand was designed to be a thin bracelet strapped around the wrist, but because the sensors took up a large amount of space, a storage compartment was added to hold them. However, this storage compartment now gives the potential to add a light emitting diode screen, among other options, on top of the compartment, which could be used to enhance the user experience. Based on survey responses, certain features could be added to the band and mobile app to improve user benefit. One common suggestion was a GPS system to determine the location of the attack to better notify the caretakers, as well as a screen on the wristband itself that shows how far away the caretaker is to give an estimate of how long it would take for them to arrive. Another feature was for the app to not only notify caretakers, but also inform teachers or coworkers that a tic attack is occurring. Several individuals who were students mentioned that they were embarrassed to raise their hands to tell teachers that they needed to leave the classroom during a tic attack, so this mechanism would effectively avoid said embarrassment by providing a tacit signal to the teacher that the user needs some time and space away from class to calm down.

We would like to test the current accuracy of the band among patients with TS to determine specific values for the regression model, see which areas need to be improved on, and understand how new features can be incorporated (eg, the exercise mode). A common request from the survey was a way to also send information on the severity of the attack so as not to worry the caretaker if the attack is only mild. Adding this would be extremely helpful but would require a great deal of testing and experimentation to measure severity. We are also looking to
enhance our algorithm to potentially predict tic attacks before they occur based on previous behavior patterns and also scale down the size and cost of TSBand through a custom-printed circuit board to fit better on the wrist. In terms of sensors, upgrading the hand to include more accurate and precise sensors, such as galvanic skin response and blood pressure sensors, would allow it to detect tic attacks more effectively and accurately. We filed a provisional patent with the United States Patent and Trademark Office on October 8, 2022, and we hope to finalize these upgrades and finish conducting this research by September 2023.

Conclusion
In this work, machine learning and audio analysis are used to detect tic attacks. LOF is used to individualize the detection process, with a regression model used to ensure greater accuracy. To reiterate, we were not able to test these machine learning components with actual patients due to funding and other concerns; we aim to do this in the future. Audio analysis is used to check for repeated phrases over a time interval to detect vocal tics. In addition to these features, we also have an emergency audio backup method along with our standard backup button. A recurrent neural network was trained on a Google Speech data set to obtain a 92% speech accuracy rate. Within the next year, we hope to add new features, scale down the size of the device, add new sensors, and test the wristband among patients with TS. We conducted a survey involving 70 participants with TS to gather data on commonalities in tic attacks, the efficacy of having a caretaker nearby, and qualitative feedback to help determine limitations and solicit suggestions on the development of the wristband. The benefit of a platform that connects patients at risk with caretakers is not limited to those with TS. The elderly or people at risk of seizures can benefit from having an alert automatically sent to a caretaker when they are not able to physically move or request help themselves. Any person that requires an easy method of requesting assistance can use this wristband and receive help faster. This wristband has vast potential and can not only be applied to TS but used in many different fields of health care and for patient treatment.

Acknowledgments
We would like to thank the individuals who completed our survey.

Data Availability
The data sets generated during and/or analyzed during this study are available in the Open Science Framework repository [12].

Conflicts of Interest
DKC, AR, and MEK were involved in the production and development of software and hardware for the device and filed a provisional patent with the United States Patent and Trademark Office on October 8, 2022.

References

12. Tourette's. OSF. URL: https://osf.io/c3qp6/?view_only=2e3a16e650ee42cf8e1b63daae5102f0 [accessed 2023-04-10]

**Abbreviations**

GDPR: General Data Protection Regulation  
HIPAA: Health Insurance Portability and Accountability Act  
LOF: local outlier factor  
TS: Tourette syndrome

---

©Agni Rajinikanth, Davis Kevin Clark, Marianna Evangelia Kapsetaki. Originally published in JMIR Neurotechnology (https://neuro.jmir.org), 25.04.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Neurotechnology, is properly cited. The complete bibliographic information, a link to the original publication on https://neuro.jmir.org, as well as this copyright and license information must be included.
A Digital Telehealth System to Compute Myasthenia Gravis Core Examination Metrics: Exploratory Cohort Study

Marc Garbey\textsuperscript{1,2,3,4}, PhD; Guillaume Joerger\textsuperscript{2,4}, PhD; Quentin Lesport\textsuperscript{1,3,4}, MSc; Helen Girma\textsuperscript{5}, BS; Sienna McNett\textsuperscript{5}, BS; Mohammad Abu-Rub\textsuperscript{5}, BS; Henry Kaminski\textsuperscript{5}, MD

\textsuperscript{1}Department of Surgery, School of Medicine & Health Sciences, George Washington University, Washington, DC, United States
\textsuperscript{2}ORintelligence LLC, Houston, TX, United States
\textsuperscript{3}Laboratoire des Sciences de l'Ingénieur pour l'Environnement (LaSIE UMR-CNRS 7356), University of La Rochelle, La Rochelle, France
\textsuperscript{4}Care Constitution Corporation, Washington, DC, United States
\textsuperscript{5}Department of Neurology & Rehabilitation Medicine, School of Medicine & Health Sciences, George Washington University, Washington, DC, United States

Corresponding Author:
Marc Garbey, PhD
Department of Surgery
School of Medicine & Health Sciences
George Washington University
2120 L St NW
Washington, DC, 20037
United States
Phone: 1 2815363178
Email: garbeymarc@gmail.com

Abstract

**Background:** Telemedicine practice for neurological diseases has grown significantly during the COVID-19 pandemic. Telemedicine offers an opportunity to assess digitalization of examinations and enhances access to modern computer vision and artificial intelligence processing to annotate and quantify examinations in a consistent and reproducible manner. The Myasthenia Gravis Core Examination (MG-CE) has been recommended for the telemedicine evaluation of patients with myasthenia gravis.

**Objective:** We aimed to assess the ability to take accurate and robust measurements during the examination, which would allow improvement in workflow efficiency by making the data acquisition and analytics fully automatic and thereby limit the potential for observation bias.

**Methods:** We used Zoom (Zoom Video Communications) videos of patients with myasthenia gravis undergoing the MG-CE. The core examination tests required 2 broad categories of processing. First, computer vision algorithms were used to analyze videos with a focus on eye or body motions. Second, for the assessment of examinations involving vocalization, a different category of signal processing methods was required. In this way, we provide an algorithm toolbox to assist clinicians with the MG-CE. We used a data set of 6 patients recorded during 2 sessions.

**Results:** Digitalization and control of quality of the core examination are advantageous and let the medical examiner concentrate on the patient instead of managing the logistics of the test. This approach showed the possibility of standardized data acquisition during telehealth sessions and provided real-time feedback on the quality of the metrics the medical doctor is assessing. Overall, our new telehealth platform showed submillimeter accuracy for ptosis and eye motion. In addition, the method showed good results in monitoring muscle weakness, demonstrating that continuous analysis is likely superior to pre-exercise and postexercise subjective assessment.

**Conclusions:** We demonstrated the ability to objectively quantitate the MG-CE. Our results indicate that the MG-CE should be revisited to consider some of the new metrics that our algorithm identified. We provide a proof of concept involving the MG-CE, but the method and tools developed can be applied to many neurological disorders and have great potential to improve clinical care.

*(JMIR Neurotech 2023;2:e43387)* doi:10.2196/43387
KEYWORDS

telehealth; telemedicine; myasthenia gravis; ptosis; diplopia; deep learning; computer vision; eyes tracking; neurological disease

Introduction

With the COVID-19 pandemic, there was a rapid increase in the use of telemedicine in routine patient care [1] and in clinical trials that moved to video evaluations to maintain subject follow-up [2]. Telemedicine was already commonly used for acute stroke care and was in development for Parkinson disease, but the vast majority of neurologists were not using such approaches and were suddenly thrust into unfamiliar territory [3-5]. Diagnosis and monitoring of neuromuscular disorders, in particular, rely on a nuanced physical examination, and specialists would be particularly reticent to use telemedicine. However, telemedicine has great potential to provide improved assessment of aspects of neurological examinations, and facilitate patient monitoring and their education [6], while reducing patient burden in attending in-person clinic visits and potentially increasing access. Further, there is great potential for rigorous video assessment to enhance clinical trial performance, which could reduce the burden on study participants and thereby enhance recruitment and retention.

The Myasthenia Gravis Core Examination (MG-CE) [7] was recommended for telemedicine evaluation of patients with myasthenia gravis (MG), and it involves specific aspects of neurological examinations critical to the comprehensive assessment of patients with MG. The National Institutes of Health Rare Disease Clinical Research Network dedicated to MG, MGNet, initiated an evaluation to assess the feasibility and validity of MG-CE for use in future clinical trials. These assessments were video recorded using the software Zoom (Zoom Video Communications), and we used the evaluations performed at George Washington University with the following 2 objectives: (1) assess workflow efficiency by making the data acquisition and analytics fully automatic and (2) evaluate the potential to quantitate the evaluations.

Methods

MG-CE and Automatic Data Acquisition

The study used recorded telemedicine evaluations of individuals with a clinical- and laboratory-confirmed diagnosis of MG. The patients were provided instructions regarding their position in relation to the cameras and level of illumination, and were told to follow the examiner’s instructions. We used videos of 6 subjects recorded twice within 7 days to develop our algorithms. One normal control subject was used to evaluate the methodology prior to evaluating MG subject videos.

The MG-CE is summarized in Table 1, and a full description has been provided previously [7]. The examination required 2 broad categories of processing: (1) the computer vision algorithm to analyze video focusing on eye or body motions and (2) the analysis of the voice signal, which requires a completely different category of signal processing methods. We describe successively each of the techniques used in these categories and summarize the digitalization process in Table 2.

Table 1. Myasthenia Gravis Core Examination exercises and evaluation metrics [7].

<table>
<thead>
<tr>
<th>Variable</th>
<th>Normal (0)</th>
<th>Mild (1)</th>
<th>Moderate (2)</th>
<th>Severe (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyelid droop (ptosis)</td>
<td>No ptosis</td>
<td>Eyelid above the pupil</td>
<td>Eyelid at the pupil</td>
<td>Eyelid below the pupil</td>
</tr>
<tr>
<td>Double vision (right/left)</td>
<td>No diplopia with a gaze of 61 seconds</td>
<td>Diplopia with a gaze of 11-60 seconds</td>
<td>Diplopia with a gaze of 1-10 seconds</td>
<td>Immediate diplopia</td>
</tr>
<tr>
<td>Cheek puff</td>
<td>Normal “seal”</td>
<td>Transverse pucker</td>
<td>Opposes lips but air escapes</td>
<td>Cannot perform the exercise</td>
</tr>
<tr>
<td>Tongue to cheek</td>
<td>Normal: full convex deformity in the cheek</td>
<td>Partial convex deformity in the cheek</td>
<td>Able to move the tongue to the cheek, but no deformity</td>
<td>Cannot perform the exercise</td>
</tr>
<tr>
<td>Counting to 50</td>
<td>No dysarthria at 50</td>
<td>Dysarthria at 30-49</td>
<td>Dysarthria at 10-29</td>
<td>Dysarthria at 1-9</td>
</tr>
<tr>
<td>Arm strength</td>
<td>No drift for &gt;120 seconds</td>
<td>Drift at 90-119 seconds</td>
<td>Drift at 10-89 seconds</td>
<td>Drift at 0-9 seconds</td>
</tr>
<tr>
<td>Sit-to-stand maneuver</td>
<td>No difficulty</td>
<td>Slow with effort but no hands</td>
<td>Need to use hands</td>
<td>Unable to stand unassisted</td>
</tr>
</tbody>
</table>
Table 2. Summary of our algorithm tool box to assist the clinician with the Myasthenia Gravis Core Examination.

<table>
<thead>
<tr>
<th>Exercise</th>
<th>Description</th>
<th>Observation</th>
<th>Metric</th>
<th>Digital tool</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pupil</td>
<td>Patients hold their gaze up for 60 seconds.</td>
<td>Weakness of the upper eyelid and eyelid going above the pupil.</td>
<td>Distance between the eyelid and the pupil, and distance between the upper and lower eyelids.</td>
<td>High-definition camera and eye segmentation.</td>
</tr>
<tr>
<td>Double vision</td>
<td>Patients hold their gaze right and then left for 60 seconds.</td>
<td>Misalignment of the eyes and moment of double vision.</td>
<td>Track the distance between anatomic landmarks such as the upper/lower lid, and pupil and iris left and right boundaries.</td>
<td>High-definition camera and eye segmentation.</td>
</tr>
<tr>
<td>Cheek puff</td>
<td>Patients puff their cheeks and hold it.</td>
<td>• Assess muscle strength and fatigability.</td>
<td>• Track face feature variation, mouth curvature, and dimension in particular.</td>
<td>• Depth camera or Lidar.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Extent of puffiness at baseline and versus external pressure placed on the cheeks.</td>
<td>• Symmetry of cheek puff (left vs right).</td>
<td>• High-definition camera with face landmark monitoring.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Track face feature variation, mouth curvature, dimension, and orientation in particular.</td>
<td></td>
<td>• Track change of illumination in the region of interest.</td>
</tr>
<tr>
<td>Counting to 50</td>
<td>Patients count out loud from 1 to 50.</td>
<td>Assess for respiratory muscle fatigue and shortness of breath.</td>
<td>• Loudness of the voice.</td>
<td>Lip tracking and sound analysis of the exercise clip.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Various types of spectral analysis of the voice and mouth motion.</td>
<td>• Energy metric of the voice.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Track body pose and different angles.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Length of time the patient can hold the arm in the pose.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Trajectory of the arm over time.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm strength</td>
<td>Patients hold their arms straight.</td>
<td>Assess for muscle fatigue via sustained abduction of the arm.</td>
<td>Pose detection on high-definition images.</td>
<td>Pose detection on high-definition images.</td>
</tr>
<tr>
<td>Sit-to-stand maneuver</td>
<td>Patients stand up with and without crossing their arms.</td>
<td>Assess for muscle fatigue.</td>
<td>Body pose tracking.</td>
<td>Pose detection on high-definition images.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Ability of the patient to stand without using the arms for assistance.</td>
<td>Compare standing up speed between clips.</td>
<td></td>
</tr>
</tbody>
</table>

Deep Learning and Computer Vision Analysis

**Machine Learning to Track Body Landmarks and Face Landmarks**

Tracking faces or all body motions has become a standard tool [8] thanks to publicly available deep learning libraries with a standard model (Figure 1). To track body positions during the test of arm position fatigue and the sit-to-stand maneuver (Figure 1), we used a deep learning model that is publicly available (the pretrained machine learning model BlazePose GHUM 3D from MediaPipe) (Figure 1) [9]. For eye detection, we first needed to localize the face in the video frame.

Among the most commonly used algorithms [10,11], we chose OpenCV’s implementation of the Haar Cascade algorithm [12], based on the detector from Lienhart et al [13]. Our criteria to select the method were speed and reliability for real-time detection.
To focus on the regions of interest (ROIs) of the eyes and lids, we used the pretrained DLib 68 points facial landmark detector that is based on the shape regression approach [14,15]. It is a machine learning algorithm that places 68 characteristic points on a detected face. The model is pretrained on the I-BUG 300-W data set, which is comprised of 300 face pictures (Figure 1) [16]. This software was used for the assessment of ptosis and eye position, as well as for the test of counting to 50 and the single-breath test in order to document lip reading and tracking of jaw motion (Table 1).

Overall, both libraries provided robust results and could be used to annotate the video in real time for the ROIs. However, we found that the accuracy of the landmark points in the model of Figure 1 obtained by this library was not adequate to provide metrics that could be used in eye motion assessment in the context of a standard telehealth session. Therefore, we developed a hybrid method that began from deep learning to identify the ROIs and refine the search for the pupil, eyelid, and iris as described next.

**Eye and Lid Image Segmentation**

Assessment of ptosis and ocular motility requires precise tracking of the eyelid, pupil, and iris. Precise metrics of these measures have been developed [17-20]. Established techniques to detect the iris location [21] are the circular Hough transform [22] and the Daughman algorithm method [23]. However, we found that these methods lack robustness due to their insensitivity to the low resolution of the ROIs of the eyes, poor control for illumination of the subject, and specific eye geometry consequent to ptosis. The eye image in a standard Zoom meeting may not be bigger than about 40 pixels wide and 20 pixels high. Liu et al [24] assessed eye movements for a computer-aided examination, but with highly controlled data and a highly controlled environment. We did not have optimum control of telehealth footage with patients at home, and the eye region has only one-tenth, at best, of the image frame dimension. Therefore, we took a more versatile approach that began with the ROI given by the previous deep learning library that we had used and then concentrated on a local search of the iris boundary, pupil center, and upper/lower eyelid (Figure 2). Since we started from a good estimate of the ROI for the eye, we used a combination of a local gradient method and clustering technique to compute the spatial coordinate and distance between landmarks of interest, and we have described this in the Results section. There are 2 classes of assessment depending on whether we compute the geometric dimension on an individual image or the dynamic of eye motion on video clips. We retrieved, for example, the relaxation time of the eyelid versus equilibrium, with some of the patients performing both eye exercises (Figure 2). However, there is no mention of such a metric in the core examination [11]. The incorporation of this new information in the standard core remains to be determined.

**Figure 2.** Approximations on ptosis to assess the field of view: distance between the upper and lower eye lids (left), eye area opening (center), and distance from the upper lid to the pupil (right).
Body Image Segmentation

To have reproducible results with the entire view of the body during the examination, we tested our telehealth platform Inteleclinic on 1 patient and several control subjects. The pretrained machine learning model BlazePose GHUM 3D from MediaPipe [9] has been evaluated extensively, so we only provide some examples of the results obtained with the MG-CE. The arms of the patient are extended for 2 minutes during the exercise, and we used the segments joining the landmark point (12) to (14) to track the right arm position and the landmark point (11) to (13) to track the left arm position (Figure 1B). We computed the angle formed by the arm’s segment as described above and the horizontal line going through the landmark points (11) and (12) of the upper torso in the model (Figure 1B). If the arms stay horizontal, the 2 angles we track for the model (Figure 1B) should be approximately zero. As the arm strength of the patient may fatigue during the exercise, the arms fall from the horizontal position, and the angle would decrease and become negative. A similar approach was used for the sit-to-stand exercise by tracking the hip landmarks (23) and (24) of the body motion model (Figure 1B).

Cheek Deformation

The ROI for cheek deformation was the polygon delimited by points (3), (15), (13), and (5) of model 1 (Figure 1A) for the cheek puff exercise. We could restrict this ROI to one half of the polygon for the tongue-to-cheek push exercise that is only performed on one side. As we aimed to reconstruct the local curvature of the cheek during the test involving (3) and (4) that can lead to cheek deformation, we used a depth camera and computed the depth map to assess the contour of the deformation in the ROI. When it came to the depth map, our first approach was to use a depth camera that could directly reconstruct the local curvature of the surface seen. The depth camera Intel Realsense D435 (Intel) has, according to the vendor, a relative accuracy below 2% for a distance less than 2 meters. This technology uses infrared and stereo cameras to analyze the deformation of a projected pattern of a scene and reconstruct from this information the depth, but requires camera calibration [25-28]. All tests were performed in realistic conditions for telehealth, that is, the distance of the face from the camera was 1 meter at minimum and the patient was directly facing the camera.

The second approach we used was to assess a pure computer vision technique that works on a standard video. Our objective was to define basic information regarding when the cheek deformation starts, when it ends, and how it may become weaker during the examination period. In practice, this is what the medical doctor may grade during a telehealth consultation.

The first solution exploits the local skin appearance alterations as the cheek becomes dilated [29]. We could then compute the ROI “centered” on the cheek area where we expect the deformation to be most significant and the average pixel value of the blue dimension of the RGB code. To track the ROI, we used the mouth location and external boundary of the cheek that can be recovered from the model (Figure 1A). We could then track the average value over time during the exercise, that is, before the push to its end. We show in the Results section the limitation of this method that is a priori not robust with respect to light conditions and may depend on skin color.

The second solution is based on the observation that cheek deformation impacts the mouth geometry. For example, in the cheek puff exercise, the mouth is closed and invariably the lip shape features change from those in the rest position. In the one-side tongue-to-cheek push, the upper lip is deformed. All these changes can be monitored in time easily by tracking the relative position of the points in the facial model that mark the mouth (Figure 1A).

We describe our computer vision methods based on an analysis performed with 3 different formats of videos. The first was acquired with our new telehealth platform using a high-definition camera with a patient who has a normal cheek puff response. The second was acquired on a control subject with a cell phone camera (Apple 13 system, Apple Inc), and the third was extracted from the MGNet data set. We tested the impact of diversity with White subjects, subjects with dark suntan, and subjects who were African American. We demonstrate in the Results section which metrics appeared to provide the best assessment.

Voice Analysis

Our goal was to assess breathing and change in speech in patients with MG from analyzing counting to 50 and single-breath count. Dysarthria is not a simple concept and is classified in several ways [30]. Shortness of breath was easier to define but could be compromised by multiple factors. Shortness of breath and pulmonary function can be assessed from speech as appreciated by others [29,31]. Previous studies have used machine learning and artificial intelligence (AI) techniques that require large training sets, and they are not specific to any neurological disorder or specific to a voice acquisition protocol.

A good example of dysarthria detection has been published previously [32]. The rate of success of a neural network is modest, that is, about 70% when competing with standard diagnostic performance. An alternative solution is to use a fractal feature as reported previously [33]. This methodology seems to reach a greater accuracy of about 90% and does not require a training set.

Lip and jaw movements are related to dysarthria [34]. We are not aware of any systematic study that combines automatic lip motion tracking and speech digital analysis to assess breathing and dysarthria in patients with MG. We assessed more than half a dozen algorithms producing various sound metrics to check for the potential best voice analysis candidate to assess MG patients. As the analysis of the pitch of voice did not show any outliers in the data set and the energy metric analysis was impacted by the environment and control of the exercise, we restricted the description to the most promising algorithm. To compute voice features, we used the following steps. We separated the interval of time when the subject spoke from when the subject was silent. We used the MATLAB function “detectSpeech” [35] on the original signal. The function “detectSpeech” provides the start and end times of each so called “speech segment.” The frequency of signal acquisition was...
about 1000 Hz. For comparison, we used our own custom-made algorithm to extract speech segments using sampling of size 60 of the voice signal. The signal now had an equivalent frequency of acquisition of about 17 Hz. We then used averaging on each sample of the original signal to dampen noise. The signal was then smoother, and we could use a threshold to filter out noise without building up a large number of small gaps corresponding to “no sound.” We looked in the sound track of “counting to 50” exercises for the largest 50 time intervals of sound above noise level. All voice features presented below were computed on the sound track that contained speech only.

We present below the list of voice features we computed systematically for each of the sound tracks for both voice exercises. All these individual metrics or combinations of metrics were candidates to grade the severity of symptoms. The Results section reports which metric worked the best. The features are as follows:

• Loudness of voice: Loudness was computed based on the algorithms defined in the ITU-R BS.1770-4 and EBU R 128 standards. The loudness of voice was integrated over all speech segments.
• Pitch or fundamental frequency of voice: The pitch was computed for each speech segment. The speech of a typical adult man will have a fundamental frequency from 85 Hz to 155 Hz and that of a typical adult woman will have a fundamental frequency from 165 Hz to 255 Hz.
• Spectral energy on a frequency interval: Both voice exercises were considered as breathing exercises, so we computed the L2 norm spectral energy of the voice signal over all speech segments in a frequency window that focused on the breathing rate (5 Hz to 25 Hz).
• Teager-Kaiser energy: It was used in tone detection [36].
• Spectral entropy of the voice signal: Spectral entropy is a measure of spectral power distribution. Spectral entropy’s concept is based on Shannon entropy or information entropy. Spectral entropy treats the signal’s normalized power distribution in the frequency domain as a probability distribution and calculates the Shannon entropy of it. The Shannon entropy has been used for feature extraction in fault detection and diagnosis [37,38]. Spectral entropy has also been widely used as a feature in speech recognition [39] and biomedical signal processing [40].
• Special feature of the single-breath count: The airflow volume expansion during speech is in first approximation related to the square of the amplitude of the sound wave [41]. We computed the integral of the square of the amplitude of the sound wave during the time window of the patient’s speech. Since there is no calibration of the microphone, the metric might be biased. There was considerable variability of diction during this exercise. Some subjects counted more slowly, while others appeared anxious and pronounced words quickly. We computed as an additional feature the percentage of time with vocal sound versus total time.

For the voice analysis test in particular and for tests in general, there was significant variability in the parameters of data acquisition under clinical conditions, such as sound level. Providing guidance in real time to the patient will be essential to improve the ability to quantitate the telehealth examination.

The Need for a Novel Telehealth Platform to Support the Protocol and Improvement of Data Acquisition

Reproducibility requires that the various examinations are run in similar conditions. While we have mainly evaluated our algorithms on an existing data set of standard Zoom video evaluations with 6 patients, we next describe our new hardware and software solution named “Inteleclinic” (Figure 3) designed to improve data acquisition.
Figure 3. View on the patient side of our cyber-physical system named “Inteleclinic” used to uniformize the sessions and improve the quality of the metrics. HD: high-definition.

Controlling the Setting and Hardware
To avoid changes in the quality of the recording (frames and audio), it is important that the hardware used is identical for all sessions and is calibrated. In an attempt to improve the quality of data acquisition with the future development of clinical studies, we built a new telehealth system with a high-definition camera and microphone that can be controlled remotely by the examiner. The recording is now performed on the patient side to obtain the raw footage of the video and audio in order to optimize maximum resolution and avoid any issues with network connection quality during the examination. Different interfaces and tools are added compared to Zoom’s control system to assist the patient and the doctor to focus on the consultation and not the technology. We demonstrate in the Results section the benefits of Inteleclinic compared to a standard Zoom video call of a patient at home using various technologies.

Controlling Time
Some of the tests, such as lid and eye positions as well as arm position, require precise timing from start to end. To avoid any manual entry errors, our digital health system automatically computes start and end times. The single-breath test as practiced now has no control on loudness and timing. Breath capacity is the product of the air outflow flux and the duration of the exercise. To be more precise, breath capacity is the time integration of the time-dependent output flow on the time interval of the exercise. We found that the maximum number counted is weakly correlated with the duration of the counting exercise. The maximum number reached is dependent on diction and may not be used as a valuable metric. Outflow during speech is proportional in the first approximation to the square of the energy source of sound [41]. Depending on how loud the count is, one may expect different airflow output values for the patient. We tested on our platform a visual aid on the telehealth display to guide patient counting with a consistent rhythm of about 1 number counted per second in both the count to 50 and single-breath counting exercises.

Controlling the Framing of the ROI and the Distance From the ROI to the Camera
The digitalization of the tests involving ptosis, diplopia, cheek puff, tongue to cheek, arm strength, and sit-to-stand movement depends heavily on vision through the telehealth system. While we used a standard Zoom video that was preregistered in this study, it is straightforward with our system to provide guidance on the quality of video acquisition to make sure that distance between landmarks of interest use approximately the same number of pixels in order to provide quality and consistency for the results. In practice, we can provide a mark on the display of the patient with Inteleclinic to make sure the individual is properly centered and distanced from the camera.
Controlling Sounds

Every telehealth session may have different loudness of the sound track depending on the microphone setting and how loud or how soft the patient is speaking. Loudness is computed based on the algorithms defined in the ITU-R BS.1770-4 and EBU R 128 standards. If the microphone is calibrated with a benchmark sound, the loudness of the sound track can be computed continuously and guidance can be provided to the patient on how loud or soft they should try to keep their voice during the exercises.

Ethics Approval

All participants provided written consent for inclusion in the study. The study that provided the data has been approved by the George Washington University Institutional Review Board (IRB# NCR224008).

Results

Standardization of the Data Acquisition

We evaluated our methods and identified large variability in the data acquisition and mode of operation for the assessments performed by the single examiner. The purpose of the primary study from which we obtained the videos was to assess test/retest variability and interexaminer variation in performance of telemedicine evaluations (manuscript in preparation). Our goal was to assess accurate and robust measurements from the MG-CE in order to remove human bias. The videos from the clinical study are quickly showing some limitations as the hardware used to film was not identical and the recording was performed on the doctor side, linking the quality of the frames to the quality of the network on both sides. We will next present our methodology and the platform. One of the purposes of our project was to standardize the data acquisition during the telehealth session and provide real-time feedback of the quality of the assessments for the examiner.

Eyelid Position and Eye Movements

We have used a data set of images of 6 patients and 3 healthy subjects with broad diversity in skin color, eye color, ocular anatomy, and image frame resolution to test the accuracy of our approach. We identified 72 ROIs of patients’ eye movements and then annotated them with ground true measures obtained by manually zooming in the computer images. On average, we found the pupil location within 3 pixels and the distance from the pupil to the upper eyelid within 2 pixels independent of the image frame resolution. The relative accuracy in pixels was independent of the camera used. The standard Zoom video has 450×800 pixels per frame, a smartphone has 720×1280 pixels, and the Lumens B30U PTZ camera (Lumens Digital Optics Inc) has a resolution of 1080×1920. Overall, Inteleclinic doubles the resolution of a standard Zoom call and provides a submillimeter accuracy of lid position and eye motion. Figure 4 provides an example of the localization of the upper lid, lower lid, and iris lower boundary detected automatically with our hybrid method using digital zooming of the face of the patient with both ROIs. We underline that the patient is sitting about 1 meter from the camera during the telehealth eye exercises, and one can see the patient’s face and shoulders. No particular effort was made to focus on the eyes of the patient in the video. The 6 red circles in each eye correspond to the markers of the ROI obtained with the deep learning library of model 1 (Figure 1A). The bottom markers are slightly off, and our local computer vision technique provides the ability to correct the position of the lower lid.

In Figure 5, we show tracking of the distance between the lower boundary of the iris and the upper lid with a black curve, and the distance between the bottom of the iris and the lower lid with a red curve. One can check that the patient performs the exercise properly and can measure a 15% decay of the ptosis distance during the 1-minute exercise. As shown in the green least square fit with the green line, this decay is both linear and statistically significant. This decay is in fact difficult to notice during a medical examination without our method.

In Figure 6, we report on the second exercise that tests diplopia. The red circle locations of the deep learning model of Figure 1A in the ROIs are accurate. We tracked the vertical border of the iris and computed the barycentric coordinate of the most inner points of the boundaries to compute any eventual misalignment of both eyes. The patient did not report double vision, and the quasisteady variation of the barycentric coordinates, as reported in Figure 7, confirmed this. However, the positions of the eyes of patients might be so extreme that some of the pupils might be partially obstructed during the exercise, which limits the value of the conclusion. In addition, we clearly observed ptosis during the exercise as the vertical dimension of the eye opening reached about half of what it was during the ptosis exercise.
Figure 4. Image during the ptosis exercise. Digital zoom on the view of the patient obtained with the Inteleclinic system showing anatomic markers obtained by computer vision in green, starting from the landmarks of the regions of interest obtained by deep learning.

Figure 5. Graphic representation of the distance between anatomic landmarks to assess ptosis dynamically during the first eye exercise.
Figure 6. Image during the diplopia exercise. Digital zoom on the view of the patient obtained with the Inteleclinic system showing anatomic markers obtained by computer vision in green, starting from the landmarks of the regions of interest obtained by deep learning.

Figure 7. Graphic representation of the bariatric coordinate of the anatomic landmarks used to assess eye alignment dynamically during the third eye exercise.
Cheek Puff and Tongue to Cheek

We used a low-cost depth camera from Intel to reconstruct the local curvature of the cheek in laboratory conditions with a healthy subject who produced a large deformation, which was at the noise level of the signal. This evaluation would have failed for any patient who has difficulty to push the tongue into the cheek. Better depth accuracy could be obtained by sensors that use time-of-flight technology [42].

The variety of videos demonstrates the limits and potential of our approach. In one video of the cheek puff exercise, the patient was told to blow his cheeks for about 2 seconds. The video was cut after 15 seconds because the patient was asked to test the stiffness of the skin with his fingers. The placement of the fingers on the cheek completely confused the AI tracking algorithm. The change in the mean value of the third component (blue) of the RGB classification inside the ROI on both sides of the cheek of the patient is not reliable unless the left cheek or right cheek ROI has good illumination. The detection is usually far less reliable on one of these ROIs because it is difficult to achieve good illumination on both sides of the face of the patient.

Tracking mouth deformation during the exercise was a superior approach. First, we easily detected if and when the patient had the ability or did not have the ability to keep the mouth closed. Second, we tested several features, such as the distance between the corners where the upper and lower lip meet, that is, the segment delimited by the points (49) and (55) in the model (Figure 1A), the deformation of the mouth in the vertical direction, and the mean curvature of the upper lip and lower lip. Figure 8 shows the feature that measures the normalized distance between the upper lip and the bottom of the nose during the cheek puff exercise using a standard Zoom video with 450×800 pixels per frame in an ADAPT (Adapting Disease Specific Outcome Measures Pilot Trial) patient. We obtained a curve that was close to the step function in this ADAPT patient, which accurately detected when the deformation of the cheek started and ended, and indicated how strong the deformation was. Not all features work all the time for all patients. As expected, variability in the anatomy of patients causes differences in which features work the best. Form our experience, we found that the combination of several features helps identify the extent of cheek puff during the exercise.

We obtained very similar results for the tongue-to-cheek push exercise. In Figure 9, an ADAPT patient pushes the left cheek with the tongue and then pushes the right cheek at 5.6 seconds.

Figure 8. Normalized distance of the upper lip to the lower part of the nose during the cheek puff exercise.
The geometric feature we used was the angle formed by the mouth and the horizontal axis. The exercise breaks the symmetry of the face, and this feature is particularly adapted to capture the one-side deformation of the cheek. The illumination figure shows only marginal change for the second part of the exercise and is therefore not very robust. One may expect however that better control of the light during the telehealth session will resolve this issue.

These techniques will not work for a subject with a moustache or beard. The shape of the face of patients with a high BMI may also impact the quality of the results. More work needs to be done on the digitalization of this specific test. As mentioned before, the depth camera would need to be highly accurate in order for the signal to be above the noise level, which is not the case with entry-level and low-cost systems.

**Arm Position and Sit-to-Stand Movement**

Most videos of the MGNet data set offered only partial views of the body during these exercises and showed great variability. The model (Figure 1) failed under such conditions.

Figure 10 shows a representative example of the arm angle decay due to weakening during the 120-second assessment of one of the ADAPT patients. The measurement exhibited some minor noise. We used a high-order filtering method [43] to provide a meaningful graphic to limit the noise of the method and maintain the trend that could be used for the physical examination assessment. The decay of both arms was linear and significant. It was however difficult for the medical examiner to quantify the slope or even notice it.

Figure 11 shows an example of the vertical elevation examination with respect to time for both hips, involving tracking the elevation of landmark points (23) and (24) (Figure 1B) as a function of time. From this measurement, we could not only compute acceleration and speed as indicators of muscle function but also assess the stability of the motion by measuring lateral motion in the x-coordinate.

One of the benefits of having the whole body tracked during these MG-CE evaluations is the ability to access additional information, such as the ability of the patient to stay stationary and keep their balance. While all measures are in pixels in the video itself, we recovered a good approximation of the physical dimension using the known dimension of the seat.
Counting Exercise

This evaluation is used to assess breathing and speech quality. We used a data set of 6 patients involving 2 sessions and 9 additional healthy subject voice exercises. Audio files were cut to start and end approximately within 1 to 3 seconds of initiation and the end of counting. Based on the evaluation of patients performed by the physician according to the protocol [7], there were rarely differences between the first visit and the second controlled visit for ptosis and diplopia grading. We found however that most of the metrics described above had some variability from one visit to another, and might be considered as more sensitive metrics than the current physician examination. We will report here on our main findings with these metrics.

Instead of using the maximum number reached during the single-breath counting exercise, we used the duration of the exercise itself to grade the exercise. We found that the maximum number counted was weakly correlated with the duration of the single-breath counting exercise. The maximum number reached was indeed dependent on the speed of diction that varies greatly from one patient to another. To be more precise, one may expect that the airflow output value for the patient depends on the loudness of the voice and the pitch of the voice. In fact, we found that loudness and pitch computed with our algorithm...
varied dramatically from one patient to another. There had been no calibration of the microphone at the patient’s home, so we used the duration of the single-breath counting exercise as an indicator of MG severity. We suspected that a lower duration of the single-breath counting exercise is associated with more severe shortness of breath symptoms. We formulated the hypothesis that breathing difficulty might be detected by analyzing the signal in a range of frequencies concentrating on the typical breathing rate window. We used a fast Fourier transform to obtain the spectrum of the voice signal during the complete duration of the counting to 50 exercise and computed the energy of the signal restricted in the low-frequency window (5 Hz to 25 Hz). We found a weak correlation between the energy and MG severity estimated as described above (Figure 12). There were 2 outliers corresponding to 1 of the 6 patients who had severe symptoms according to the examiner annotation (Figure 12). The voice of the patient was so weak in the acquisition that the breathing signal information might have been at the noise level of the method.

We did not proceed with the identification of dysarthria per say, but looked for a relationship involving one of the generic metrics that could be computed such as spectral entropy or Teager-Kaiser energy. An example of the mean entropy of the voice signal (Figure 13) shows that this criterion is promising and may separate patients from healthy controls. Counting the number of singular picks in entropy during the examination provides better separation between patients and healthy subjects. The argument would be that an MG patient has a more monotonic voice than a healthy subject. More evaluations will be needed to confirm if entropy is a good metric. In contrast, Teager-Kaiser energy did not clearly separate MG patients.

![Image](https://neuro.jmir.org/2023/1/e43387)
Discussion

Principal Findings

We have systematically built a series of algorithms that can automatically compute the metrics of the MG-CE, which is a standardized telemedicine physical examination for patients with MG. This effort was motivated by the increasing use of telemedicine and the appreciation of inherent limitations of presently used clinical outcome measures [44,45]. For the MG-CE, the examiner ranked the subjective observation of each examination item into categories, but this separation among classes was performed a priori and was not the result of data mining in a large population. In that context, the threshold numbers used to separate metrics, such as duration, are likely to be artificial. The data collection for these tests during a teleconsultation is tedious, repetitive, and demanding for the physician. We demonstrated a methodology, which can accelerate the data collection and provide the rational for a posteriori classification of MG severity based on a large population of patients.

Other ranking of the test might be intuitive, for example, how to define or compare difficulty in standing up. It may involve tedious motion due to muscle weakness, arthritis, or obesity. Currently, the duration of cheek deformation is not counted, but our methodology may eventually provide a precise measurement. Based on the new data set that our method provides, one should investigate further if the MG-CE classification, as well as all other categorical measures in MG, should be revisited to consider the new metrics that our algorithm can provide. In particular, the dynamic component of muscle weakness, which is a hallmark of MG and an important factor in quality of life, is not captured well by existing clinical outcome measures and not at all in routine clinical practice [46].

Our study exposed limitations in aspects of neuromuscular examination. The ability to deform the cheek does not say much about the ability to hold pressure and for how long. The cheek deformation exercise did prove to be the most difficult for achieving proper digitalization. The scoring of this exercise in the original medical protocol appeared particularly limited. We have refined mouth deformation monitoring under laboratory conditions with our Inteleclinic system to better apply computer learning techniques. Moreover, the counting exercises can be used to assess respiration function, but the number achieved does not fully equate to the severity of respiratory insufficiency. Another challenge for our evaluation is that patients can compensate for some level of weakness and reduce the apparent severity assessed by the examination. For example, the ability to precisely compute the trajectory of the patient’s hip movement during the sit-to-stand exercise may identify if there is...
compensation by one leg supporting the movement more than the other. This situation could be particularly difficult for a human examiner to identify. Overall, our algorithms should give unbiased results and remove any potential subjectivity from the medical examination.

The accuracy of every computer algorithm must be constantly interrogated. Every metric should, in principle, come with an error estimate, which is not frequently the case in the current solutions, including that of the human examiner. One key component to ensure such quality of results is to control the condition of the acquisition of video and sound during the telemedicine session. With voice analysis, we would need to ensure proper calibration of the microphone at the patient’s home, as well as check during the sound registration that the patient speaks with a loudness within acceptable bounds. The later can be done automatically in order to provide guidance during the examination. Similarly, the AI and computer vision aspects of the data acquisition require the patient’s distance from the camera and the light condition to always be consistent with the exercise requested. This is technically feasible because the telehealth system can compute in real time the dimension in pixels of any ROI and the quality of segmentation in order to correct any obvious mistake in the data acquisition. For example, the AI model of Figure 1B that tracks the sit-to-stand exercise fails if the patient’s head leaves the video frame. This kind of problem can be immediately reported to the examiner during the test. Another example is that the single-breath counting test may poorly define the initial state, speed, and loudness of speech, as counting greatly varies between patients and has an impact on breath performance evaluation.

Conclusion
Systematic digitalization and control of quality of the MG-CE are advantageous and would allow trained medical assistants to perform standardized examinations, allowing the physician to concentrate on patient questions and education instead of managing the logistics of the test. We also assessed our hardware-software “Inteleclinic” solution for telehealth consultation, which appears to be able to enhance data quality (described in a provisional patent; number 63305420; Garbey M and Joerger G, 2020). Our methods and technology would be particularly applicable to clinical trials, which are limited in requiring a large number of examiners who all perform assessments in slightly different manners. A trial could substitute present operations with a central telemedicine facility. We envision that our telehealth approach can be applied to other neuromuscular diseases beyond MG and will provide objective, reproducible, and quantitative health care assessments that go beyond the present capabilities.

Acknowledgments
The work to gather clinical data was supported in part by the MGNet, a member of the Rare Disease Clinical Research Network Consortium (RDCRN) (NIH U54 NS115054). Funding support for the Data Management Coordinating Center is provided by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Neurological Disorders and Stroke (NINDS).

Conflicts of Interest
None declared.

References


Abbreviations

ADAPT: Adapting Disease Specific Outcome Measures Pilot Trial
AI: artificial intelligence
MG: myasthenia gravis
MG-CE: Myasthenia Gravis Core Examination
ROI: region of interest

Edited by P Kubben; submitted 12.10.22; peer-reviewed by V Ochs, M Banf, PP Zhao; comments to author 30.12.22; revised version received 27.02.23; accepted 02.03.23; published 19.04.23.

Please cite as:
A Digital Telehealth System to Compute Myasthenia Gravis Core Examination Metrics: Exploratory Cohort Study
JMIR Neurotech 2023;2:e43387
URL: https://neuro.jmir.org/2023/1/e43387
doi:10.2196/43387
PMID:37435094

©Marc Garbey, Guillaume Joerger, Quentin Lesport, Helen Girma, Sienna McNett, Mohammad Abu-Rub, Henry Kaminski. Originally published in JMIR Neurotechnology (https://neuro.jmir.org), 19.04.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Neurotechnology, is properly cited. The complete bibliographic information, a link to the original publication on https://neuro.jmir.org, as well as this copyright and license information must be included.
Clinical Perspectives on Using Remote Measurement Technology in Assessing Epilepsy, Multiple Sclerosis, and Depression: Delphi Study

Jacob A Andrews1,2, BA, MA, PhD; Michael P Craven1,3, PhD; Boliang Guo4, PhD; Janice Weyer5, BA, BSc; Simon Lees5; Spyridon I Zormpas5, MSc; Sarah E Thorpe5, BSc; Julie Devonshire5; Victoria San Antonio-Arce6, MD, PhD; William P Whitehouse5, BSc, MBBS; Jessica Julie6, BSc; Sam Malins6, PhD; Alexander Hammers10, MD, PhD; Andreas Reif11, MD; Henricus G Ruhe12,13, MD, PhD; Federico Durbano14, MD; Stefano Barlati15, MD; Arjune Sen16, BM BCh, MA, PhD; Jette L Frederiksen17, MD; Alessandra Martinelli18, MD, PhD; Antonio Callen19, MD; Joan Torras-Borrell20, MD; Nuria Berrocal-Izquierdo21, MD, PhD; Ana Zabalza22,23, MD, PhD; Richard Morriss1,2, MD; PhD; Chris Hollis1,2, BSc, MBBS, DCH, PhD; The RADAR-CNS Consortium24

1National Institute for Health and Care Research MindTech MedTech Co-operative, University of Nottingham, Nottingham, United Kingdom
2Academic Unit of Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom
3Human Factors Research Group, Faculty of Engineering, University of Nottingham, Nottingham, United Kingdom
4National Institute for Health and Care Research Applied Research Collaboration East Midlands, School of Medicine, University of Nottingham, Nottingham, United Kingdom
5Patient Advisory Board, RADAR-CNS, Kings College London, London, United Kingdom
6Freiburg Epilepsy Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
7Division of Child Health, Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham, United Kingdom
8National Institute for Health and Care Research Biomedical Research Centre for Mental Health, Kings College London, London, United Kingdom
9Nottinghamshire Healthcare National Health Service Foundation Trust, Nottingham, United Kingdom
10School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
11Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University, Frankfurt am Main, Germany
12Department of Psychiatry, Radboud University Medical Center, Nijmegen, Netherlands
13Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, Netherlands
14Department of Mental Health and Addictions, Aziende Socio Sanitarie Territoriali Melegnano e della Martesana, Lombardy, Italy
15Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
16Oxford Epilepsy Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom
17Department of Neurology, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark
18Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
19Department of Neurology, Parc Sanitari Sant Joan de Déu, Barcelona, Spain
20Centre d’Atencio Primària Sant Llàtzer, Consorci Sanitari de Terrassa, Barcelona, Spain
21Parc Sanitari Sant Joan de Déu, Barcelona, Spain
22Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain
23Vall d’Hebron Institut de Recerca, Barcelona, Spain
24Kings College London, London, United Kingdom

Corresponding Author:
Jacob A Andrews, BA, MA, PhD
National Institute for Health and Care Research MindTech MedTech Co-operative
University of Nottingham
Institute of Mental Health
Triumph Road
Nottingham, NG7 2TU
United Kingdom
Phone: 44 01157484 218
Email: jacob.andrews@nottingham.ac.uk

https://neuro.jmir.org/2023/1/e41439
Abstract

Background: Multiple sclerosis (MS), epilepsy, and depression are chronic central nervous system conditions in which remote measurement technology (RMT) may offer benefits compared with usual assessment. We previously worked with clinicians, patients, and researchers to develop 13 use cases for RMT: 5 in epilepsy (seizure alert, seizure counting, risk scoring, triage support, and trend analysis), 3 in MS (detecting silent progression, detecting depression in MS, and donating data to a biobank), and 5 in depression (detecting trends, reviewing treatment, self-management, comorbid monitoring, and carer alert).

Objective: In this study, we aimed to evaluate the use cases and related implementation issues with an expert panel of clinicians external to our project consortium.

Methods: We used a Delphi exercise to validate the use cases and suggest a prioritization among them and to ascertain the importance of a variety of implementation issues related to RMT. The expert panel included clinicians from across Europe who were external to the project consortium. The study had 2 survey rounds (n=23 and n=17) and a follow-up interview round (n=9). Data were analyzed for consensus between participants and for stability between survey rounds. The interviews explored the reasons for answers given in the survey.

Results: The findings showed high stability between rounds on questions related to specific use cases but lower stability on questions relating to wider issues around the implementation of RMT. Overall, questions on wider issues also had less consensus. All 5 use cases for epilepsy (seizure alert, seizure counting, risk scoring, triage support, and trend analysis) were considered beneficial, with consensus among participants above the a priori threshold for most questions, although use case 3 (risk scoring) was considered less likely to facilitate or catalyze care. There was very little consensus on the benefits of the use cases in MS, although this may have resulted from a higher dropout rate of MS clinicians (50%). Participants agreed that there would be benefits for all 5 of the depression use cases, although fewer questions on use case 4 (triage support) reached consensus agreement than for depression use cases 1 (detecting trends), 2 (reviewing treatment), 3 (self-management), and 5 (carer alert). The qualitative analysis revealed further insights into each use case and generated 8 themes on practical issues related to implementation.

Conclusions: Overall, these findings inform the prioritization of use cases for RMT that could be developed in future work, which may include clinical trials, cost-effectiveness studies, and the commercial development of RMT products and services. Priorities for further development include the use of RMT to provide more accurate records of symptoms and treatment response than is currently possible and to provide data that could help inform patient triage and generate timely alerts for patients and carers.

(JMIR Neurotech 2023;2:e41439) doi:10.2196/41439

KEYWORDS
mobile health; mHealth; wearable; wearable technology; smartphone; use case; implementation; epilepsy; multiple sclerosis; MS; depression; depressive disorder; Delphi; remote measurement technology; RMT; central nervous system; nervous system disorder; neurology; neurological disorder; expert panel; expert opinion; perspective; mobile phone

Introduction

Background

Digital and mobile health technologies, including smartphone-based monitoring and wearable devices, have a wide range of applications in clinical practice [1-3]. A clinical “use case” describes how a technology can be implemented in a clinical context, including the expected benefit and expected beneficiary. Clinical use cases are essential for determining the outcomes to be used in trials evaluating effectiveness as well as for obtaining regulatory approvals and explaining the benefits of a health care technology to potential funders and patients. The adoption and scaling of novel technologies in health care are dependent on a well-defined use case with a clearly defined problem to be addressed [4]. The inclusion of clinicians in the development of such technologies is known to be important for successful implementation, as it ensures the appropriateness of technology for the specific requirements of patients and the health care system [5].

Remote Assessment of Disease and Relapse–Central Nervous System (RADAR-CNS) was a 6-year project to understand the feasibility and acceptability of using remote measurement technology (RMT) to collect health-relevant data from individuals living with epilepsy, multiple sclerosis (MS), or depression [6]. The project was a collaboration across 6 European countries (Denmark, Germany, Italy, the Netherlands, Spain, and the United Kingdom) and has involved the development of a bespoke, open-source platform RADAR-base. The platform collates data from commercially available Fitbit smart watches measuring activity, heart rate, and heart rate variability; the Empatica E4 wrist-worn epilepsy seizure detection device; Bittium Faros accelerometer and electrocardiogram Holter devices; and bespoke apps for passive sensing and active collection of user-entered data (THINC-it) [7]. We refer to the combination of the platform, the apps, and the commercial devices as the RADAR-CNS RMT system. Observational studies have been conducted to establish the feasibility and acceptability of collecting data from individuals living with MS, epilepsy, or depression using these sensors, apps and platform to develop new predictive algorithms based on the data set [8-10]. Patient involvement has been conducted throughout the program, and patient focus groups and other involvement studies have been conducted in multiple European countries (Denmark, Germany, Italy, the Netherlands, Spain, and the United Kingdom) and has involved the development of a bespoke, open-source platform RADAR-base. The platform collates data from commercially available Fitbit smart watches measuring activity, heart rate, and heart rate variability; the Empatica E4 wrist-worn epilepsy seizure detection device; Bittium Faros accelerometer and electrocardiogram Holter devices; and bespoke apps for passive sensing and active collection of user-entered data (THINC-it) [7]. We refer to the combination of the platform, the apps, and the commercial devices as the RADAR-CNS RMT system. Observational studies have been conducted to establish the feasibility and acceptability of collecting data from individuals living with MS, epilepsy, or depression using these sensors, apps and platform to develop new predictive algorithms based on the data set [8-10].
countries to elicit patient views and inform the RMT under development [10-13].

The aim of this study was to specify priority use cases for RMT in 3 central nervous system disorders (epilepsy, MS, and depression). An initial set of 13 use cases were developed through discussion with health care professionals (HCPs) and researchers working in each of the 3 clinical work packages within the project. The development of these use cases considered the fit to the target population, the potential for a positive impact on the health and safety of patients, whether the use case would offer an improvement on current methods, and the existence of prior evidence to support the use case. These were also informed by our prior work, which included: a small-scale survey with patient advisers, HCPs, and researchers [14]; in-depth interviews with HCPs [15]; and a large-scale survey of 1006 clinicians on the current and potential use of RMT and apps in clinical practice [16] and the potential value of remote measurement data [17]. The Delphi study then sought to prioritize among the 13 use cases (5 in epilepsy, 3 in MS, and 5 in depression) to determine which of these would be most practicable and useful in the eyes of the expert clinician panel, who were outside of the consortium and so offered a more objective point of view. The number of use cases included in the study was considered to be manageable without overburdening participants.

The use cases were also presented to the RADAR-CNS Patient Advisory Board (PAB) to seek further input ahead of this study in a short consultation via Microsoft Teams, with diagrams and descriptions of use cases provided by email in advance. The RADAR-CNS PAB includes members living with each of the 3 conditions from multiple countries across Europe. Illustrations of the 13 use cases are included in Multimedia Appendix 1.

The final use cases for epilepsy are as follows:

1. Seizure alert: enabling real-time seizure warnings to patients and carers.
2. Seizure counting: improving detection of different types of seizures to enable more accurate overall seizure records.
3. Risk scoring: detecting cycles of seizure occurrence to reveal risk levels at different times.
4. Triage support: enhancing patient triage based on RMT data submitted wirelessly to patient record systems.
5. Trend analysis: reliably detecting a change in the number of seizures that a patient has over a specified period.

The final use cases for MS are as follows:

1. Detecting silent progression: making use of more granular measurements to detect otherwise invisible markers of progression, enabling patients to evidence changes they experience.
2. Detecting depression: identifying markers of depression in the first year after MS diagnosis.
3. Data donation: automatic collection and storage of patient data in biobanks or mega-databases.

The final use cases for depression are as follows:

1. Detecting trends: detailed symptom tracking and aggregation of multiple types of data.
2. Treatment review: measuring adherence to cognitive behavioral therapy or other treatment regimens and treatment response.
3. Self-management: monitoring and providing nudges to a patient to improve their condition.
5. Carer Alert: providing an alert to a carer or relative when a person with depression is in a period of very low activity.

Aims and Objectives

The aim of this work was to prioritize the use cases with the potential for the greatest benefit for further development according to the views of HCPs external to the project. We sought to establish the type of benefit that each might offer according to a medical device design framework [18]. We also aimed to explore further related issues:

1. Acceptability of the level of burden (clinical time) required to apply RMT in practice.
2. Acceptability of the amount of data that would be generated by RMT.
3. The extent of required technical support for clinicians to make the best use of RMT.
4. Preferred mode of training or technical support for clinicians.
5. The extent of required technical support for patients to make the best use of RMT.

We aimed to seek a consensus in these areas, where prior work has shown that there is a disagreement between HCPs. In addition, we aimed to determine which prior known concerns about the use of RMT in clinical practice would actually prevent or discourage HCPs from using RMT with patients. As we recruited an international sample, we were also interested in exploring how the potential implementation of RMT might differ between countries.

Methods

Overview

The Delphi methodology has been widely used in health care research to gather expert opinions [19-21]. Key characteristics of the Delphi method include consultation of experts, elements of iteration and feedback to participants to enable a form of communication between them, and statistical methods used to summarize group responses to ensure the robustness of analyses [22]. Delphi studies can be used without face-to-face contact while still enabling the gathering of group opinions, which is of benefit when those whose opinions are required have busy schedules (eg, in clinical settings) or may be located across multiple countries [23-25], as is the case in this study. There were also obvious benefits to this approach during the COVID-19 pandemic.

Delphi studies feature multiple survey rounds, with feedback given to the participants between each. For example, Murphy et al [21] used a 3-round model to gather views and opinions on the potential of digital tools for mental health in the United Kingdom. The first round of a Delphi study typically asks open-ended questions, and these are used to generate closed
questions for a survey in the second round, often with Likert-style responses. In the third round (if there is one), participants review the summarized results from the prior round and are then able to change their responses if required [26]. This results in either greater consensus among the groups or sustained disagreement, both of which are of interest [25]. Other models may omit the first qualitative round [19] and may include follow-up interviews after the final survey round [27].

Procedure

Overview

This study adopted the Delphi methodology for the context of RADAR-CNS. The study procedure is summarized in Figure 1. As the project had already canvassed opinions from HCPs in surveys and interviews, we replaced the first qualitative round with a reanalysis of our existing data to generate the survey for use in this study. It is recommended that Delphi surveys be completed within 30 minutes [25]. Thus, we used diagrams of use cases (included in Multimedia Appendix 1) to aid rapid comprehension and to permit engagement with the ideas presented.

Figure 1. Flowchart showing study process. DE: Germany; DK: Denmark; ES: Spain; IT: Italy; MS: multiple sclerosis; NL: Netherlands; RADAR-CNS: Remote Assessment of Disease and Relapse–Central Nervous System; RMT: remote measurement technology; UK: United Kingdom.
There was a gap of 3 months between the dissemination of the first survey round and the dissemination of the second survey round. After the first round, the research team gathered responses and produced graphs and tables to form a Summary of Results document. In a further adaptation to the traditional Delphi methodology, this Summary of Results was presented to the RADAR-CNS PAB to request commentary on clinicians’ responses. Patients who reviewed the round 1 responses consisted of 2 people: 1 living with epilepsy (male) and 1 living with MS (female). Unfortunately, the members of the PAB living with depression did not respond to requests to provide comments. Patients were sent a summary of round 1 results in graphs, tables, and free-text comments, along with a short video explaining what was expected from them. They wrote their comments in a word document or email and returned them to the first author.

For round 2, HCP participants received the Summary of Results, which incorporated patient comments, together with a link to the round 2 survey for completion, and were instructed to review the Summary of Results before completing the second round. The Summary of Results was personalized to each participant, with their own responses indicated next to graphs showing summary responses (Figure 2). Graphs were used to provide an “at-a-glance” overview of the results for quick interpretation. Free-text comments from Delphi experts and from patients were provided in boxes below the graphs for participants to review.

**Figure 2.** An example showing the style of feedback provided to Delphi panel members after round 1 and showing how individual responses were combined with group responses in the Summary of Results. RMT: remote measurement technology.

<table>
<thead>
<tr>
<th>EPILEPSY USE CASE 1 - TOTAL RESPONSES</th>
<th>YOUR RESPONSES:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall, I think it would be beneficial for me and the clinical team to incorporate this use of RMT into the way we care for patients.</td>
<td>Strongly Agree</td>
</tr>
<tr>
<td>Overall, I think it would be beneficial for my patients to incorporate this use of RMT into the way I care for my patients.</td>
<td>Strongly Agree</td>
</tr>
<tr>
<td>I think this use of RMT would catalyze (speed up) processes in the care of my patients.</td>
<td>Strongly Agree</td>
</tr>
<tr>
<td>I think this use of RMT would enhance (improve) the care I give to my patients.</td>
<td>Strongly Agree</td>
</tr>
<tr>
<td>I think this use of RMT would facilitate (make easier) the care of my patients.</td>
<td>Strongly Agree</td>
</tr>
<tr>
<td>I think this use of RMT would enable (make possible) something which isn’t currently possible.</td>
<td>Strongly Agree</td>
</tr>
<tr>
<td>If it were technically possible, I think it would be practically possible to employ RMT for this use in the care of my patients.</td>
<td>Strongly Agree</td>
</tr>
</tbody>
</table>

Delphi studies have been criticized for their closed nature, which prevents discussion of the results [26]. This study sought to overcome this criticism by including follow-up interviews to discuss the results with individual participants. Therefore, we used a mixed method sequential explanatory approach to collect our data. Figure 1 shows a flowchart summarizing the process.

**Recruitment**

HCPs were recruited from multiple countries where RADAR is active via multiple routes. The main method of recruitment was by clinical academics within the RADAR-CNS consortium disseminating recruitment materials to their clinical academic colleagues. In addition, we contacted specialist associations representing clinicians treating each of the 3 conditions across the 6 European countries of the consortium (the United Kingdom, Germany, Italy, Spain, the Netherlands, and Denmark). We also contacted prior research participants external to the consortium and contacted clinicians who had previously expressed interest in the RADAR-CNS project.

**Inclusion Criteria**

We required participants to be experts in the area by virtue of their experience working in the clinical care of people with epilepsy, MS, or depression. We specified that participants should not be members of the RADAR-CNS consortium to gain an external view of the potential of the technology in clinical practice.

**Survey Design**

The survey was composed of 4 main sections: demographics, use case evaluation, questions related to the implementation of RMT, and rating of concerns. The full survey is included in Multimedia Appendix 2.
There were 3 separate use case evaluation sections, one for each clinical condition. The epilepsy section evaluated 5 use cases, the depression section evaluated 5 use cases, and the MS section evaluated 3 use cases. For each use case, there were 7 questions, which included general evaluations of practicality and benefit, plus 4 adapted from the framework of medical device design by Sharples et al [18]. Using this framework, we sought to identify the specific type of benefit offered by each use case: whether it “enabled” something new, “enhanced” existing practices, “facilitated” (made easier) existing processes, or “catalyzed” (sped up) existing processes. Respondents rated each item on a 5-point scale, ranging from 1 (strongly agree) to 5 (strongly disagree).

The “further questions” section covered clinical time, frequency of data collection, technical support requirements, usefulness or value of data, and payment and reimbursement. The “rating of concerns” section was intended to explore the extent to which different barriers to use discovered in our prior work would affect respondents’ intention to use RMT in clinical practice. Each response option in this section was more detailed and required longer to read than those in the previous sections, so we kept the number of response options low to facilitate completion (the options were “Would not prevent me using RMT with my patients”; “Would prevent use in some situations”; “Would prevent use entirely”; or “Don’t know”).

The second round survey was identical to the first, except that demographics questions were omitted, and coauthorship of the resulting paper was offered via an opt-in tick box. We chose to request full recompletion of the survey rather than only requesting completion of questions where consensus had not been reached because we were equally interested in areas of disagreement as we were in gaining consensus.

Follow-up Interviews
A subset of participants who indicated interest in a follow-up interview were contacted to arrange a 30-minute slot for a web-based interview using Microsoft Teams. The interviews followed a semistructured format using an interview guide instrument (Multimedia Appendix 3). The aims of the interviews were to gain further insight into HCPs’ views of the use cases for the RADAR-CNS RMT system and to understand country-specific contextual factors that might affect the implementation of RMT in each country. As such, we conducted interviews across a range of European countries and across the 3 conditions.

Ethics Approval
The methods were performed in accordance with relevant guidelines and regulations and were approved by the University of Nottingham Faculty of Medicine and Health Sciences Research Ethics Committee (ref: 315-0721; Multimedia Appendix 4).

Analysis
Quantitative Analysis
The quantitative data consisted of Likert-style responses from the 2 survey rounds. These were scored from 1 (strongly disagree) to 5 (strongly agree), except for the final question on barriers to RMT use, which was scored using a 3-point scale, plus an option for “do not know.” Numbers reporting “do not know” were included in the denominator of the percentage calculations.

To evaluate the consensus among respondents in each round, we used a predetermined threshold percentage of similar responses on an item [25]. We determined that consensus had been reached if 70% of the responding participants scored an item within the same grouping (agree, neutral, or disagree), where scores of 4 or 5 were grouped as “agree,” scores of 1 or 2 were grouped as “disagree,” and scores of 3 were considered neutral. This effectively recreated a 3-point scale, which is considered preferable over the analysis of 5-point scales for survey data in clinical contexts [28].

To evaluate the stability between rounds, we used the Gwet agreement coefficient, which is found to have more stable performance than kappa scores [29]. The scores were weighted to account for ordinality in the variables. The coefficients were compared against benchmarks from Altman [30].

Analyses were conducted only on responses received—no imputation was judged to be necessary to account for missing data, given that the study focused on eliciting a small number of expert opinions, with only descriptive statistics used to analyze the data.

Qualitative Analysis
Survey comments and interview transcripts were analyzed using template analysis [31]. An a priori theme was included in the initial template for each use case, and for each implementation topic covered in the survey. Themes were iteratively added, deleted, renamed, and reorganized to create the final template of themes. We used the final template of themes to triangulate the qualitative and quantitative data.

Results
Participants
A total of 23 clinicians treating patients with epilepsy, MS, or depression were recruited, with participation from all 6 European countries where RADAR-CNS is active (the United Kingdom, Germany, Spain, Denmark, the Netherlands, and Italy) and with representation from clinicians treating each of the 3 clinical conditions (Table 1). We expected some dropouts between the first and second rounds but were able to retain 74% (17/23) of the round 1 participants in round 2. A total of 9 respondents completed the interviews.
Table 1. Participant demographics.

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>Round 1 (n=23), n (%)</th>
<th>Round 2 (n=17), n (%)</th>
<th>Interviews (n=9), n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-39</td>
<td>6 (26)</td>
<td>6 (35)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>40-49</td>
<td>5 (22)</td>
<td>4 (24)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>50-59</td>
<td>9 (39)</td>
<td>5 (29)</td>
<td>5 (56)</td>
</tr>
<tr>
<td>60-70</td>
<td>3 (13)</td>
<td>2 (12)</td>
<td>2 (22)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Woman</td>
<td>8 (35)</td>
<td>6 (35)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>Man</td>
<td>15 (65)</td>
<td>11 (65)</td>
<td>6 (66)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Job role</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Consultant (medical)</td>
<td>16 (70)</td>
<td>11 (65)</td>
<td>8 (89)</td>
</tr>
<tr>
<td>Health care scientist or researcher</td>
<td>2 (9)</td>
<td>2 (12)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Clinical psychologist</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>General practitioner</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Nurse</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Psychological well-being practitioner</td>
<td>1 (4)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Other (unspecified)</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Relevant condition treated</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Depression</td>
<td>10 (43)</td>
<td>8 (47)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>8 (35)</td>
<td>6 (35)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>3 (13)</td>
<td>2 (12)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Multiple sclerosis, epilepsy, and depression</td>
<td>1 (4)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Epilepsy and multiple sclerosis</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>1 (11)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>8 (35)</td>
<td>5 (29)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Spain</td>
<td>5 (22)</td>
<td>4 (24)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Italy</td>
<td>4 (17)</td>
<td>3 (18)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Germany</td>
<td>3 (13)</td>
<td>2 (12)</td>
<td>3 (33)</td>
</tr>
<tr>
<td>Denmark</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Australia</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Netherlands</td>
<td>1 (4)</td>
<td>1 (6)</td>
<td>1 (11)</td>
</tr>
</tbody>
</table>

Quantitative Results: Consensus and Stability

The research team decided that a third survey round was not required: 97.4% (114/117) of question items had a high or very high level of stability of responses between rounds 1 and 2, indicating that a third round would have had limited benefit. Multimedia Appendix 5 [30] presents the results for consensus and stability for all questions in the survey.

Epilepsy Use Case Questions

The threshold for consensus was reached on 74% (26/35) of questions on the epilepsy use cases in the first round and 86% (30/35) of questions in the second round, demonstrating a move toward consensus. For all of these items, consensus was reached that respondents agreed or strongly agreed with the statements presented, rather than selecting “disagree,” “strongly disagree,” or “neutral.” Five of the questions moving to consensus in round 2 concerned the fifth epilepsy use case, using RMT for trend analysis, and indicated a change in views toward agreement that this use case would “enable” new possibilities, “facilitate” care (make care easier), “enhance” care, and benefit patients and clinical teams.

It is notable that in round 1, for epilepsy use cases 1 to 3, the question on “catalyzing” (speeding up) existing processes received fewer “agree” or above responses than all other statements, indicating less confidence that these use cases would speed up existing processes. The PAB identified this pattern, and their comments were fed back to the participants ahead of round 2. There was comparatively low stability for these questions between round 1 and round 2, suggesting that
participants changed their minds about this question, perhaps in response to the PAB’s comments.

The point estimate for the Gwet agreement coefficient statistic fell in the “very good” strength of agreement range (0.80-1.00) for 94% (33/35) of items, indicating a very high overall stability of epilepsy responses between rounds 1 and 2.

**MS Use Case Questions**

The threshold for agreement was reached on 10% (2/21) of questions on the MS use cases in the first round and 0% (0/21) of questions in the second round, demonstrating a move away from consensus. Where consensus was reached, it was a consensus that respondents “agreed” or “strongly agreed” with the statements presented rather than selecting “disagree,” “strongly disagree,” or “neutral.”

Fewer participants completed the MS use case questions in the second round (n=3) compared with the number completing epilepsy questions (n=6) and depression (n=9). This meant that even when a majority of 67% (2/3) of participants expressed an opinion, this did not cross the threshold of 70%, requiring a unanimous vote for this to occur. This explains the comparatively lower number of questions showing consensus in the MS group.

The point estimate for the Gwet agreement coefficient fell in the “very good” strength of agreement range (0.80-1.00) for 81% (17/21) of items, indicating a high overall stability of responses between rounds 1 and 2.

**Depression Use Case Questions**

In the depression use cases, the threshold for agreement was reached on 83% (29/35) of questions in the first round and 89% (31/35) of questions in the second round. Where consensus was reached, it was a consensus that respondents “agreed” or “strongly agreed” with the statements presented, rather than selecting “disagree,” “strongly disagree,” or “neutral.”

The point estimate for the Gwet agreement coefficient fell in the “very good” strength of agreement range (0.80-1.00) for all 100% (35/35) of items, indicating a very high overall stability of responses between rounds 1 and 2.

**Further Questions Section**

There were 19 questions on further considerations of RMT (clinical time, frequency of data collection, technical support requirements, usefulness or value of data, and payment and reimbursement), which were rated by all 17 participants who completed both rounds. Participants reached a consensus of “agree” or “strongly agree” on 42% (8/19) of questions in round 1 and maintained this level of consensus in round 2 (Multimedia Appendix 5). A smaller proportion of questions in this section reached consensus than those in the section on use cases. For 11% (2/19) of questions in this section, participants moved from no consensus to a consensus that they “disagreed” or “strongly disagreed” with the statement. These questions were that “receiving data on a patient’s condition would be an added burden” and that “mood scores need to be collected from patients at risk of mental health conditions on a daily basis.” A total of 9 question items in this range did not reach agreement in the first or second rounds. The Gwet agreement coefficient showed “very good” stability between rounds (Altman benchmark 0.80-1.00) on only 63% (12/19) of questions in this range, indicating greater changeability between rounds for these questions compared with those relating to the use cases.

**Concerns Questions**

There were 7 questions on concerns about RMT, which could be rated as a serious concern (“Would prevent use entirely”), a medium concern (“Would prevent use in some situations”), or a lesser concern (“Would not prevent me using RMT with my patients”). There was no consensus for any question in this set in round 2.

The stability of responses between rounds 1 and 2 for these questions was lower than that for other parts of the survey. The change in responses was not uniform in one direction or the other, and neither was there a distinct movement toward or away from extreme responses (rating a concern as severe or lesser), indicating less certainty in relation to these questions compared with other sections of the survey.

**Qualitative Findings: Final Template and Triangulation**

**Overview**

The triangulation of the results is interwoven with the overall exposition of the qualitative results below. The final template consisted of 8 themes, each with multiple subthemes (Table 2).
Table 2. Final template of themes and subthemes.

<table>
<thead>
<tr>
<th>Theme</th>
<th>Subthemes</th>
</tr>
</thead>
</table>
| 1 Comments on specific use cases | • Depression (UCs 1-5, general comments)  
  • Epilepsy (UCs 1-5, general comments)  
  • Multiple sclerosis (UCs 1-3, general comments) |
| 2 Clinical time | • Implementing RMT\(^b\) would be time costing  
  • Implementing RMT would be time-saving  
  • Other views on RMT and clinical time |
| 3 Value of RMT data | • Disease-specific value  
  • Moving beyond the subjective  
  • Positive or negative views on value  
  • Value is related to amount of data accessible |
| 4 Frequency, amount, and type of data collection | • Collecting large amounts of data (over a year)  
  • Daily reporting and recording  
  • Desired frequency of data collection  
  • Passive data collection vs active data collection  
  • Technical support and its effect on clinical time |
| 5 Payment and reimbursement | • Funding in clinical settings to support introduction of new technologies  
  • Political drivers  
  • Requirement for extra resource  
  • Requirement to save costs or improve care |
| 6 Country or context-specific factors relating to RMT implementation | • Germany  
  • Netherlands  
  • Spain  
  • United Kingdom  
  • Setting-specific factors |
| 7 Inevitability of change and ongoing change in health care services | • Preference for at-distance care  
  • Patients use RMT and bring data to clinic  
  • Patients use RMT but don’t bring data to clinic  
  • Coronavirus pandemic as stimulus for change |
| 8 Barriers and concerns | • Comments on barriers listed in the survey  
  • Clinician time  
  • False alarms, false positives, false negatives  
  • Interoperability  
  • Patient anxiety  
  • Reducing number of appointments  
  • Other barriers not covered in the survey  
  • Requirement for further research  
  • Health care culture  
  • Legal and regulatory  
  • Patient behavior and situation |

\(^a\)UC: use case.  
\(^b\)RMT: remote measurement technology.

**Comments on Specific Use Cases**

The results on condition-specific use cases from the interviews inform the prioritization of use cases, as participants indicated which of the use cases they would find most useful and which least useful, with reasons to support these indications. Extracts from the interview transcripts for each use case are provided in Multimedia Appendix 6.

**Epilepsy**

All 5 epilepsy use cases were considered plausible, although participants stated that their utility depended on practicality and accuracy. Use cases 1, 2, and 4 (seizure alert, seizure counting, and triage support, respectively) were considered the most useful. This supported the quantitative data across both rounds.

Use case 1 (seizure alert) was considered helpful for motor seizures, which are highly associated with a sudden unexpected death in epilepsy. One participant working in Germany questioned the novelty of the solution (“we already have this...”)
for some devices” [Participant 2]), although it is understood that this is only for a patient at rest (not moving) and there is still a need for wearables that can detect motor seizures from active status. Participants indicated that an adequate level of sensitivity and specificity would be required, with 1 participant providing a detailed account of acceptable sensitivity and specificity (Multimedia Appendix 6).

Epilepsy use case 2 (seizure counting) was also considered useful, assuming appropriate levels of accuracy. Comments indicated that passive monitoring may be more accurate than patient diaries, for example, where a patient might forget to record some seizures. It was considered not to be feasible for clinicians to review data between clinic visits unless the system indicated the requirement for additional review based on particular thresholds and therefore performed some sort of triage.

Use case 3 (risk scoring) was thought to be less practical and more difficult to achieve. Interviewees thought there would be medicolegal risks and that they would not want to prevent patients from taking part in enjoyable activities where unnecessary. Use case 4 (triage support) was considered useful but less so than use cases 1 and 2. Concerns included lack of infrastructure, false positives, staffing resources, legal complications, and low availability of staff.

Use case 5 (trend analysis) was again considered potentially useful depending on evidence to support its effectiveness. Some responses to interview questions indicated that trend analysis could be one of the most useful applications of RMT in epilepsy, although quantitative findings from round 1 did not reach agreement.

Multiple Sclerosis

MS use case 1 (detecting silent progression) was considered useful for detecting progression early enough to slow down the condition. However, its benefits were considered to be restricted by the limited availability of medications to treat disease progression. Measuring gait was thought to be a useful mechanism for detecting silent progression (“to detect progression, the most useful would be all the tools that would be used to detect gait disorders” [Participant 3]).

There were mixed views on the usefulness of detecting depression in MS (use case 2). One interviewee indicated that the use of RMT in this way could be useful to open “a bit more conversation” with the patient (participant 19). Another interviewee stated, “it may be that detecting depression would show the development of the disease, but that would not help us so much” (participant 3). These contrasting views reflect the lack of consensus among experts in the quantitative survey results.

Use case 3 (biobanking MS data) was considered useful for future patients but not for current patients (“that it is very useful to collect this data, so I’ll be interested, [...] but it will not necessarily have a direct impact to my patients” [Participant 19]), which explains the lack of consensus on the question about patient benefit. It was highlighted that there already exist biobanks for MS data and that RMT data could be added to these.

**Depression**

Interviewees indicated that use cases 1, 2, and 3 (detecting trends, reviewing treatment, and self-management, respectively) would be the most useful. Use case 1 (detecting trends) was thought to enable easier and better recording of patient-reported outcomes, which could save administrative time. Use case 2 (reviewing treatment) was considered useful if it could be implemented successfully within the treatment pathway. It was considered that use case 3 (self-management) would work well for some (but not all) patients.

It was considered that use case 4 (comorbid monitoring) might increase the rate of detecting depression (“we might encounter much more depression if we manage to do this” [Participant 12]), but this was considered the least viable use case, partly because it may not be possible to effectively treat comorbid depression if found, and partly because of concerns about confounding symptoms. These findings supported the quantitative data, where consensus was only reached on 4 of 7 questions about use case 4, compared with 6 of 7 or 7 of 7 for all other use cases. Use case 5 (carer alert) was also considered less useful, as participants thought that carers might not take on the required responsibility, being unwilling or unable to offer the right support and care.

**General or Non–Condition-Specific Questions**

Clinical Time

The responses showed that implementing RMT could be overall time saving if it reduced admissions, although the potential for RMT to identify otherwise unidentified symptoms may in fact require more clinical time to evaluate. RMT may reduce emergency department burden, where conditions are better managed. Comments suggested that time saving would depend on high accuracy. Several participants described practical ways in which RMT could be used to save time, eg, the use of thresholding, and having a patient manager specifically trained to manage RMT data. Some also suggested that the value of RMT may be in having a more detailed picture to improve care rather than saving time. Interviewees stated that having good quality, easily available technical support could save time for clinicians and encourage the continued use of RMT, although some were concerned about the cost of technical support.

**Value of RMT Data**

Interviewees suggested that RMT data would be useful in conditions outside the 3 covered in RADAR-CNS, eg, in the monitoring of bipolar disorder:

> I wonder whether you also consider bipolar disorder if you talk about depression, I think you have to. Even if patients come from the unipolar depression side, they still might switch into mania. [Participant 11]

To some extent, the value of the RMT data was correlated with the amount of data that could feasibly be collected. It was considered that “the more data you have, the less uncertainty there is” (participant 4) and that the data could give otherwise unavailable insights into patient condition:

> Having the RMT background information in terms of their activities throughout the week, I think it will

https://neuro.jmir.org/2023/1/e41439

JMIR Neurotech 2023 | vol. 2 | e41439 | p.56

(page number not for citation purposes)
probably give us a little bit more information in terms of how they’ve been during the week rather than, you know, on that day, this is what they reported.

[Participant 5]

This linked with a wider subtheme on “moving beyond the subjective.” Interviewees stated that RMT could provide objective data that would otherwise be represented only by subjective patient self-reports. It was also considered that RMT would enable clinicians to determine how much the patient’s condition affected their everyday lives even when the patient said they were “fine.”

**Frequency, Amount, and Type of Data Collection**

The required frequency of data collection would depend on the stage of the disease and treatment phase. In relation to mood, participants’ desired frequency of mood report data ranged from daily to once fortnightly with various suggestions in between.

There was a suggestion that passive data collection was more valuable than active data collection, as compliance with active measures was expected to be low and because active measures can have the undesirable effect of inducing negative mood states:

> From another trial, assisted active monitoring can even induce bad mood states because people then tend to ruminate, tend to think about the situation more than they probably should. So it should stress passive monitoring. [Participant 11]

**Payment and Reimbursement**

Many participants expressed that the introduction of RMT in these use cases would require a large amount of extra resources, for the cost of devices, for staff who would monitor patient data, and for staff members who would help patients set up the technology. Interviewees also expressed that the essential requirement for the introduction of RMT would be that it could demonstrably save costs or provide strong evidence of an improvement in patient care:

> Whatever you implement must not increase your workload, because otherwise especially doctors in their own practice won’t use it because they don’t get any extra money for that. So they must see a time saving benefit or a real quality improvement for patient care. That is what they expect, and here it's really important to stress that it's not putting extra work on doctors, but makes life easier actually. [Participant 11]

There were mixed views on whether reducing the number of patient appointments, as a result of monitoring their condition remotely, would be useful. This reflected the quantitative survey results, where 9 of 17 reported that their service would lose money if appointments were reduced and 7 of 17 reported that their service would not. Payment regulations for a clinician treating epilepsy in Germany meant that a reduction in the number of appointments would cause a reduction in income for his service. He stated that a political change would be required to incentivize the use of new wearable solutions in epilepsy. Conversely, a clinician treating epilepsy in the United Kingdom stated that where appointments were saved for 1 patient, these would be filled by another, as the demand for the service was so great: “There’s too much demand, so don’t worry about dropping income because of dropping demands” (participant 4).

**Country- or Context-Specific Factors Relating to RMT Implementation**

**Germany**

Interviewees in Germany gave mixed reports on the potential for the reimbursement of RMT. One interviewee said that some wearable devices were already provided to patients with epilepsy, paid for by the health service, providing evidence of a precedent for the funding of RMT. They added that RMT may have limited cost-saving benefits because of the requirement for additional staff. Another interviewee said that the organization of remuneration for health care in Germany is old fashioned and limits the ability to introduce new technologies. Another said that where doctors run their own clinics, they are free to use any technologies they see fit as long as they can convince their budget manager of the benefit the new technology will offer. This interviewee also mentioned the German law introduced in recent years to incentivize the introduction of digital health technologies and described the requirement for these technologies to provide strong supporting evidence:

> They need to demonstrate, well, evidence for helpfulness. It’s not the level of a randomized control trial, but they need to have data that the app would be instrumental in reducing health care burden, and then the provider gets reimbursed. So it’s like prescribing a medication or something like that. [Participant 11]

**The Netherlands**

The single interviewee from the Netherlands explained that there is hope and enthusiasm that RMT may offer patient and health care service benefits in depression in the Netherlands, but that there is as yet little implementation. They contrasted the National Health Service (NHS) in the Netherlands with the situation in Germany, where it was perceived that individual German hospitals needed to attract patients and that RMT may offer a competitive advantage, whereas the Dutch NHS did not need to do so.

**Spain**

The interviewee treating patients with MS in Spain suggested that regulatory factors might complicate the introduction of RMT in Spain and that there was little money in the Spanish health service to introduce RMT. However, they mentioned that because of the COVID-19 pandemic, many patients with MS whose condition is stable now have remote visits via videoconferencing as a matter of course, which have laid the cultural groundwork for a change in patient monitoring and management.

**The United Kingdom**

Interviewees distinguished the United Kingdom from other countries by highlighting how health care practitioners treating MS in other countries may be paid per visit, and it is thus in their interest to have patients attend clinics. However, in the
United Kingdom, no such pay-per-appointment system is in place. Therefore, UK practitioners may be more keen than those in other countries to make the best use of RMT data to cancel appointments where unnecessary.

It was also highlighted that insurer-based health systems compete for patients, but the UK NHS does not, so there would be less motivation to introduce RMT as a competitive advantage in the NHS.

Although interviewees pointed out that there is a political push for increased implementation of digital solutions in the NHS, 1 interviewee suggested it would be politically unpopular for the NHS to offer consumer-grade electronic goods for health-related purposes free on the NHS:

*Say with an Apple Watch retail price, probably three, 400 pounds, I don’t know. You could see the social envy creeping up and saying, oh I’m not paying for epilepsy patients to get an Apple Watch which I can’t afford myself so consumer electronics is one thing.* [Participant 9]

Similar to other countries, UK interviewees stated that funding for new medical technologies is focused on research trials rather than on implementation. They stated that implementation is assumed and is not highly regarded in terms of researcher or practitioner prestige.

**Setting-Specific Factors**

In relation to clinical alert-based systems (ie, those where crossing a threshold in patient RMT data may trigger an alert to a medical team), interviewees stated that these would have easier applications in acute hospital settings rather than in community-based settings. However, there was concern that larger centers or hospitals would be likely to see greater adoption of remote technologies because they have more funds available to cover excess costs and that this would contribute to inequality:

*You end up having three hospitals that they are already providing a good care to provide a bit better care. So if anything, the inequality of care will widen.* [Participant 19]

**Inevitability of Change in Health Services**

Interviewees commented that changes were inevitable in health care services and that pathways and procedures are often evolving. In relation to RMT, some interviewees indicated that they were aware of patients already using wearables to monitor health, with some of these sharing data with clinicians (and some not). The coronavirus pandemic was discussed as a stimulus for lasting change that may lay the groundwork for the future implementation of different types of RMT. Respondents mentioned as key issues worthy of consideration when implementing new technologies.

**Barriers and Concerns**

**Barriers Covered in the Survey**

There were mixed views on whether false positives and false negatives from RMT would be problematic, reflecting the lack of consensus in this area in the quantitative results. One interviewee stated that false positives or negatives would not undermine the usefulness of RMT, as such results can be expected from any measure, whether digital or analog. Interviewees also mentioned interoperability and patient anxiety (covered in the survey), where if RMT made patients more anxious, this could drive the increased use of clinical resources, which could be problematic. Another interviewee mentioned that carers may be made more anxious by the introduction of RMT:

*Someday parents can sometimes focus too much on stuff that’s not relevant, and then that gets in the way of them focusing on the more important things.* [Participant 4]

**Barriers Not Covered in the Survey**

There was concern among interviewees that patients may not adhere well to monitoring regimes; that devices would be lost, stolen, or sold; or that patients may not have suitable internet or mobile data to enable the use of RMT. Other worries were that patients may buy cheap, less accurate, and unregulated devices if the appropriate devices are not provided for free and that the implementation of RMT would only be successful if patients believed that it would work, requiring adequate patient education.

Health care culture was identified as an important barrier. It was suggested that HCPs were often unaware of what technologies are readily available to support their patients. Interviewees stated that, in the United Kingdom, it is very difficult for an HCP to persuade more senior staff members of the necessity for any particular kind of technology that they were aware of:

*They would say, oh, you gotta do a business case if you want to introduce new technology. The business case is quite difficult to do. There’s very little admin support for it, unless it’s a very high priority of the trust.* [Participant 4]

Legal and regulatory systems were also highlighted, with interviewees suggesting that these are not currently set up for technologies that are recurrently updated, eg, algorithms that update themselves. Data protection and ownership were also mentioned as key issues worthy of consideration when implementing new technologies.

Further research is necessary to determine the accuracy and reliability of off-the-shelf consumer technologies used within the system. CIs for their precision would be required to make use of these parameters successfully. The participants recommended trials of the specific use cases of the technologies under development to establish cost-effectiveness.

**Discussion**

**Overview**

The purpose of this mixed methods, sequential explanatory Delphi study was to prioritize among use cases for RMT in central nervous system disorders, which had been cocreated with clinicians and patients within the RADAR-CNS consortium. The results from the study have identified those likely to be of the most practical use and clinical benefit.
study has also contributed knowledge on country- and context-specific factors affecting implementation and revealed areas of consensus and disagreement among HCPs on practical aspects of RMT implementation.

**Principal Findings**

**Epilepsy**

Priority use cases for RADAR-CNS RMT in epilepsy from this study are: seizure alert, seizure counting, triage support, and trend analysis. All 5 use cases for epilepsy were considered “beneficial to patients”; however, use case 3 (risk scoring) was considered less likely to facilitate or catalyze care or be beneficial to clinical teams. Participants suggested that risk scoring would bring medicolegal risks and would be less practical and more difficult to achieve than other use cases.

Although other authors have commented on the potential of technology in these areas [32-34], our study has validated these as the most useful applications of RMT with clinicians treating epilepsy across Europe. Participants in the study were concerned about the possible medicolegal consequences of using devices to estimate the risk of seizures in epilepsy, which might be expected, given that prior work has highlighted the medicolegal responsibilities of clinicians treating patients with epilepsy in relation to driving and employment in the teaching profession [35].

**Multiple Sclerosis**

There was little consensus on the benefits of the use cases in MS. Despite repeated efforts to avoid dropout, the results in round 2 were only obtained from 3 participants, limiting the robustness of these results. There was greater consensus among the 6 participants completing round 1, particularly for use case 1 (detecting silent progression) and use case 2 (detecting depression in MS). The qualitative findings showed some dependencies, eg, that the system could hold value for the detection of silent progression of the disease if relevant treatments are available, whose delivery could be optimized by applying them at specific times relevant to the timely detection of changes by the system.

On reviewing our findings, patients commented that cognition is an important aspect of MS to measure the silent progression of the disease. They also mentioned that compliance with monitoring programs may be greater where they experienced a decline or instability in their condition. Related work has found that clinicians have concerns about collecting data with little clinical relevance [3,36], and our work illustrates this in the specific case of MS, where HCPs were skeptical about the benefits of detecting silent progression if no treatments were available to address it.

The UK Biobank now includes data on sleep and physical activity from wearable devices, and researchers have begun to analyze these data for various purposes [37]. Here, we provide evidence that some clinicians support such storage of data from patients with MS, although some are unclear about the benefits to the donating patient. Issues around the security and privacy of patient wearable data in biobanks were mentioned by the interviewees. The World Medical Association has adopted a declaration on ethical considerations regarding health databases and biobanks [38], and such issues will need to be duly considered for any future storage and sharing of wearable and smartphone sensor data in biobanks.

**Depression**

The use cases to be prioritized for RMT in depression include detecting trends, reviewing treatment, and self-management. Participants agreed that there would be benefits for all 5 of the depression use cases, although there was less consensus for use case 4 (comorbid monitoring), where qualitative results showed that participants thought it would be difficult to distinguish between symptoms of depression and symptoms of comorbid physical illnesses. Use case 5 (carer alert) was criticized in the interviews, as informal carers may not have the requisite skills or knowledge to adequately support patients with depression. Use cases 1 to 3 were seen as useful provided evidence could be generated to support their effectiveness.

Self-management was one of the most favored use cases for RMT in depression. There is some evidence supporting the effectiveness of smartphone apps for depression self-management [39], although qualitative evidence shows that users may download apps for short-term, inquisitive trials and may not adhere for longer term use [40]. Further work is required to establish what factors affect adherence to depression self-management apps and how the RADAR-CNS RMT system can be presented to patients to encourage continued use.

Other use cases supported by participants for depression were use case 1, detecting trends and use case 2, reviewing treatment, including monitoring of treatment response and side effects. Existing methods of detecting trends and monitoring treatment response rely predominantly on pen-and-paper mood diaries and outcome measures, such as the Patient Health Questionnaire-9. However, many such outcome measures have been converted to digital versions [41-43], and electronic mood diaries are also becoming available as smartphone or web applications [44,45], with some efforts to automatically detect symptoms and analyze trends from these user-entered data [2]. The multimodal, passive, and active combinations that could be offered using the RADAR-CNS RMT system are less commonly available, although some research has begun in this area [46]. This type of approach likely requires a higher level of regulatory approval than electronic mood diaries [47].

**Further Questions**

There was lower consensus and stability on these questions than those relating to the use cases, suggesting more differences of opinion and less fixed views on these issues. However, our findings clarify some points: It was expected that the implementation of RMT would require greater amounts of staff time and financial resources than the status quo. Evidence of cost-effectiveness was considered imperative. The RMT data were considered valuable for reducing uncertainty and moving beyond subjective measures. It has been suggested that RMT could offer benefits under conditions other than the 3 under consideration in RADAR-CNS, eg, bipolar disorder. There were mixed views on how frequently the data should be collected. Passive data were considered more useful than actively collected...
data because they required less input from the patient, who may forget to complete questionnaires and because passive data were considered to be less subjective.

Country-specific comments highlighted the difference between countries with NHSs (the United Kingdom, the Netherlands, and Spain) compared with countries with insurer-based health care systems (Germany). It was mentioned that RMT could be used to persuade customers to join 1 particular insurer or health service over another. Differences were also highlighted where countries may have a pay-per-patient-visit setup, wherein the use of RMT to check patients are stable and therefore reduce appointments would be financially problematic. The interviews covered only a limited range of countries, and there may be other barriers or facilitators to using RMT in health care systems in other countries. Barriers were raised regarding inequality between settings, patient behavior, health care culture, legal or regulatory issues, and use of off-the-shelf technologies.

**Limitations**

We would caution against overinterpretation of the consensus scores for MS, where only 3 participants responded in the second round. Unfortunately, we could not recruit more experts in MS during the time available for the study, despite extending the recruitment window and using multiple recruitment methods. This is a shortcoming of many studies seeking the views of MS clinicians, as there are few medics specializing in this condition. However, the combination of item ratings and interview findings relating to MS provides useful insights into how RMT could be used for patient benefits in this condition.

In addition, the aim of this study was to explore the applicability of the RADAR-CNS RMT system in 3 central nervous system disorders, limiting its relevance to other conditions or monitoring platforms. However, the methodology set out here will likely be of interest to others seeking approaches to evaluate the application of novel systems in health care, and the findings will be of interest to those developing a variety of digital interventions for the specific conditions discussed.

**Interpretation and Implications for Research and Practice**

Our work highlights the potential value of the implementation of RMT for 3 central nervous system disorders, including which applications of RMT would enable something new, enhance existing care, speed up existing processes, or facilitate or make easier the care of patients [14,18]. These results indicate that clinicians would consider RMT patient data to have sufficient value that it would be worth a financial outlay to implement RMT in clinical practice. However, health economic evaluation is required to determine the cost-effectiveness of applying RMT in each of these conditions [48]; and the choice to implement is likely to be determined by whether cost-effectiveness is judged to meet local criteria that can vary by country [49].

The findings from this study and our prior work provide an indication of where costs may be incurred if RMT is implemented in a health care service [17]. The costs are likely to include introducing staff roles to manage patient data and provide technical support. Technical support staff could assist patients in setting up and maintaining RMT devices and support clinicians in making the best use of patient RMT data. The extra time for clinical staff to review patient data would be cost incurring, where fewer patients can be seen, although if this results in improvements in care and thereby patient condition, there may be an overall improvement in efficiency. The devices themselves and their maintenance also incur a cost for a health care service wishing to implement them. Although many of the technical devices incorporated within the RADAR-CNS system are consumer-grade technologies that may be owned by patients, our findings suggest that there is a need to provide each patient with devices meeting specific standards of accuracy, adding to costs.

Participants largely suggested that decisions about the implementation of new technologies were top-down and that commissioners and health service leaders would need to be convinced of the benefits of RMT for it to be implemented. In the United Kingdom, commissioners are often involved in redesigning services to incorporate new and beneficial technologies or products [50]. The exception to this was Germany, where doctors who run their own services at a local level are able to work with their budget holders to decide on the implementation of particular technologies. However, it is expected that these technologies should be demonstrably both clinically effective and cost-effective. In the United Kingdom, the National Institute of Health and Care Excellence provides guidance on the evidence required for approval of digital technologies [51]. Similarly, in the European Union, the European Medicines Agency works with groups to develop novel health care technologies to provide scientific advice [52]. Close working with these organizations would facilitate the further development and evaluation of the RADAR-CNS RMT system.

**Conclusions**

RMT offers new possibilities for the assessment of epilepsy, MS, and depression by enabling new ways of caring for patients, enhancing existing processes, facilitating care, and, in some areas, catalyzing or speeding up existing processes. Our study shows promise for the use of wearable technologies such as Fitbits, wrist-worn epilepsy seizure detection devices, and other wearable accelerometers, together with smartphones, in remote measurement and assessment systems. Priority use cases for the further development and evaluation of RMT in epilepsy according to this study are: more accurate seizure records, automatically analyzing trends, improving triage through review of RMT data, and alerting patients and carers to imminent seizures. In depression, priority use cases are using RMT to detect trends or changes in the condition, monitoring treatment response and using data to inform treatment decisions, and self-management through monitoring and behavioral nudges. Some clinicians recognize the benefits of RMT in the management of MS by enabling the detection of the silent progression of the disease, detecting depression, and enabling the donation of data to biobanks, although clear priorities among these cannot be distinguished from our results.

The implementation of RMT will have different implications in different health service models. Cost-effectiveness studies will be required to understand the economic value of
implementing RMT in clinical practice in different regions. Future work could also usefully explore the potential of RMT in other clinical conditions, as well as seeking to understand factors affecting adherence to remote measurement regimes in real-world conditions. Clinicians participating in this study considered passive data to be more reliable than active data, and further work is required to understand whether digital biomarkers based on passive remote measurement data can be used as proxies or replacements for existing measures in these and other clinical conditions. Overall, the Delphi method has been useful for prioritizing use cases and deriving insights into the practical application of RMT in clinical practice.

Acknowledgments
The authors would like to acknowledge the support of all members of the Remote Assessment of Disease and Relapse—Central Nervous System (RADAR-CNS) consortium, who are named on the RADAR-CNS web page [6]. The RADAR-CNS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant 115902 [53]. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. This communication reflects the views of the RADAR-CNS consortium, and neither the Innovative Medicines Initiative nor the European Union and European Federation of Pharmaceutical Industries and Associations are liable for any use that may be made of the information contained herein. The funding body has not been involved in study design, data collection or analysis, or data interpretation. This research was supported by the National Institute for Health and Care Research MindTech MedTech Co-operative, National Institute for Health and Care Research Nottingham Biomedical Research Centre, and National Institute for Health and Care Research Applied Research Collaboration East Midlands (United Kingdom). The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute for Health and Care Research, or the Department of Health and Social Care. We are grateful for the contributions of all members of the Patient Advisory Board and its coordinators at Kings College London.

Data Availability
The data from the study may be requested from the authors and will be made available on reasonable request, on approval by all members of the Remote Assessment of Disease and Relapse—Central Nervous System consortium, in accordance with the contractual agreements in place between institutions. A bilateral agreement must be entered to determine the terms and conditions of data sharing.

Authors' Contributions
The survey and interview guide were designed by JAA, MPC, RM, and CH, with input from JW, SL, SET, JD, and SIZ. Recruitment was conducted by JAA, with assistance from the Remote Assessment of Disease and Relapse—Central Nervous System consortium. The members of the expert panel included VSA-A, WPW, JJ, SM, AH, AR, HGR, FD, SB, AS, JLF, AM, AC, JT-B, NB-I, and AZ. The results were analyzed by JAA, MPC, and BG. The manuscript was drafted by JAA. Comments on the manuscript have been provided by all coauthors. All authors have read and approved the manuscript.

Conflicts of Interest
AZ has received travel expenses for scientific meetings from Biogen Idec, Merck Serono, and Novartis; speaking honoraria from Eisai; and a study grant from Novartis. RM has received research funding from Magstim plc, P1Vital Ltd and Electromedical Products Inc. RM has also received fees for serving on a Data Monitoring and Ethics Committee from Novartis.

Multimedia Appendix 1
Illustrations of final use cases.
[DOCX File , 2132 KB - neuro_v2i1e41439_app1.docx ]

Multimedia Appendix 2
Delphi study survey instrument.
[DOCX File , 198 KB - neuro_v2i1e41439_app2.docx ]

Multimedia Appendix 3
Interview guide.
[DOCX File , 15 KB - neuro_v2i1e41439_app3.docx ]

Multimedia Appendix 4
Research Ethics Committee Letter of Approval for Delphi Study.
[DOCX File , 167 KB - neuro_v2i1e41439_app4.docx ]
Multimedia Appendix 5
Results of consensus and stability analyses.
[DOCX File, 59 KB - neuro_v21e41439_app5.docx]

Multimedia Appendix 6
Illustrative extracts from interview transcripts relating to each use case.
[DOCX File, 18 KB - neuro_v21e41439_app6.docx]

References


Abbreviations
MS: multiple sclerosis
NHS: National Health Service
PAB: Patient Advisory Board
RADAR-CNS: Remote Assessment of Disease and Relapse–Central Nervous System
RMT: remote measurement technology
A Semantic Relatedness Model for the Automatic Cluster Analysis of Phonematic and Semantic Verbal Fluency Tasks Performed by People With Parkinson Disease: Prospective Multicenter Study

Tom Hähnel¹, Tim Feige², Julia Kunze¹, Andrea Epler¹, Anika Frank¹,², Jonas Bendig¹, Dr med; Nils Schnalke¹,², Dr med; Martin Wolz³, Dr med; Peter Themann⁴, Dr med; Björn Falkenburger¹,², Dr med

¹Department of Neurology, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
²German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany
³Department of Neurology and Geriatrics, Eiblandklinikum Meißen, Meißen, Germany
⁴Department of Neurology, Klinik am Tharandter Wald, Halsbrücke, Germany

Corresponding Author:
Tom Hähnel, Dr med
Department of Neurology
University Hospital and Faculty of Medicine Carl Gustav Carus
Technische Universität Dresden
Fetscherstraße 74
Dresden, 01307
Germany
Phone: 49 351 458 ext 11880
Fax: 49 351 458 8811880
Email: tom.haehnel@uniklinikum-dresden.de

Abstract

Background: Phonematic and semantic verbal fluency tasks (VFTs) are widely used to capture cognitive deficits in people with neurodegenerative diseases. Counting the total number of words produced within a given time frame constitutes the most commonly used analysis for VFTs. The analysis of semantic and phonematic word clusters can provide additional information about frontal and temporal cognitive functions. Traditionally, clusters in the semantic VFT are identified using fixed word lists, which need to be created manually, lack standardization, and are language specific. Furthermore, it is not possible to identify semantic clusters in the phonematic VFT using this technique.

Objective: The objective of this study was to develop a method for the automated analysis of semantically related word clusters for semantic and phonematic VFTs. Furthermore, we aimed to explore the cognitive domains captured by this analysis for people with Parkinson disease (PD).

Methods: People with PD performed tablet-based semantic (51/85, 60%) and phonematic (69/85, 81%) VFTs. For both tasks, semantic word clusters were determined using a semantic relatedness model based on a neural network trained on the Wikipedia (Wikimedia Foundation) text corpus. The cluster characteristics derived from this model were compared with those derived from traditional evaluation methods of VFTs and a set of neuropsychological parameters.

Results: For the semantic VFT, the cluster characteristics obtained through automated analyses showed good correlations with the cluster characteristics obtained through the traditional method. Cluster characteristics from automated analyses of phonematic and semantic VFTs correlated with the overall cognitive function reported by the Montreal Cognitive Assessment, executive function reported by the Frontal Assessment Battery and the Trail Making Test, and language function reported by the Boston Naming Test.

Conclusions: Our study demonstrated the feasibility of standardized automated cluster analyses of VFTs using semantic relatedness models. These models do not require manually creating and updating categorized word lists and, therefore, can be easily and objectively implemented in different languages, potentially allowing comparison of results across different languages. Furthermore, this method provides information about semantic clusters in phonematic VFTs, which cannot be obtained from traditional methods. Hence, this method could provide easily accessible digital biomarkers for executive and language functions in people with PD.
cognition; executive function; language function; mild cognitive impairment; Parkinson disease; Parkinson disease dementia; semantic clusters; semantic relatedness; verbal fluency tasks

Introduction

Cognitive Deficits in People With Parkinson Disease

Parkinson disease (PD) is the fastest growing neurological disease and the second most common neurodegenerative disease [1]. Cognitive deficits are a frequent problem in people with PD. Approximately 10% to 20% of people with PD show a mild cognitive impairment [2], and approximately 46% of people with PD develop PD dementia (PDD) within 10 years after diagnosis [3]. PDD results in higher health-related costs and a reduced quality of life and, therefore, is of high importance for affected people and health care systems [2]. In addition, PDD constitutes 1 of the 4 milestones that occur, on average, 4 years prior to death and usher the terminal phase of the disease [4].

Cognitive decline in people with PD is characterized by deficits in attention, executive functions, visuospatial functions, memory, and language function [5]. Cognitive functions in people with PD are normally measured using paper-based neuropsychological tests [5,6]. These tests are time-consuming and require experienced raters.

Clusters in the Verbal Fluency Task Transcript

Verbal fluency tasks (VFTs), by contrast, require less time and can report both executive and language functions [5,7]. There are 2 types of VFTs. In the semantic VFT, participants have to produce as many words as possible from 1 specific semantic category within 1 minute. The category “animal” is used most often. In the phonematic VFT, participants have to produce as many words as possible starting with a specific letter within 1 minute. Counting the total number of words produced by the person constitutes the most common analysis for both types of VFTs.

People generally do not produce these words in an evenly spaced temporal sequence but in clusters that often share semantic or phonematic similarities [8-15]. Traditionally, these clusters have been determined manually using 2 methods described by Troyer et al [9]. Words produced in the semantic VFT tend to form clusters of semantically related words. For example, a participant could start with a cluster of pets (dog and cat) and switch to a cluster of animals from Africa (elephant, giraffe, and lion). In the traditional analysis, the identification of these clusters and switches between clusters is based on predefined lists of, for example, animals (eg, a list of African animals and a list of pets). Words produced in the phonematic VFT have traditionally been analyzed using a set of phonematic rules [9]. One of the rules, for example, is to group words starting with the same 2 letters (eg, simple, simulate, and silly).

After the identification of word clusters, characteristics such as the mean cluster size and number of switches between clusters are calculated. Several studies suggested that the size of clusters is associated with language functions [10,14,16], whereas the number of switches is more strongly associated with executive functions [10,17]. Other authors, however, obtained conflicting results [12,17,18], and some studies found the cluster size and number of clusters to be highly correlated, which means that they might not represent independent parameters at all [7,17,19].

Analysis of word clusters in the VFT has been limited by several factors. First, the lists used to analyze the semantic VFT must be created manually, which entails subjectiveness. Second, they can exclusively be used for only 1 language. Third, simple lists may not capture all the individual associations that occur during testing. Fourth, the relatedness of consecutive words can only be classified dichotomously, that is, the word either belongs to the same cluster or not. Thus, it is not possible to quantify the semantic or phonematic “distance” of consecutive words.

In recent years, several approaches have been developed to overcome these disadvantages and allow for an automated, more objective, and quantitative analysis. In general, these approaches identify semantic clusters based on the semantic relatedness of words using mathematical models trained on a large text corpus [20-31].

In some approaches, semantic relatedness is directly estimated from structured knowledge sources such as ontologies or encyclopedias. For example, databases storing hierarchical relations between words have been used to estimate semantic relatedness [20]. Thus, an ontology where cat and dog are both elements of the parent group carnivore leads to a higher semantic relatedness between these animals than between cat and cow. Other models estimate semantic relatedness based on the link structure between web-based encyclopedia articles [32]. These models make explicit use of knowledge created by humans, but they require complex and highly structured training sets.

A more widely used approach for estimating semantic relatedness is the latent space analysis, which is based on the co-occurrence of words in training texts [21-23]. Thereby, 2 words are assumed to be semantically related if they co-occur with similar words in the training texts.

Finally, recent approaches also consider the position of words in relation to each other [24-29]: Word2Vec, for instance, uses a sliding window to estimate semantic relatedness by analyzing surrounding words [33]. In this approach, a neural network is trained to predict a word given its surrounding words (continuous bag-of-words method) or to predict the surrounding words given a centered word (skip-gram method). On the basis of this training, semantic relatedness can be estimated from the similarity of the learned context in which these words occur.

Most previous studies analyzed VFTs performed by people with mild cognitive impairment, Alzheimer disease [20,25,28,30], or psychiatric diseases [22,23,27,29]. For people with PD, there is only very limited evidence from 1 study [17]. In this study,
Farzanfar et al [17] showed that applying a semantic relatedness model to semantic VFTs performed by people with PD is feasible. Here, executive function correlated with the number of cluster switches but not with the cluster size. Whether a semantic relatedness model can also be applied to phonemic VFTs performed by people with PD has not been explored yet.

Aim of This Study

The aim of this study was to evaluate the feasibility of an automatic cluster analysis based on semantic relatedness in people with PD using voice recordings of semantic and phonemic VFTs. In addition, we aimed to validate the potential of the resulting cluster parameters as digital biomarkers for executive and language functions in people with PD. Finally, we provide our previously trained models for semantic relatedness in different languages to facilitate further research by others [34,35].

Clinical Implications

Our study provides a tool for the automatic identification of semantically related word clusters in VFTs. VFTs are a widely used assessment for capturing cognitive functions in clinical practice and research. Although counting the total number of words produced within 1 minute constitutes the commonly used analysis for VFTs, further analysis of word clusters can provide additional information about executive and language functions. However, traditional methods of cluster identification lack standardization, require considerable manual work, and are language specific, thus limiting their applicability.

We show that cluster identification is possible using a model of semantic relatedness that overcomes these limitations. We prove that this automated approach provides valid digital biomarkers for executive and language functions.

By publishing our source code together with a readily trained model, we will allow other researchers to easily use this approach in their own studies. Thus, this study will allow further trials to capture more information about executive and language impairments without requiring additional time-consuming assessments. Furthermore, this will lead to more reliable and better comparable measurements of executive and language functions as cognitive outcomes in clinical trials. This approach is not limited to people with PD and can also be applied to people with other diseases with impaired executive or language function.

Methods

Recruitment

People with PD were recruited from 3 inpatient and outpatient movement disorder clinics in east Saxony, Germany, between May 2021 and August 2022. Participants with a clinically probable diagnosis of PD according to the current clinical diagnostic criteria [36], sufficient German language skills, and a Montreal Cognitive Assessment (MoCA) score >15 were included in the study. The severity of motor symptoms was assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) subscale III [37]. Levodopa equivalent doses were calculated using the recommended conversion factors [38].

Ethics Approval

This study was approved by the institutional review board of Technische Universität Dresden, Germany (IRB00001473 and BO-EK-149032021). Written informed consent was obtained from all the participants before inclusion in the study.

Phonematic and Semantic VFTs

Phonematic and semantic VFTs were performed without supervision using a self-developed app on an iPad 8 (Apple Inc) running iOS version 14. The semantic VFT was added later to the app, thus leading to fewer recordings for this task. For both VFTs, words with the same word stem, word repetitions, and proper names were not allowed. Instructions for the VFTs outlining these rules were presented to the participants before the test on the tablet. The phonematic VFT was performed first, and the semantic VFT was performed second. After reading the general instructions, the participant was requested to continue to the next page. At this time, the letter “S” (for the phonematic VFT) or the category “animals” (for the semantic VFT) was shown, and the voice was recorded for 60 seconds using the tablet’s internal microphone. Speech was detected and transcribed automatically using the Apple Speech Framework (Apple Inc) in iOS 14, which allows local speech processing on the device itself. The transcripts were checked manually by an investigator, and speech recognition errors were corrected. The transcripts were also checked for words that violated any of the aforementioned rules. Transcripts with >25% of violations were excluded from the analysis. In addition, recordings with no words spoken within the first 10 seconds were removed from the analysis because it was deemed unclear whether the person had understood the task.

Speech Recognition Error Rate Calculation

The error rate of the automatically transcribed VFT recordings was measured as normalized Levenshtein distance. Therefore, we counted the numbers of insertions, deletions, and substitutions of words that would be required to change the automatically transcribed word list to the correct word list. This was done using the Python package pyl LEV (version 1.4) [39]. Levenshtein distance was normalized by dividing it by the number of words in the correct word list.

List-Based Clustering of the Semantic VFT

Traditional cluster analysis of the semantic VFT is based on fixed thematic lists of animals. These are based on shared features, such as geographical regions (eg, Africa), habitats (eg, water, farm, and pets), or species (eg, birds). To create these categorical lists, we translated the categories and animal lists used in the study by Troyer [11]. All animal words that were not covered by this translation were assigned to existing categories, or the category “animals” (for the semantic VFT) was created as needed. Animal words were allowed to be part of multiple lists (eg, parrot is part of the lists “pet” and “bird”). The resulting categories and corresponding animal word lists can be found in Multimedia Appendix 1.

Clusters were formed of consecutive words that occurred on at least 1 common list. The size of a cluster was determined by the Levenshtein distance between the word list and the correct word list.
Different semantic relatedness thresholds were used for the optimization, which is described in detail in this section. The listed parameters are the result of hyperparameter tuning for model training were identical between both VFTs. Semantic and phonematic VFTs. All other hyperparameters used for model training were identical between both VFTs. The mean cluster size was obtained by also including clusters of single words. The number of switches was defined as the number of clusters, including clusters of single words, minus 1. To maintain consistency with the protocol of Troyer et al [9], rule violations were not excluded in the calculation of these cluster characteristics. The total word count comprised the number of words after removing rule violations.

**Rule-Based Clustering of the Phonematic VFT**

Traditional cluster analysis of the phonematic VFT is based on fixed phonematic rules. Usually, four rules are used to identify words belonging to a cluster: (1) words starting with the same 2 letters (eg, summer and Sunday); (2) rhyming words (eg, sand and stand); (3) words differing only in 1 vowel sound (eg, sat and seat); and (4) homonyms, if indicated by the test person (eg, some and sum) [9]. Clusters were formed of consecutive words that fulfilled at least 1 common phonematic rule. The size of a cluster was calculated as the number of words within the cluster minus 1. The mean cluster size was obtained by also including clusters of single words. The number of switches was defined as the number of clusters, including clusters of single words, minus 1. To maintain consistency with the protocol of Troyer et al [9], rule violations were not excluded in the calculation of these cluster characteristics. The total word count comprised the number of words after removing rule violations.

**Semantic Relatedness Clustering**

In addition to the traditional clustering methods, we implemented a semantic relatedness model based on a Word2Vec approach. In brief, this model is based on a neural network that depicts the semantic context of words in texts. To achieve this, the neural network is trained on a large text corpus in which the words surrounding each given word are analyzed. As a result, the semantic context of each word can be represented as a high-dimensional vector. The semantic relatedness (“distance”) of 2 words can be expressed as the cosine between 2 of these vectors.

The Word2Vec model was created and trained using the Python package gensim version 4.0.1 [40] with Python 3.9.5 [41]. We used the freely available German Wikipedia (Wikimedia Foundation) corpus for model training [42]. To obtain optimal training results, 3 hyperparameters needed to be set: the dimensionality of the semantic relatedness space, window size for the surrounding words, and training algorithm. In addition, a fixed threshold for semantic relatedness needed to be set to define the word clusters. To find the optimal hyperparameter values, we performed a grid search using the following values:

<table>
<thead>
<tr>
<th>Dimensions of semantic relatedness space</th>
<th>Semantic VFT</th>
<th>Phonematic VFT</th>
</tr>
</thead>
<tbody>
<tr>
<td>200, 500, and 1000</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Skip-gram</td>
<td>Skip-gram</td>
<td>Skip-gram</td>
</tr>
<tr>
<td>0.30</td>
<td>0.30</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Hyperparameters used for training the semantic relatedness model and identifying semantically related clusters.

The listed parameters are the result of hyperparameter optimization, which is described in detail in this section. Different semantic relatedness thresholds were used for the semantic and phonematic VFTs. All other hyperparameters used for model training were identical between both VFTs.
Paper-Based Neuropsychological Tests

The overall cognitive function of all the participants in this study was assessed using the MoCA [43]. In addition, the Frontal Assessment Battery (FAB) and Trail Making Test (TMT) B were used as measures of executive function [44,45]. The Boston Naming Test (BNT) [44] and Mehrfachwahl-Wortschatz-Intelligenztest B (MWT) [46] were performed to measure language function and crystallized intelligence. In the MWT, the participant has to distinguish existing words from fictive words in several word lists. The German versions of all the aforementioned tests were used.

Statistical Analyses

The correlation of the MDS-UPDRS III item “Dysarthria” with the speech recognition error rate was calculated using Spearman rank correlation. All other correlations were calculated as Pearson correlations. For the comparison of the neuropsychological test results, a Mann-Whitney U test was performed because the neuropsychological test results were not normally distributed. Statistical tests were performed using Python 3.10.8 [41] with the scipy 1.9.3 package [47]. The network graph was created using the networkx 2.8.8 Python package [48]. For clarity, the following data are not shown in the network graph: correlations between 2 neuropsychological test results, neuropsychological test results with no correlation with the clustering characteristics, and Pearson correlation coefficients between 2 cluster characteristics.

Figure 1. Block diagram of the study design. VFT: verbal fluency task.

Results

Patient Characteristics and Speech Recognition

In total, 137 recordings were obtained from 85 people with PD, specifically 80 recordings (94% of participants) for the phonematic VFT and 57 (67% of participants) for the semantic VFT. Of the 137 recordings, 6 (4.4%) recordings (phonematic: n=5, 6%; semantic: n=1, 2%) were excluded because the rules of the test were violated, 1 (1%) phonematic recording was removed because not a single word was spoken within the first 10 seconds of the task, and 5 (6%) phonematic and 5 (9%) semantic recordings were excluded because the participants misunderstood the task. This resulted in 69 (out of 80, 86%) phonematic VFT and 51 (out of 80, 89%) semantic VFT transcripts, which were used for traditional and semantical relatedness analyses (Figure 1).

Clinical characteristics of the patients are listed in Table 2. The recordings were transcribed using automatic speech recognition and checked manually for errors. The total error rate, calculated as normalized Levenshtein distance for both VFTs, was 61.8%. In detail, the semantic VFT showed a somewhat lower error rate (52%) than the phonematic VFT (69%), but this difference was not statistically significant (\(P=0.15\); Figure S1A in Multimedia Appendix 2). Furthermore, the error rate correlated significantly with the extent of dysarthria as reported by the corresponding MDS-UPDRS III item (\(p=0.26, P=0.005\); Figure S1B in Multimedia Appendix 2).

---

Figure 1. Block diagram of the study design. VFT: verbal fluency task.
Table 2. Clinical characteristics of people with Parkinson disease included in the phonematic and semantic analyses.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Phonematic VFT (n=69)</th>
<th>Semantic VFT (n=51)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>61.2 (12.3)</td>
<td>60.4 (12.3)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>27 (39)</td>
<td>16 (31)</td>
</tr>
<tr>
<td>Male</td>
<td>42 (61)</td>
<td>35 (69)</td>
</tr>
<tr>
<td>Hoehn and Yahr ON&lt;sup&gt;b&lt;/sup&gt;, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild (0-2)</td>
<td>52 (75)</td>
<td>44 (86)</td>
</tr>
<tr>
<td>Moderate (2.5-3)</td>
<td>14 (20)</td>
<td>6 (12)</td>
</tr>
<tr>
<td>Severe (4-5)</td>
<td>3 (4)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Disease duration (years), mean (SD)</td>
<td>7.4 (5.1)</td>
<td>5.9 (4.0)</td>
</tr>
<tr>
<td>Subtype, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tremor dominant</td>
<td>13 (19)</td>
<td>11 (22)</td>
</tr>
<tr>
<td>Akinetic rigid</td>
<td>28 (41)</td>
<td>19 (37)</td>
</tr>
<tr>
<td>Mixed</td>
<td>28 (41)</td>
<td>21 (41)</td>
</tr>
<tr>
<td>LEDD&lt;sup&gt;c&lt;/sup&gt;, mean (SD)</td>
<td>692 (356)</td>
<td>670 (349)</td>
</tr>
<tr>
<td>MDS-UPDRS&lt;sup&gt;d&lt;/sup&gt; III, mean (SD)</td>
<td>21 (12)</td>
<td>19 (10)</td>
</tr>
<tr>
<td>MoCA&lt;sup&gt;e&lt;/sup&gt; score, mean (SD)</td>
<td>26.5 (2.6)</td>
<td>26.7 (3.0)</td>
</tr>
<tr>
<td>DBS&lt;sup&gt;f&lt;/sup&gt;, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>7 (10)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>No</td>
<td>62 (90)</td>
<td>47 (92)</td>
</tr>
</tbody>
</table>

<sup>a</sup>VFT: verbal fluency task.
<sup>b</sup>People with Parkinson disease can be examined in an ON or OFF state. ON refers to the typical functional state when patients are receiving medication and have a good response.
<sup>c</sup>LEDD: levodopa equivalent daily dose.
<sup>d</sup>MDS-UPDRS: Movement Disorder Society - Sponsored Revision of the Unified Parkinson's Disease Rating Scale.
<sup>e</sup>MoCA: Montreal Cognitive Assessment.
<sup>f</sup>DBS: deep brain stimulation.

## Traditional Clusters and Semantically Related Clusters

Cluster characteristics were analyzed for both phonematic and semantic VFTs using (1) traditional clustering methods and (2) the novel semantic relatedness method.

For the phonematic VFT, the traditional cluster analysis is based on phonematic rules, as described in the Methods section. In our data, most of the phonematic word pairs (297 word pairs) were identified as clusters because the words shared the same first 2 letters. Only a few clusters were identified by applying the remaining phonematic rules: 6 word pairs were identified as clusters because the words rhymed, 1 word pair was identified as a cluster because the words differed only in 1 vowel, and no homonyms were found. An example of rule-based phonematic clusters is shown in Figure 2A.

In contrast to these phonematic rules, the semantic relatedness method identifies clusters based on a model that can quantify the relatedness of word pairs (Figure 3). The semantic relatedness model was trained on the German Wikipedia corpus. On the basis of this large training data set, this method can identify entirely different clusters from those identified through the rule-based system, for example, the sequence salad, celery, and salami (German: *salat*, *sellerie*, and *salami*) or Zambia and Senegal (German: *Sambia* and *Senegal*), in which words did not share phonematic similarities (Figure 2C). Compared with the traditional rule-based clustering method, in the semantic relatedness method, the clusters had a smaller size, and switches between clusters occurred slightly more often (Table 3). Nonetheless, the number of switches obtained through both methods correlated strongly ($r=0.77; P<.001$), whereas the mean cluster size did not correlate between the clustering methods ($P=.13$; Figure 4), potentially because these clusters were construed differently.

For the semantic VFT, the traditional clustering method is based on lists of animals with different themes (eg, farm animals or birds). Words are recognized as a cluster if they are found on at least 1 common list. An example of such list-based clusters is shown in Figure 2B. The clusters in the semantic VFT identified through the list-based method were in general comparable with those identified through the semantic relatedness approach (Figure 2D). This is consistent with the
fact that the clusters were generated in a more similar way for the semantic VFT than for the phonematic VFT. However, some additional clusters were detected through the semantic relatedness method. For instance, the cluster bunny and hedgehog may be based on a familiar German fairy tale, and the cluster fox and goose may be based on a common German nursery rhyme.

As for the phonematic VFT, switches between clusters occurred slightly more often with the semantic relatedness method than with the traditional list-based clustering method, and the clusters identified through the semantic relatedness method were slightly smaller than those identified through the traditional list-based clustering method (Table 3). The numbers of switches obtained using the 2 methods correlated significantly ($r=0.59; P<.001$), as did the cluster sizes ($r=0.32; P=.02$; Figure 4). The strength of the correlation observed in our work is comparable with that observed in a recent study that analyzed traditional and semantic clusters obtained from the semantic VFT performed by people with PD [17].

Figure 2. Phonematic and semantic clustering examples. Cluster examples for the traditional rule-based (A) and list-based (B) technique and the semantic relatedness technique (C and D). Words belonging to the same cluster are displayed in the same color (in blue or orange). For the list-based clustering (B), the common lists for clusters with >1 word is displayed next to each word pair. VFT: verbal fluency task.
Figure 3. Identification of clusters by calculating the pairwise semantic relatedness. The figure depicts the pairwise semantic relatedness of all sequential word pairs from the phonematic verbal fluency task (VFT) shown in Figure 2C. Words with a pairwise semantic relatedness above the threshold form clusters.

Table 3. Characteristics of the traditional (rule and list based) and semantic relatedness clusters.

<table>
<thead>
<tr>
<th></th>
<th>Phonematic VFTa</th>
<th>Semantic VFT</th>
<th>Semantic VFT</th>
<th>Semantic VFT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rule based</td>
<td>Semantic relatedness</td>
<td>List based</td>
<td>Semantic relatedness</td>
</tr>
<tr>
<td>Total word count, mean (SD)</td>
<td>12.3 (4.6)</td>
<td>12.3 (4.6)</td>
<td>19.6 (5.7)</td>
<td>19.6 (5.7)</td>
</tr>
<tr>
<td>Mean cluster size, mean (SD)</td>
<td>0.4 (0.4)</td>
<td>0.2 (0.1)</td>
<td>0.9 (0.6)</td>
<td>0.7 (0.6)</td>
</tr>
<tr>
<td>Switches, mean (SD)</td>
<td>9.5 (4.1)</td>
<td>10.7 (4.0)</td>
<td>10.3 (3.5)</td>
<td>12.1 (4.4)</td>
</tr>
<tr>
<td>Mean sequential semantic relatedness (%), mean (SD)</td>
<td>N/Ab</td>
<td>18.9 (4.4)</td>
<td>N/A</td>
<td>36.8 (5.3)</td>
</tr>
</tbody>
</table>

aVFT: verbal fluency task.
bN/A: not applicable.

Figure 4. Correlation of traditional rule- and list-based and semantic relatedness cluster characteristics. Correlations of the semantic-related cluster characteristics (y-axis) with the traditional rule- and list-based cluster characteristics (x-axis) for the phonematic verbal fluency task (VFT; top row) and the semantic VFT (bottom row). Pearson correlation coefficients and corresponding P values are shown.
Next, we investigated the effect of sex, age, and disease duration on clustering. Performing sex-specific subgroup analysis revealed no differences between male and female patients except for a slightly higher number of switches in female patients (10.9 vs 8.7; Tables S1 and S2 in Multimedia Appendix 2) in the semantic relatedness analysis of the phonemic VFT. In general, younger patients produced more total words (21.4 vs 17.5) than older patients in the semantic VFT. There were no differences in other cluster characteristics or the phonemic VFT (Tables S3 and S4 in Multimedia Appendix 2). Longer disease duration was associated with slightly more switches between semantically related clusters for the phonemic VFT (11.6 vs 9.6), whereas no difference was observed in other cluster characteristics or the phonemic VFT (Tables S5 and S6 in Multimedia Appendix 2).

Comparing the phonemic and semantic VFTs, we obtained higher total word counts (19.6 vs 12.3; \(P<.001\)) and larger clusters for the semantic VFT, which is consistent with previous research [49]. The semantic relatedness approach showed a much higher mean sequential relatedness between sequential words for the semantic VFT than for the phonemic VFT (36.8\% vs 18.9\%; \(P<.001\); Table 3).

When we compared the cluster characteristics of the phonemic VFT and semantic VFT for each patient, we observed strong correlations independent of the method used for clustering (Figure S2 in Multimedia Appendix 2). Specifically, we found positive correlations between the total word count and the number of switches. A higher number of switches was associated with a lower mean cluster size, except for the semantic relatedness clusters of the phonemic VFT. Moreover, a higher mean sequential relatedness was associated with larger clusters in the semantic relatedness method, consistent with recent publications on this matter [17,19].

In summary, our semantic relatedness method produced meaningful results consistent with previous work by others. Therefore, we trained the semantic relatedness model on the English, French, and Spanish Wikipedia word corpora (see the Methods section) [34,35]. Examples of semantic relatedness clusters in these languages are presented in Figure S3 to S8 in Multimedia Appendix 2.

Correlations With Neuropsychological Tests of Executive and Language Functions

To investigate which cognitive domains are captured by the above-described cluster characteristics, we compared the obtained cluster characteristics with the results of paper-based cognitive tests. In general, the VFT can be seen as a measure of executive and language functions; specifically, the number of switches is considered a measure of executive function, and the cluster size is considered a measure of language function [9,10]. To assess the executive domains in more detail, we used the FAB and TMT B. A lower TMT B score indicates a better result. To assess language function in a standardized fashion, we performed the MWT and BNT. Overall cognition was measured using the MoCA. Correlations between clustering characteristics and neuropsychological tests are shown in Table 4 for the phonemic VFT and in Table 5 for the semantic VFT.

The most important readout of the VFT is the total word count. It correlated with the overall cognitive performance as measured by the MoCA for both the phonemic VFT (\(r=0.38\); \(P=.002\)) and semantic VFT (\(r=0.45\); \(P=.001\)). The MoCA also correlated significantly with cluster characteristics for both types of VFT obtained through the semantic relatedness method. Specifically, a higher MoCA score was associated with a higher mean sequential relatedness in the semantic VFT (\(r=0.28\); \(P=0.04\)), a higher mean cluster size (\(r=0.28\); \(P=0.02\)) in the phonemic VFT, and a higher number of switches (\(r=0.25\); \(P=0.04\)) in the phonemic VFT (Figure 5; Tables 4 and 5). Interestingly, no significant correlations with the MoCA were found for the cluster characteristics obtained through traditional clustering methods (Tables 4 and 5).

With respect to executive functions, the FAB score correlated significantly with the total word count (\(r=0.38\); \(P=0.005\)) and number of switches in the phonemic VFT obtained through the traditional rule-based clustering method (\(r=0.28\); \(P=0.04\)) and semantic relatedness method (\(r=0.28\); \(P=0.04\)). Larger clusters obtained from the semantic relatedness method were associated with a higher FAB for the phonemic VFT (\(r=0.27\); \(P=0.05\)). Regarding the semantic VFT, a higher number of switches obtained through the traditional method was associated with a higher FAB score (\(r=0.34\); \(P=0.04\)). Taken together, the FAB score thus correlated more strongly with the results of the phonemic VFT than with the results of the semantic VFT. This is consistent with previous findings by other studies [50,51]. Better TMT B results were associated with smaller clusters (\(r=0.63\); \(P=0.006\)) and a higher number of switches (\(r=-0.47\); \(P=0.05\)) for the semantic VFT as obtained through the semantic relatedness clustering method. The different correlations of FAB and TMT B demonstrate that executive function is not a homogeneous concept and support using different assessment methods. Collectively, these findings demonstrate that the semantic relatedness method can reproduce the association of VFT cluster characteristics with measures of executive function.

With respect to language function, interestingly, we observed no correlations of BNT and MWT with the clustering characteristics of the phonemic VFT. As for the semantic VFT, we found a lower number of switches to be associated with a higher MWT score (\(r=−0.54\); \(P=0.02\)) in the traditional clustering method. BNT scores correlated with the mean sequential relatedness of the semantic VFT in the semantic relatedness method (\(r=0.54\); \(P=0.02\)). These findings are consistent with the idea that clustering in VFTs is associated with language function [9,10] and demonstrate that the semantic relatedness method can reproduce associations of VFT cluster characteristics with language function.
Table 4. Correlations of the phonematic VFT\(^a\) cluster characteristics with neuropsychological test results.

<table>
<thead>
<tr>
<th></th>
<th>Overall cognition</th>
<th>Executive function</th>
<th>Language function</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MoCA(^b)</td>
<td>FAB(^c)</td>
<td>TMT B(^d)</td>
</tr>
<tr>
<td>Total VFT word count</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(r)</td>
<td>0.38 (g)</td>
<td>0.38</td>
<td>-0.03</td>
</tr>
<tr>
<td>(P) value</td>
<td>.002</td>
<td>.005</td>
<td>.89</td>
</tr>
<tr>
<td>Mean cluster size (rule based)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(r)</td>
<td>0.16</td>
<td>0.05</td>
<td>0.00</td>
</tr>
<tr>
<td>(P) value</td>
<td>.20</td>
<td>.74</td>
<td>.99</td>
</tr>
<tr>
<td>Switches (rule based)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(r)</td>
<td>0.21</td>
<td>0.28</td>
<td>-0.06</td>
</tr>
<tr>
<td>(P) value</td>
<td>.09</td>
<td>.04</td>
<td>.77</td>
</tr>
<tr>
<td>Mean cluster size (semantic relatedness)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(r)</td>
<td>0.28</td>
<td>0.27</td>
<td>-0.18</td>
</tr>
<tr>
<td>(P) value</td>
<td>.02</td>
<td>.047</td>
<td>.40</td>
</tr>
<tr>
<td>Switches (semantic relatedness)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(r)</td>
<td>0.25</td>
<td>0.28</td>
<td>0.03</td>
</tr>
<tr>
<td>(P) value</td>
<td>.04</td>
<td>.04</td>
<td>.88</td>
</tr>
<tr>
<td>Mean sequential relatedness (semantic relatedness)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(r)</td>
<td>0.00</td>
<td>0.14</td>
<td>-0.15</td>
</tr>
<tr>
<td>(P) value</td>
<td>.97</td>
<td>.32</td>
<td>.47</td>
</tr>
</tbody>
</table>

\(^a\)VFT: verbal fluency task.  
\(^b\)MoCA: Montreal Cognitive Assessment.  
\(^c\)FAB: Frontal Assessment Battery.  
\(^d\)TMT B: Trail Making Test B.  
\(^e\)BNT: Boston Naming Test.  
\(^f\)MWT: Mehrfachwahl-Wortschatz-Intelligenztest.  
\(^g\)Significant values are in italics.
<table>
<thead>
<tr>
<th></th>
<th>Overall cognition</th>
<th>Executive function</th>
<th>Language function</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MoCA</td>
<td>FAB</td>
<td>TMT B</td>
</tr>
<tr>
<td><strong>Total VFT word count</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>r</em></td>
<td>0.45 <strong>g</strong></td>
<td>0.24</td>
<td>−0.01</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>.001</td>
<td>.16</td>
<td>.96</td>
</tr>
<tr>
<td><strong>Mean cluster size (list based)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>r</em></td>
<td>0.22</td>
<td>−0.16</td>
<td>0.20</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>.12</td>
<td>.34</td>
<td>.42</td>
</tr>
<tr>
<td><strong>Switches (list based)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>r</em></td>
<td>0.15</td>
<td>0.34</td>
<td>−0.27</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>.30</td>
<td>.04</td>
<td>.28</td>
</tr>
<tr>
<td><strong>Mean cluster size (semantic relatedness)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>r</em></td>
<td>0.19</td>
<td>0.10</td>
<td>0.63</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>.18</td>
<td>.57</td>
<td>.006</td>
</tr>
<tr>
<td><strong>Switches (semantic relatedness)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>r</em></td>
<td>0.20</td>
<td>0.16</td>
<td>−0.47</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>.16</td>
<td>.34</td>
<td>.050</td>
</tr>
<tr>
<td><strong>Mean sequential relatedness (semantic relatedness)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>r</em></td>
<td>0.28</td>
<td>0.07</td>
<td>0.45</td>
</tr>
<tr>
<td><em>P value</em></td>
<td>.045</td>
<td>.69</td>
<td>.06</td>
</tr>
</tbody>
</table>

*a*VFT: verbal fluency task.

*b*MoCA: Montreal Cognitive Assessment.

*c*FAB: Frontal Assessment Battery.

*d*TMT B: Trail Making Test B.

*e*BNT: Boston Naming Test.

*f*MWT: Mehrfachwahl-Wortschatz-Intelligenztest.

**g**Significant values are in italics.
Figure 5. Network graph of Pearson correlations between clustering characteristics and neuropsychological test results. Significant ($P<0.05$) correlations for the (A) phonematic and (B) semantic verbal fluency tasks (VFTs) are shown as a network graph. The thickness of the connections and the distance between parameters indicate the magnitude of the correlation (thicker lines and shorter distances indicate stronger correlations). The Pearson correlation coefficients are shown for correlations between clustering characteristics and neuropsychological test results. BNT: Boston Naming Test; FAB: Frontal Assessment Battery; MoCA: Montreal Cognitive Assessment; MWT: Mehrfachwahl-Wortschatz-Intelligenztest; TMT: Trail Making Test.

Discussion

Principal Findings

In this study, we present an automated approach to identify semantically related clusters in VFT transcripts. Speech recordings of semantic and phonematic VFTs were generated by people with PD without supervision using a tablet computer. The obtained cluster characteristics correlated with overall cognitive, executive, and language functions. Moreover, the cluster characteristics provided additional information compared with the total word count alone.

Automatic Speech Recognition

The approach presented here allows for the automated execution and analysis of semantic and phonematic VFTs. By using a standard tablet computer and its integrated microphone, the test can be performed anywhere without the need for an experienced rater, making it a promising digital biomarker for the smartphone-based or tablet-based home monitoring of cognitive functioning.

However, the occurrence of a high percentage of speech recognition errors in automatic transcription for people with PD still limits the feasibility of completely automating this process for participants with dysarthria, consistent with previous results [52]. Advances in speech recognition technologies may help overcome this restriction in the future. The speech recognition error rate may already be lower for other languages and more advanced speech recognition algorithms [52].

Advantages of the Semantic Relatedness Method

In contrast to traditional list-based and rule-based approaches, we used a mathematical model based on the semantic relatedness of words in a large text corpus to identify clusters and calculate the semantic relatedness between words. This demonstrated that the semantic relatedness model is different from and has advantages over the traditional approaches. First, this model allows for an exact and quantitative measurement of the semantic relatedness between 2 words. This is different from traditional methods, which only allow a dichotomous distinction, that is, whether words form a cluster or not.

Second, the estimation of semantic relatedness solely relies on the presence of words in the text corpus that was used for training the model. Thus, the detected clusters do not rely on the subjective decisions of the raters who manually created the word lists. For instance, we consider the clustering of words that occur together in fairy tales or nursery rhymes appropriate. In addition, we demonstrated that the semantic relatedness model can capture more complex relationships between words that go beyond simple lists of characteristics such as geographical regions or simple phonematic rules.

Within our German cohort, we found only a minimal number of rhymes and vowel-only differences and no homonyms for the phonematic VFT. This suggests language-specific differences in rule-based clusters, which limit their usability in an international research context. This limitation does not apply to the semantic relatedness model used in this study. In our view, this method might yield results that can be easily generalized to different languages. The strong correlation of the cluster characteristics of the phonematic VFT as determined by the semantic relatedness model with MoCA and FAB scores further substantiates the validity of this approach (Figure 5; Table 4). In addition, the semantic relatedness method allows for a comparison between the cluster characteristics of the semantic VFT and the cluster characteristics of the phonematic VFT.

Advantages of the Automated Analysis

Using a semantic relatedness model as described above allows for the automation of cluster analysis in VFTs, which results in further advantages. Traditional list-based clustering requires a significant amount of manual work to create the animal lists and update them with new animals listed by the patients. If
patients are to be tested again, a different category must be used for the modified test, and the 2 sets of lists might yield differing results. With the semantic relatedness approach, a modified VFT using a different category (eg, fruits instead of animals) can be analyzed using the same method without the need for extensive testing of the new word lists.

The traditional rule-based approach relies on manual work. The detection of homonyms depends on the meaning of the words, and the detection of rhymes depends on the pronunciation and not the spelling of the words. Both features would require more complex approaches, that is, databases identifying the meaning of words and algorithms incorporating the pronunciation of words. Such an automated phonetic analysis has been described, but it resulted in large differences between automated and manual cluster identification [53]. This manual work is not required when using a semantic relatedness model as described here.

As described earlier, the semantic relatedness model shows advantages when applied to different languages. Traditional list-based clustering requires the animal lists to be translated and adapted to the local and cultural circumstances. By contrast, the semantic relatedness model can be easily adapted using a freely available text corpus, such as Wikipedia in a different language. No specific adaptations or list translations need to be performed manually because all language-specific adaptations are already integrated into the text corpus used for training the model.

To further facilitate the use of the semantic relatedness method for VFT analysis, we publish with this manuscript pretrained models for the English, German, French, and Spanish languages, which are based on the corresponding language-specific Wikipedia corpora [34]. In addition, we provide a software to train the model, which will allow other researchers to apply the model to different corpora and new languages [35].

Despite these advantages, our approach also has several limitations. Most of the texts used for training the model are written text and not spoken language, some of which are written in a scientific style. Thus, a corpus of more common texts such as books or interviews may be more appropriate. Although the Wikipedia corpus is available in many languages, not all versions are as extensive as the German and English versions, which could potentially result in less accurate models. In this case, the corpus could be supplemented with books, newspaper articles, or other types of texts.

**Correlations of Cluster Characteristics With Neuropsychological Parameters**

We used the traditional clustering methods to identify hyperparameters for the automated semantic relatedness method that provided a good correlation with the traditional method for the semantic VFT. For the phonemic VFT, the correlation between the automated semantic relatedness method and the traditional manual method was weaker. This can be explained by the different constructs used for phonemic rules and semantic relatedness.

We observed a correlation between executive functions and cluster characteristics, specifically the number of switches in the semantic and phonemic VFTs, which is consistent with previous data [13,17] and the concept that switching in VFTs reflects executive functioning [9,10]. We were able to replicate these findings for both semantic and phonemic VFTs in the semantic relatedness clustering method. Although semantic relatedness reflects a different construct compared with traditional rule-based clustering, the number of switches between semantically related clusters in the phonemic VFT also showed significant correlations with executive function as reported by the FAB. Regarding the language function, our results do not support the idea of cluster sizes as a marker of language function [9,10]. Similarly conflicting results were also reported by other researchers, and these showed either no correlations of clustering characteristics with language function or correlations of the number of switches with language function [17,18]. The heterogeneity of these results may be caused by the subjectiveness of the animal lists required for traditional clustering and by the correlation of the mean cluster size with the number of switches, as observed in our data and described elsewhere [7,17,19]. By applying the semantic relatedness method, we were able to observe that a higher mean sequential relatedness is associated with a higher BNT score. This shows that the cluster characteristics obtained through the semantic relatedness method yield additional information about language function that cannot be inferred from the total word count or from the traditional clustering method.

Because the phonematic and semantic VFTs were conducted in the same order in all patients, we cannot rule out a negative bias toward the second task caused by fatigue. We assume that the impact of not randomizing the order of the VFTs is limited because the VFT is a very short assessment taking only 1 minute to complete.

Overall, our semantic relatedness clustering method when applied to the semantic VFT yielded results comparable with those published in a recent study [17], highlighting a robust correlation with executive function in people with PD. Our study is the first to investigate semantically related clusters for the phonemic VFT in people with PD. In this study, we showed for the first time that the semantic relatedness method can also be applied to the phonematic VFT in people with PD and that the resulting clustering characteristics are a robust marker of executive function.

**Conclusions**

In summary, our work demonstrates the feasibility of a standardized cluster analysis of semantic and phonemic VFT transcripts using a semantic relatedness model. This model overcomes numerous disadvantages of traditional clustering methods, allows for the automation of cluster identification, and shows strong correlations with executive functions. The presented automated approach enables a more objective identification of semantic clusters in different languages: going forward, it could help overcome the heterogeneity of previously published studies in this field. Longitudinal trials are required to determine whether cluster characteristics are associated with differences in cognitive decline or disease progression. In the future, this automated semantic relatedness method could
provide easily accessible digital biomarkers for executive function in PD.

Acknowledgments
The present data analysis is part of the project ParkinsonNetzwerk Ostsachsen (PANOS). The PANOS project is funded by the German Federal Ministry of Health under the grant 2519FEP009 (Bundesministerium für Gesundheit [Federal Ministry of Health]/Bundesverwaltungsamt [Federal Office of Administration]). In addition, this project is cofinanced by tax funds based on the budget of the Saxon Ministry of Social Affairs and Social Cohesion passed by the Saxon Parliament, by the Sächsische Aufbaubank under the application number 100386587 (Sächsisches Staatsministerium für Soziales und Gesellschaftlichen Zusammenhalt [Saxon State Ministry for Social Affairs and Social Cohesion]/Sächsische Aufbaubank [Saxon Development Bank]), and by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung) under the application number 16DKWN1113A.

Conflicts of Interest
None declared.

Multimedia Appendix 1
Animal lists used for traditional clustering.
[XLS File (Microsoft Excel File), 16 KB - neuro_v2i1e46021_app1.xls]

Multimedia Appendix 2
Additional figures for speech recognition error rates and correlations between cluster characteristics and subgroup analyses (age, sex, and disease duration). Furthermore, we have presented semantic relatedness cluster examples for the languages English, Spanish, and French based on the corresponding language-specific Wikipedia corpuses.
[DOC File, 2558 KB - neuro_v2i1e46021_app2.doc]

References


Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNT</td>
<td>Boston Naming Test</td>
</tr>
<tr>
<td>FAB</td>
<td>Frontal Assessment Battery</td>
</tr>
<tr>
<td>MDS-UPDRS</td>
<td>Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale</td>
</tr>
<tr>
<td>MoCA</td>
<td>Montreal Cognitive Assessment</td>
</tr>
<tr>
<td>MWT</td>
<td>Mehrfachwahl-Wortschatz-Intelligenztest</td>
</tr>
<tr>
<td>PD</td>
<td>Parkinson disease</td>
</tr>
<tr>
<td>PDD</td>
<td>Parkinson disease dementia</td>
</tr>
<tr>
<td>TMT</td>
<td>Trail Making Test</td>
</tr>
<tr>
<td>VFT</td>
<td>verbal fluency task</td>
</tr>
</tbody>
</table>

https://neuro.jmir.org/2023/1/e46021

JMIR Neurotechnology 2023 | vol. 2 | e46021 | p.81
(page number not for citation purposes)